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Abstract 
 
Complement receptor type 2 (CR2, CD21) is a cell surface protein that links the 
innate and adaptive immune response through its binding to C3d, a cleavage fragment 
of the major complement component C3. Factor H (FH) is a major plasma protein that 
is the major regulator of the activity of C3b in the alternative pathway. FH binds to C3u, 
which is formed from C3 by hydrolysis, and C3u shows functional similarities to C3b. 
In this thesis, X-ray scattering, analytical ultracentrifugation and constrained modelling 
were used to determine solution structures and interactions of CR2 with C3d and FH 
with C3u. Structural studies reveal that the overall CR2 structure is unaffected by 
change in ionic strength or when C3d is bound to it. Unbound C3d exists in monomer-
dimer and monomer-trimer equilibria in low salt buffer, but as a monomer only in 
physiological buffer. The CR2-C3d interaction is not formed in physiological salt 
conditions, but was observed in low salt conditions. The solution structure and self-
association of C3u were investigated. C3u underwent weak salt-dependent dimerisation, 
similar to that for C3d. Modelling showed that the functionally-important TED/CUB 
domains in the C3d part of C3u were extended away from the rest of the C3u structure. 
This TED/CUB conformation is intermediate between those of C3 and C3b. C3u and 
FH were observed to interact as 1:1 and 2:1 complexes in a salt-dependent manner. The 
modelling of the interaction showed that no major conformational changes occurred in 
C3u or FH, and suggested that C3u binds separately to FH at two independent sites. 
These results provide new insights in the activation of C3 and the complement 
regulatory activity of CR2 and FH. 
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(1.1) History of the complement system 
Complement is a major defence and clearance system in the blood stream. The 
complement system plays a major role in the recognition and elimination of microbial 
intruders and other pathogenic cells. It is a mediator between the innate and adaptive 
immune responses. It consists of proteins that react to each other in a biochemical 
cascade and work together to eliminate invading microganisms through both antibody-
dependent and independent mechanisms (Border & Gengou, 1901). 
 
The complement system was first discovered in the late nineteenth century, when 
blood serum was found to lyse bacteria (Nuttal, 1888; Buchner, 1889). Then Bordet, a 
Belgian scientist in Paris, described the loss of the lytic activity of serum from immune 
animals following heating, and the subsequent restoration of activity with the addition of 
non-immune serum. He concluded that two factors were involved: heat-labile and heat-
stable factors. He named these as “alexin” and “sensitizer” (Bordet, 1909). Alexin is 
later known as complement and “sensitizer” is recognised as antibody. 
The term “complement” was first used by Ehrlich and Morgenroth in the late 
1890s. As part of their large theory of immune system, “complement” describes a heat-
labile component of the immune system that was thought to complement the action of 
the cells of the immune system. Ehrlich believed that each antigen-specific antibody 
(called amboceptor) has its own specific complement, whereas Bordet believed that 
there is only one type of complement. In the early 20th century, this controversy was 
resolved when it became understood that complement can act in combination with 
specific antibodies, or on its own in a non-specific way. 
During the first half of the 20th century, it was established that the system 
comprised at least four proteins (Pillemer et al., 1941). In the late 19th century, the 
components of complement were first observed as the globulin (also called mid-piece) 
and pseuglobulin (end-piece) fractions of serum. It was found that neither of them on 
their own could destroy bacteria. Ferrata (Ferrata, 1907) later showed that 
recombination of these two parts of fractions from guineas pig could destroy bacteria. 
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The midpiece contained a protein that could interact with erythrocyte-bound haemolytic 
antibody. This protein was named C1. The globulin fraction reacted with antibody first, 
and then the albumin fraction caused cell lysis. In the early 20th century, a third 
component was confirmed by several observers (Coca, 1914). On removal of this 
component, serum becomes inactive. In 1926, Gordon reported the existence of the 
fourth component of complement, showing ammonia destroyed heat-stable factor in 
serum, which is distinct from the third complement (Gordon et al., 1926). By the late 
1950s it was believed that heat-inactivated serum was devoid of C1 and C2; zymosan 
and cobra venom-treated serum was deficient in C3, and ammonia destroyed C4. These 
studies showed the sequential nature of complement activation. 
With the advent of improved methods of plasma protein fractionation, most of 
the complement proteins became possible to purify and characterise. Mathematical 
models were applied to analyse the protein reactions and to clarify the steps in the 
sequence. By the late 1960s, complement was known to comprise eleven proteins: C1q, 
C1r, C1s, C4, C2, C3, C5, C6, C7, C8 and C9. 
 From the 1960s, the complement activation pathways were gradually 
discovered. In the 1960s, Nelson and Müller-Eberhard characterized an 
immunologically activated pathway, named as the classical pathway (Nelson et al., 
1966; Müller-Eberhard, 1968). Later, the alternative pathway was discovered. (Ellman 
et al., 1970; Götze & Müller-Eberhard, 1971). In 1972 Pepys (Pepys, 1972) observed an 
impaired acquired immune response occurs on C3-depleted mice. This finding indicated 
that the innate immune system is able to instruct the acquired immune response and 
showed that the complement system plays a more interesting role than had previously 
been thought. Recently, the lectin pathway was discovered with the purification of 
mannan-binding lectin (MBL) from rabbit liver (Kawasaki et al., 1978) and human 
(Kawasaki et al., 1983). Now, the each pathway is recognised as a third pathway of 
complement activation (Ikeda et al., 1987; Ji et al., 1988). 
More than a hundred years after the initial reports, the central role of 
complement system in immune defence is much better known. Complement activation 
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activates pro-inflammatory mediators, generates anaphylactic peptides, cytolytic 
compounds and antimicrobial compounds, then effector cells are recruited to induce 
effector responses. These ensure that complement activation is moderate and controlled, 
in turn benefit for the host. 
 
 (1.2) Complement activation pathways 
The complement system, which comprises over 30 proteins, is able to activate 
cells involved in both the adaptive and innate immune responses (Janeway et al., 2005). 
The complement proteins normally circulate in the blood in an inactive zymogen form 
and are activated through a series of enzymatic reactions as the detection of foreign 
material in plasma. Complement activation can be triggered by any of following events: 
(a) Interaction of C1 with antigen-antibody complex, polymerised antibody IgG or IgM, 
or C-reactive protein (CRP), (b) spontaneous hydrolysis or molecular perturbation of the 
C3 complement protein, or (c) Interaction of C3 with mannan-binding lectin (MBL) that 
bind the microbial polysaccharide mannose. 
 
Any of these pathways could trigger a cascade of reactions. The goal is to 
eliminate foreign particles from the host. This involves other complement proteins, 
membrane-bound control proteins and receptors, proteases and regulatory proteins. 
Several complement proteins are zymogens. When activated, they become proteases and 
activate other proteins in the complement system by cleaving them to expose reactive 
groups or active sites. Complement is activated by three pathways namely, the classical, 
the alternative and the lectin pathways (Morley & Walport, 2000). The three pathways 
leads to the activation of C3, and the endpoint of complement activation is the formation 
of the membrane attack complex (MAC).  
 
(1.2.1) The classical pathway 
Activation of complement via the classical pathway is primarily initiated by the 
interaction of C1q of C1 (C1qr2s2) with the Fc region of IgG and IgM antibodies. 
Alternatively, activation of C1 can be achieved by its direct interaction with a variety of 
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polyanions (such as bacterial lipopolysaccharides, DNA and RNA), certain small 
polysaccharides, viral membranes and C-reactive protein, etc. C1 is a complex of three 
proteins: C1q, C1r, and C1s. Within the C1 complex, the active sites of its subunits are 
positioned in close proximity, and activation of one of the subunits leads to activation of 
the others in turn. The C1q molecule is composed of six subunits with collagen-like tails 
attached to globular heads. It can bind Fc regions of antibodies IgG and IgM, which are 
bound to bacterial and viral surfaces. The enzymatic activity of C1 is derived by 
activation of the two molecules of pro-enzyme C1r and two molecules of pro-enzyme 
C1s in the C1r2-C1s2 Ca2+ dependent complex (Law & Reid, 1995). A model for the C1 
complex is shown in Figure 1.1. 
 
 Binding of C1q to antibody causes a conformational change in C1r/C1s, which 
activates the protease function of C1r/C1s. C1s cleaves C4 and then C2 to generate C4b 
and C2b. This results in a C4b2a complex (also called C3 convertase, referring to its 
role of converting C3 into an active form). This convertase is attached to the surface of 
pathogen and cleaves C3 into C3b and C3a. The C3b molecules may diffuse away and 
then coat immune complexes and specific antigens, functioning as opsonin, or they bind 
with the C3 convertase to form a trimolecular complex C4b2a3b that is called C5 
convertase. The C3b component of C5 convertase binds C5 and alters its conformation, 
so that the rest of component of this convertase can cleave C5 into C5a, which is a 
potent anaphylatoxin and diffuse away, and C5b, which attaches to C6 and induces 
formation of the membrane attack complex (MAC) (Figure 1.2). 
 
(1.2.2) The alternative pathway 
The alternative pathway plays an important part in the innate immune system. It does 
not require antibody and primarily is initiated on microbial surfaces. Plasma protein 
C3, factor B and factor D form a positive feedback activation loop which is controlled 
by the soluble regulatory components factors H, I and P (Figure 1.2). The alternative 
pathway is the phylogenetically oldest activation pathway of the complement system 
(Armstrong et al., 1993). 
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Figure 1.1 Schematic models of the C1 complex and the MBL and MASP complex. 
R and S denote the larger catalytic domains of C1r and C1s (Law & Reid, 1995). 
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 Figure 1.2 The activation cascades of the complement system (adapted from Gilbert, 2006).
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C3 in the alternative pathway is activated differently from classical pathway 
activation. In the alternative pathway, C3, which contains an unstable thioester bond, is 
slowly hydrolysed to C3u or is cleaved by proteases to produce C3a and C3b. C3b binds 
to foreign surface antigens or even to the host cells. Due to high levels of sialic acid on 
most host cell surfaces which interacts with the control protein factor H, C3b is rapidly 
inactivated and this prevents its further interactions to lead to MAC formation. 
However, when a single C3b molecule is deposited on an activating surface, it can serve 
as a seed for the positive amplification loop which operates explosively (Nicol & 
Lachmann, 1973; Pangburn & Müller-Eberhard, 1978). Another serum protein called 
factor B interacts with C3b to form a complex. This complex is then cleaved by factor D 
to generate C3bBb that has C3 convertase activity and thus is analogous to the C4b2a 
complex in the classical pathway. The stability of C3bBb is controlled by binding to a 
serum protein called properdin. Because C3bBb possess enzymatic activity that cleaves 
unhydrolyzed C3 to generate more C3b, the initial steps are repeated and amplified. C3b 
also binds to C3bBb to generate the C3bBb3b complex, which exhibits C5 convertase 
activity, analogous to the C4b2a3b complex in the classical pathway (Law et al., 1995). 
This is shown in Figure 1.2 also. 
 
(1.2.3) The mannan-binding lectin pathway 
Lectins are proteins that recognise and bind to specific carbohydrate targets. The 
lectin pathway, like the alternative pathway, is an antibody-independent pathway. 
However, the mechanism is very similar to the classical pathway. After initiation, it 
proceeds through the reactions of C2 and C4, to produce a C5 convertase; and 
consequently activates C5 for the formation of the membrane attack complex. The lectin 
pathway is activated by the binding of mannose-binding lectin (MBL) to mannose 
residues on glycoproteins or carbohydrates on the surface of microorganisams. MBL is an 
acute phase protein produced in inflammatory responses. It functions similarly to C1q to 
trigger complement activation (Figure 1.1). After MBL binds to the surface of a cell or 
pathogen, the MBL-associated serine proteases, MASP-1 and MASP-2, binds to MBL 
(Matsushita & Fujita, 1992). MASP-2 is an enzyme component that acts in a similar 
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fashion to C1s in the classical pathway, in that this is responsible for the cleavage of C2 
and C4, which ultimately results in the formation of the C3 convertase enzyme C4b2a 
(Figure 1.2). This means of activating the C2 and C4 components to form a C5 convertase 
without the need for specific antibody binding represent an important innate defence 
mechanism comparable to the alternative pathway (Law et al., 1995). 
 
(1.2.4) Membrane attack complex  
Complement activation is terminated by complement C5b, C6, C7, C8 and C9, 
which interact sequentially to form a supra-macromolecular structure called the 
membrane-attack complex (MAC). C5 is broken down into C5a and C5b after binding 
to C5 convertase. C5a diffuses away, and C5b is quickly degraded unless C6 binds to it 
to create the C5b6 complex, to which C7 then binds. The addition of C7 changes the 
conformation of the complex, which becomes hydrophobic and is able to insert into 
lipid membrane of the target cell. C8 and up to 18 molecules of C9 then bind to the 
complex and form the MAC (Law & Reid, 1995). C8 is a complex composed of C8α, 
C8β and C8α-γ, which are distinct gene products. The binding of C8 to C5b67 takes 
place via C8β. C8β binds to the C5b part of the membrane-bound C5b67 complex to 
form the C5b678 complex, and allows the hydrophobic domain of C8α-γ to be inserted 
into the phospholipid bilayer. The final step in formation of the MAC is binding and 
polymerisation of C9 to the C5b678 complex. About ten to seventeen molecules of C9 
are thought to be involved. During polymerisation, the C9 molecules undergo a 
hydrophilic-amphilic transition, so that they can insert into the membrane. The 
completed MAC has a tubular form and functional pore size of 7-10 nm. 
 
The MAC behaves as an integral membrane protein complex or transmembrane 
channel that is permeable to water and electrolytes. Since small molecules and ions can 
diffuse freely through the channel of MAC, the cell loses its osmotic stability and is 
consequently killed by an influx of water and loss of electrolytes (Law & Reid, 1995). 
Thus, complement not only facilitates the uptake and destruction of pathogens by 
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phagocytic cells, but also lyses cells directly and play a role in the clearance of immune 
complexes and inflammation.  
 
(1.3) The regulation of complement  
Complement activation occurs in a sequential manner. Once activated, the 
complement cascade generates effector compounds that are delivered to any surface. 
However, progression of the cascade and the action of the effectors need to be 
controlled at each level by multiple complement regulators and inhibitors. When 
complement activation is not properly controlled or inhibited, it can lead to 
inflammation, pathology and ultimately autoimmune disease. 
 
The importance of complement regulation is highlighted by the relatively large 
number of regulators. Overall, active complement proteins have a short half-life, even 
without functional regulatory proteins. Regulators guard the correct level of activation 
and deactivation of complement proteins. Complement regulators are categorised in 
three major classes: a) in fluid phase. b) attached to the surface of host cells. c) 
membrane-integral complement clearance receptors. Fluid phase complement regulators 
are mainly in human plasma and in body fluid such as the synovial and vitreous fluids, 
such as factor H, properdin, Carboxypeptidase N, C1 inhibitor (C1INH), clusterin, 
vitronectin (Heinen et al., 2009; Preissner & Seiffert, 1998) and C4BP. Membrane-
bound complement regulator include: CR1, CR2, CD55 (also known as DAF), CD46 
(also known as MCP), CD59 (also known as protectin) and complement receptor of the 
immunoglobulin superfamily. Receptors for complement effectors include CR1, CR2, 
CR3, CR4, C3aR, C5aR, C5L2, C1qR and CRIg.  
 
C3b, generated by C3 convertase, can damage healthy cells by causing their 
inappropriate opsonisation. C3b is controlled by several regulators of complement 
activation (RCA) proteins including Complement receptor type 1 (CR1), Membrane 
cofactor protein (MCP) and factor H. CR1, MCP or factor H (a regulatory component) 
bind to C3b thus preventing its interaction with factor B. Factor I is a serine protease 
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which cleaves both C3b and C4b in the presence of a cofactor (CR1, MCP or factor H). 
Factor H and Factor I controls the activity of the alternative pathway C3 and C5 
convertases by competing with factor B for C3b binding. Factor I cleaves the C3b into a 
bound iC3b fragment and a soluble C3f fragment. iC3b can be further cleaved by Factor 
I, which releases C3c and leaves C3dg bound to the membrane. C3d, along with C3dg 
and iC3b, are not known to play any part in the activation of complement but are 
important as ligands for complement receptor type 2 (CR2) (Figure 1.3).  
 
This thesis will focus on the regulatory interactions between CR2 and C3, and 
between factor H and C3. Section 1.4, 1.5 and 1.6 summarise what is known of CR2, 
C3 and factor H. 
 
(1.4) Complement receptor type 2   
Complement receptor type 2 (CR2/CD21) is a member of the regulators of 
complement activation (RCA) gene family. It is a 145 kDa membrane glycoprotein, 
which has an important role of cross-linking foreign antigens with surface-bound 
antibodies and C3d on the surface of B cells. 
 
(1.4.1) CR2 expression and sequence  
CR2 is found at the RCA gene locus (Rodriguez de Cordoba et al., 1985) along 
with factor H, CR1, MCP, C4BP and DAF. The locus maps to human chromosome 1q32 
(Weis et al., 1987), in which CR2 is encoded by a single gene (Fujisaku et al., 1989). 
Regions of internal homology have been shown in the CR2 genomic organisation 
(Fujisaku et al., 1989) and from full length cDNA analysis (Weis et al., 1988). Three 
types of exons were observed: (a) Two domains are encoded on the same exon, i.e., short 
consensus repeats (SCR) domain 1 and 2, 5 and 6, 9 and 10, and 13 and 14 are encoded 
on single exons. (b) Exons encode a single SCR domain, where five SCRs (SCRs 3, 7, 
11, 15 and 16) are encoded by single exons. (c) Three SCRs (4, 8 and 12) are encoded 
by split exons, where exon 4a and 4b, 8a and 8b, and 12a and 12b are split by 250,  
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Figure 1.3 CR2 function in binding with C3 fragment C3d. 
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335 and 355 nucleotides respectively. The order of the exons within the gene is a 
repeat array of a group of four SCR domains in the order fused, single and split for 
the first three repeats and then fused, single, single for the last group, giving a total of 
16 SCR domains (Figure 1.4). Since the fused SCR exon is present in each of the 
four homology group, the CR2 gene may evolved through duplication of a basic four 
SCR domain unit.  
 
Two different forms of CR2 are present in cDNA libraries (Weis et al., 1988; 
Moore et al., 1987), one with 15 SCR domains, the other with 16 SCR domains, with 
the additional domain inserted between SCR 10 and 11 of CR2. In Figure 1.4, exon 11 
occurs before 12a of 16 SCR domains. In Figure 1.5, SCR 10a is the additional domain 
(arrowed) in the 15 SCR domains. This is due to alternative splicing of the precursor 
mRNA. The intron between exon 11 and 12a in Figure 1.4 is 79 nucleotides. The 
efficiency of splicing to the proximal 5’ splice donor site decreases when the intron is 
less than 80 nucleotides. (Fujisaku et al., 1989; Toothaker et al., 1989). 
 
CR2 is primarily expressed by B lymphocytes (Weis et al., 1984), but is also 
found on follicular dendritic cells (Reynes et al., 1985), astrocytes (Gasque et al., 
1996), early thymocytes (Tsoukas et al., 1988), epithelial cells (Young et al., 1986; 
Birkenbach et al., 1992) and a subset of CD4+ and CD8+ peripheral T lymphocytes 
(Fischer et al., 1991; Levy et al., 1992). A soluble form of CR2 has been reported to 
be released spontaneously by B and T cells (Frémeaux-Bacchi et al., 1996). 
Follicular dendritic cells selectively express the 16 SCR domain isoform of CR2 (Liu 
et al., 1997). CR2 is expressed only in early active and mature stages of B cell 
development (Tedder et al., 1984). Expression is lost in pro-B cells, pre-B cells and 
in lymphocytes at the plasma cell stage. 
 
The mature CR2 protein consists of a 111 kDa polypeptide chain with 
between eight and eleven putative N-linked glycosylation sites (Weis & Fearon, 
1985). It consists of 15 or 16 tandem SCR domains followed by a 28 amino acid 
hydrophobic transmembrane domain and a relatively short 34 amino acid 
intracytoplasmic tail (Hannan et al., 2005). Each SCR is a domain with 60-70 amino 
acids (Figure 1.5). Conserved cysteine and tryptophan residues are characteristic of 
  
 
 
 
 
 
 
 
Figure 1.4 Schematic order of exons sequence within the CR2 gene, giving 16 SCR 
domains. The numbers above the blocks represent corresponding SCR domains which are 
from the derived protein sequence (Fujisaku et al., 1989).  
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Figure 1.5 A schematic diagram of amino acid sequence of human CR2 and its 15 
SCR domains (Gilbert et al., 2006b). The position of additional domain in the alternatively 
spliced form of CR2 is indicated by the broken ellipse labelled 10a. The bracketed ranges 
show the long homologous repeats (LHR). The 15th SCR does not fit the pattern. The 11 
predicted N-linked glycosylation sites are marked by ψ symbols. The number of residues 
between each SCR domain is shown between each pair of domains. Horizontal arrows 
indicate the binding sites for its ligands. Underneath, the 15 SCR sequences of CR2 are 
aligned. (SWISSPROT entry P20023). Residues 1-20 correspond to the predicted signal 
peptide. Residues 21-974 contain 15 copies of the SCR sequences. The sequence from one 
to 20 and residue 972 onwards is not included. The N-linked glycosylation sites are 
underlined. Conserved cysteine and tryptophan residues are highlighted in red, and the 
linker sequences are highlighted in green. 
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the SCR structure. The presence of consensus repeating elements has been reported in other 
C3 binding proteins (Reid et al., 1986). Long homologous repeats have been reported that 
repeat every four SCR domains of CR2 except the last group (Weis et al., 1988). The 
cytoplasmic domain contains several potential serine and threonine phosphorylation sites 
(Feramisco et al., 1980; Moore et al., 1987; Weis et al., 1988). The sequence of CR2 is 
highly conserved across species, although the SCR 3 domain is missing in the rat CR2 
(Gilbert et al., 2006b). 
 
The first two SCR domains of CR2 contain binding sites for four known ligands 
(Figure 1.5). These include the C3 fragments (C3d, C3dg, and iC3b) (Lowell et al., 1989), the 
Epstein-Barr virus (EBV) coat glycoprotein gp 350/220 (Carel et al., 1990), interferon alpha, 
IFNα (Delcayre et al., 1991) and CD23 (Aubry et al., 1992). The SCR 5-8 domains also have 
a binding site for CD23 (Aubry et al., 1994). 
 
(1.4.2) CR2 function  
 
CR2 plays an important role in the generation of a normal immune response. Its 
deficiency causes an impaired B cell response to T-dependent antigen (Ahearn et al., 1996). 
For mature B lymphocytes, CR2 acts as a co-receptor for IgM and the B cell receptor 
(BCR). Cross-linking of CR2 and membrane IgM can cause a synergistic increase in the 
free intracellular calcium concentration in human B lymphocytes (Carter et al., 1988). It 
enhances the response of B cells to antibodies and subsequently enlarging the T cell 
responses (Hebell et al., 1991; Thyphronitis et al., 1991; Ahearn et al., 1996). In this way 
CR2 acts as a linker between the innate and humoral acquired immune response (Dempsey 
et al., 1996).  
 
CR2 mediates Epstein-Barr virus (EBV) infection by serving as the receptor for the 
EBV intrinsic membrane protein gp350/220 (Fingeroth et al., 1984). EBV is a human 
herpes virus which is carried in a latent state in the B cells of approximately 90% of 
humans. In most cases there are no symptoms, but EBV can cause infectious 
mononucleosis and is associated with Hodgkin’s lymphoma, Burkitt’s lymphoma and adult 
T cell leukaemia (Epstein et al., 1964; Weiss et al., 1989; Jones et al., 1988). EBV binds to 
CR2 on B cells through its coat glycoprotein gp350. The binding site on CR2 for gp350 has 
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been shown in the SCR1-2 domains by site-mutagenesis (Young et al., 2008). The discovery 
of this binding site may assist investigation of EBV therapy.  
 
CR2 was assessed for its importance for the binding of the human immunodeficiency 
virus immune complex (HIV-IC). Previous study showed that CR2 is a critical receptor for 
high-level HIV IC binding to PBMC and lymph node mononuclear cells (Jakubik et al., 
1999). The C3 fragments are deposited on HIV-1 and bind to CR1 and CR2 on B cells. As 
the B cells pass through the secondary lymphoid organs, the virions may be passed to FDC 
and subsequently to T cells. The discovery may assist investigation on HIV therapy.  
 
CR2 has four known types of ligands: C3 cleavage fragments, CD23 (a low affinity 
receptor for IgE), IFNα and the coat glycoprotein gp350 of EBV (Makar et al., 1998). 
Research has revealed that the SCR1-2 domains contain binding sites for C3dg, iC3b, 
gp350 and CD23 (CD23 also interacts with CR2 SCR5-8). CR2 on B cells provides a 
preferential site for C3 fragments with covalently attached antigen. The cross-linking of 
CR2 to the B-cell receptor by a C3d-antigen complex enhanced an intracellular calcium 
release through a co-activation with CD19 and CD81 (Fearon & Carroll, 2000). Also, CR2 
is a receptor for CD23. CD23, which has been shown to influence B cell growth and 
proliferation and germinal B cell survival (Liu et al., 1991), is a type two transmembrane 
protein that is a low affinity receptor for IgE. It interacts with CR2 at both SCR1-2 and 
SCR5-8. CD23 can interact with CR2 to increase interleukin-4 induced production of IgE. 
 
(1.4.3) Protein structure of CR2  
 
Since CR2 plays an important part in the human complement system, a structural 
understanding of it becomes essential. Hydrodynamic and EM studies of soluble CR2 
showed that it is a highly extended, rod-shape and flexible molecule (Moore et al., 1989). 
Figure 1.6 shows that CR2 has a beads-on-a-string arrangement and a length of 38.6 ± 3.5 nm 
overall. The crystal structure of CR2 SCR1-2 shows the first two domains from N- terminal 
form a closed V shape (Prota et al., 2002). Later, the structure of CR2 SCR1-15 in solution 
was determined by constrained scattering and ultracentrifugation modelling (Gilbert et al., 
2006b). The length of the molecule is estimated as 38 nm. This is consistent with electron 
microscopy images with 16 SCR domains. The best-fit CR2 models in solution are extended 
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Figure 1.6 Structures of CR2 by electron microscopy. Sixteen extracellular domains of 
CR2 are observed here (taken from Moore et al., 1989). 
 
 
 
 
 
 
 
 
 
Figure 1.7 CR2 SCR1-15 conformation with 15 SCR domains by solution scattering 
(adapted from Gilbert et al., 2006b). 
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and flexible with folded back regions. As shown in Figure 1.7, SCR1-2 folds back towards 
SCR 4-6, and with a further slight turn around SCR 11-13; however, due to the medium 
resolution of solution scattering, other partially folded-back structures are also possible. 
The folded back regions are a particular feature of the SCR superfamily. Previous solution 
studies for proteins with five SCR domains (mouse Crry-Ig, rat Crry and β2-glycoprotein I) 
display no tendency to form such significantly folded back SCR structures (Aslam et al., 
2003; Hammel et al., 2002), while these have been observed for factor H (Aslam & 
Perkins, 2001).  
 
There are several possibilities for causes of folded back SCR regions. To date, 
folded-back SCR regions all possess longer than usual linkers of lengths seven or eight 
residues in place of three or four. This may be caused by weak interaction between the SCR 
domains in distant part of the molecule. A Poisson–Boltzmann electrostatic map suggested 
that SCR 1-2 have predominantly basic surfaces, while SCR 5 has a partial acidic surface 
(mediated by Asp304, Asp306, Glu308 and Glu309). These could lead to an attractive force 
for folding back between non-neighbouring SCR domains. Protein–carbohydrate 
interactions could also cause protein folding back, but it is unlikely to occur, because the 
interactions are transient in relation to the observed extended CR2 structures. If the 
proposed inter-SCR interactions were stronger, it would lead to the formation of CR2 
dimers in solution; however, there is no evidence of CR2 oligomer from previous scattering 
and ultracentrifugation work (Moore et al., 1989; Gilbert et al., 2005; Gilbert et al., 2006b). 
 
The flexibility of CR2 SCR1-15 reveals the possibility for all 15 domains playing a 
role in ligand binding. Figure 1.5 shows the possible binding region for gp350, CD23, iC3b, 
IFN-α and C3d on CR2. Previous affinity studies of the CR2 ligands, C3d, IFN-α and gp350, 
which bind to domain SCR1-2, SCR1-4 and SCR1-15, showed an increase in dissociation 
constant (KD) for the complex as the number of SCR domains increased from two to 15 
(Asokan et al., 2006). This may be due to a movement of the SCR 1-2 domains closer to SCR 
3-15 to obstruct the ligand binding site at SCR 1-2 (Figure 1.7). Another scenario is that SCR 
1-2 may interact weakly with other SCR domains in CR2. In such a case, the CR2 ligands 
will compete with other SCR domains for binding to SCR 1-2, and this could also explain the 
reduced ligand affinity of CR2 SCR 1-15 compared to CR2 SCR 1-2. Experiments with a 
series of truncated CR2 constructs showed that SCR 1-2 are required for ligand binding, 
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SCR 3-4 increase the binding affinity, and the remaining SCR domains mediate the 
internalisation of the bound ligand (Carel et al., 1990).  
 
The primary ligand for CR2 is the C3d activation fragment of complement 
component C3. The binding of C3d to CR2 on mature B lymphocytes was said to cause 
reduction in the threshold of immune activation. C3d has been reported to show a self-
association of monomer-dimer in 50 mM NaCl, but this disappears during its binding with 
CR2 (Gilbert et al., 2005). The crystal structure of the complex CR2 SCR1-2 and C3d 
showed that only the SCR2 domains of CR2 interacted with C3d (Szakonyi et al., 2001). 
Mutation studies on complex confirmed the ligand binding to SCR2 (Hannan et al., 2005). 
By point mutation, SCR1 domain was also found to participate in C3d binding; in particular 
four residues of SCR1 affect ligand binding- Arg13, Arg28, Lys41 and Lys57 (labelled in 
Figure 1.8). The solution structure of CR2 SCR 1-2, both free and complexed with C3d, is a 
much more open V-shape than seen in the crystal structures (Figure 1.9(b,c)) (Gilbert et al., 
2005). This difference showed a high degree of flexibility in the linker between SCR 1 and 
2, which is able to adopt a wide range of different conformations with its ligands. 
Electrostatic calculations have been reported for the CR2-C3d complex (Hannan et al., 
2005; Morikos & Lambris, 2004; Zhang et al., 2007; Young et al., 2007). These 
calculations show that C3d has an excess charge of -4, while CR2 SCR1-2 has an excess 
charge of +8, and that CR2 SCR1-2 shows a preponderance of positive charge on its 
surface (Figure 1.8). The calculations postulate that electrostatic interactions play a role in 
complex formation. 
 
 What is not clear from these studies is the stoichiometry of the CR2-C3d interaction 
in solution. Surface plasmon resonance studies in 50 mM NaCl HEPES buffer for CR2 
SCR1-2/C3d, CR2 SCR1-4/C3d and CR2 SCR1-15/C3d demonstrate a high affinity for 
C3d, but in more physiological 125 mM NaCl buffer, the binding is much weakened 
(Asokan et al., 2006; Moore et al., 1989; Guthridge et al., 2001; Hannan et al., 2005). It is 
known that human physiological fluid contains 137 mM NaCl, and CR2-C3d binding must 
happen to trigger further signal transduction. While it is assumed that the binding affinity 
will be weakened in higher salt, it is not known whether association of CR2 and C3d is 
affected in vivo. A second question is whether CR2 undergo conformational change from 50 
mM NaCl to 137 mM NaCl similar to other flexible SCR proteins, such as factor H   
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Figure 1.8 Electrostatic representation of the CR2 SCR1-2/C3d crystal structure (Hannah et al., 2005; Gilbert, 2006). Residues 
on C3d E117, D122, D128 and D147 form part of a conserved negatively charged groove located on C3d. On the left side, they are 
coloured red and labelled in black/yellow font on the right side. The contact residue Q20 on C3d for antigen is labelled and coloured 
yellow. The contacting surface of CR2 SCR2 is mainly positive charged (blue). Positive charged residues R13, R28, K41 and K57 
were also found on SCR2 domain of CR2. 
 
 
 
  
 
 
 
Figure 1.9 Schematic diagrams of the CR2 SCR 1-2/C3d complex to show three 
alternative models for the complex. The crystal structure corresponds to (a), while the 
solution scattering structures corresponds to (b) and (c) (adapted from Gilbert et al., 2005). 
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(Okemefuna et al., 2009a). NMR or crystallography is not able to analyse the structure of 
full length CR2 SCR1-15 and the interaction between full length CR2 SCR1-15 and C3d; 
therefore, other structural methods are needed to study the overall structure. Chapter 4 
reports studies of the interaction between CR2 SCR1-15 and C3d by solution scattering and 
analytical ultracentrifugation in 50 mM NaCl and 137 mM NaCl buffers. The results 
provide further key clarification of the solution structure of the CR2-C3d complex and its 
involvement with the BCR as a coreceptor that links innate and adaptive immunity. 
 
 (1.5) Complement component C3  
C3d is a binding partner of CR2. C3d originates as a fragment of the major 
complement component C3. C3 is the most abundant complement component in serum. It 
is present in plasma at a concentration of about 1.0 mg/ml, but this level can be elevated 
considerably during inflammation and infection. The predominant producer of C3 is 
hepatocytes (Alper et al., 1969; Morris et al., 1982). A number of extrahepatic cells also 
produce C3, including leukocytes, fibroblasts, keratinocytes and endothelial cells (Basset-
Seguin et al., 1990; Ueki 1987).  
 
(1.5.1) C3 expression and biosynthesis  
Human C3 is coded for by a 41 kb gene located on the distal long arm on 
chromosome 19. The C3 gene is organised in 41 exons. The primary structure, deduced 
from the cDNA sequence, has 1663 amino acid residues, including a 22 amino acid signal 
peptide. The protein is synthesised as a single chain pre-pro molecule with the α-chain (992 
residues) and β-chain (645 residues) linked by a tetra-arginine sequence, which is removed 
by an enzyme during posttranslational modification. The α- and β-chains, linked by a 
disulphide bond and noncovalent forces, have molecular weight of 115 and 75 kDa 
respectively. Following translocation through endoplasmic reticulum to the Golgi, three N-
linked carbohydrate moieties are attached to the α- and β-chain (Perkins & Sim, 1986; Hase 
et al., 1985; Hirani et al., 1986; Section 1.5.3). Native C3 is a 189 kDa glycoprotein that 
contains three high-mannose type carbohydrates at Asn63, Asn917 and Asn1617. (Hirani et 
al., 1986; Miki et al., 1986; Hase et al., 1985). The α-chain carbohydrate may contain 
Man8GlcNAc2 or Man9GlcNAc2, while the β-chain may have Man5GlcNAc2 and 
Man6GlcNAc2. The carbohydrates together form about 2.3% of the molecular weight of C3. 
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In human, based on the agrose gel electrophoretic mobility of the allotypes, two major 
C3 polymorphisms have been identified (Welch et al., 1990, 1993), namely the C3 slow 
(C3S) and C3 fast (C3F) variants (R102G , N1216D in allele C3F; Figure 1.10). C3S is the 
more common allotype, with a frequency of 0.79 and 0.99 in White and Asian populations. 
Welch’s study showed that C3F had a lower activity than C3S in cell-surface binding. Bartók 
and Walport found no differences between binding of C3S and C3F to the majority of CR1, 
CR2 and CR3. (Bartók & Walport, 1995). A recent study showed the functional difference 
between C3S and C3F. In recipients of kidney transplantation who received C3F/F or C3F/S 
donor allotype graft, survival was significantly better than a C3S/S allotype (Brown et al., 
2006). C3F is also related to age-related macular degeneration (Yates et al., 2007). 
 
Likewise many other acute-phase reactants, the synthesis of C3 by hepatocytes is 
regulated by tumour necrosis factor, interleukin (IL)-1 β and interleukin-6. In addition, the 
extrahepatic C3 synthesis is regulated by cytokines of different cellular origin. Most of the 
cytokines up-regulate C3 expression and synthesis, but granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interferons inhibit basal C3 production in monocytes. 
Glucocorticoids and aldosterone also increase production of C3 in alveolar epithelial cells. 
As for rat, C3 produced by endometrium is regulated by oestrogen and progesterone (Hasty 
& Lyttle, 1992; Puy et al., 1993). 
 
(1.5.2) C3 sequence and structure 
Human C3 has 79% sequence identity to mouse C3 at the nucleotide level and 77% 
sequence identity at the amino acid level. Of the codons, 51% are unchanged and 26% have 
changed conservatively at the amino acid level. The similarity is highest in the α chain and 
lowest for the signal peptide (Figure 1.10).  
 
C3 is a member of the α2-macroglobulin (α2M) family of proteins. The proteins of 
this family have a primary function in host defense (Blandin & Levashina, 2004). All these 
proteins are relatively large (1400-1800 aa) with several marked functional features; a 
reactive thioester moiety enabling covalent attachment to target particles, and a highly 
variable central segment likely involved in recognition (Budd et al., 2004). C3, C4 and α2-
macroglobulin belong to the family (Reid & Porter, 1981). The protease α2-macroglobulin 
and complement component C4 show considerable homology to C3. The protein pairs of  
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                                      >------ MG1 ------------------------ 
C3_mouse      MGPASGSQLLVLLLLLASSPLALGIPMYSIITPNVLRLESEETIVLEAHDAQGDIPVTVT 60 
C3_rat        MGPTSGSQLLVLLLLLASSLLALGSPMYSIITPNVLRLESEETFILEAHDAQGDVPVTVT 60 
C3_cavpo      MGPAAGP--SLLLLLLASVSLALGDPMYSIITPNILRLENEETVVLEAHEVQGDIPVTVT 58 
C3_bovin      MKPTSGP--SLLLLLLASLPMALGNPMYSMITPNILRLESEETVVLEAHGGQGTIQVSVT 58 
C3_human      MGPTSGP--SLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVT 58 
        * *::*.   :*****:   :*** ****:****:****.***.:****  ** : *:** 
 
              ---------------------------- MG1 --------------------------- 
C3_mouse      VQDF-LKRQVLTSEKTVLTGASGHLRSVSIKIPASKEFNSDKEGHKYVTVVANFGETVVE 119 
C3_rat        VQDF-LKKQVLTSEKTVLTGATGHLNRVFIKIPASKEFNADK-GHKYVTVVANFGATVVE 118 
C3_cavpo      VHDFPAKKNVLSSEKTVLTSATGYLGTVTIKIPASKEFKSDK-GRKLVVVQAAFGGTQLE 117 
C3_bovin      VHDFPAKKQVLSNENTQLNSNNGYLSTVTIKIPASKELKSDK-GHKFVTVVATFGNVQVE 117 
C3_human      VHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVE 118 
        *:**  *: **:.*:* *.  ..::  * :.***.:*::::*  .* *.* * **   :* 
 
              ------Æ------------------- MG2 ------------------------------- 
C3_mouse      KAVMVSFQSGYLFIQTDKTIYTPGSTVLYRIFTVDNNLLPVGKTVVILIETPDGIPVKRD 179 
C3_rat        KAVLVSFQSGYLFIQTDKTIYTPGSTVFYRIFTVDNNLLPVGKTVVIVIETPDGVPIKRD 178 
C3_cavpo      KVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVDSDLLPVGRTIIVTIETPDGIPIKRD 177 
C3_bovin      KVVLISLQSGYLFIQTDKTIYTPGSTVLYRVFTVDHKLLPVGQTVFITIETPDGIPVKRD 177 
C3_human      KVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQD 178 
        *.*::*:********************:**:***: .*****:*:.: **.*:*:*:*:* 
 
 ---------------------------- MG2 ---------------Æ---------- 
C3_mouse      ILSSNNQHGILPLSWNIPELVNMGQWKIRAFYEHAPKQIFSAEFEVKEYVLPSFEVRVEP 239 
C3_rat        ILSSHNQYGILPLSWNIPELVNMGQWKIRAFYEHAPKQTFSAEFEVKEYVLPSFEVLVEP 238 
C3_cavpo      TLSSNNQHGILPLSWNIPELVNMGQWKIQAFYENSPKQVFSAEFEVKEYVLPSFEVLVEP 237 
C3_bovin      SKSSQNQFGILTLSWNIPELVNMGVWKIKAYYEDSPQQVFSAEFEVKEYVLPSFEVQLEP 237 
C3_human      SLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEP 238 
     **:** *:*.***:******** ***:*:**.:*:* **:************** :** 
 
   --------------------------- MG3 --------------------------- 
C3_mouse      TETFYYIDDPNGLEVSIIAKFLYGKNVDGTAFVIFGVQDGDKKISLAHSLTRVVIEDGVG 299 
C3_rat        TEKFYYIHGPKGLEVSITARFLYGKNVDGTAFVIFGVQDEDKKISLALSLTRVLIEDGSG 298 
C3_cavpo      TEKFYYIDDPKGLEVNIIARFLYGKNVDGTAFVIFGVQDGDQRISLAQSLTRVVIEDGSG 297 
C3_bovin      EEKFYYIDDPDGLKVNIIARFLYGEQVDGTAFVIFGVQDGDRRISLTHSLTRVPINDGNG 297 
C3_human      TEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSG 298 
    *.**** . .**:*.* *:****::*:********:** :::***. **.*: *:** * 
   --------------------------- MG3 ------------------Æ--------
C3_mouse      DAVLTRKVLMEGVRPSNADALVGKSLYVSVTVILHSGSDMVEAERSGIPIVTSPYQIHFT 359 
C3_rat        EAVLSRKVLMDGVRPSSPEALVGKSLYVSVTVILHSGSDMVEAERSGIPIVTSPYQIHFT 358 
C3_cavpo      EVVLSRQVLLDGVQPSRPEALVGKSLYVSVTVILHSGSDMVEAERSGIPIVTSPYQIHFT 357 
C3_bovin      EAILKRQVLLNGVQPSRADALVGKSIYVSATVILQSGSDMVEAERTGIPIVTSPYQIHFT 357 
C3_human      EVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFT 358 
        :.:*.*:**::**: . .: *****:***.****:******:***:************** 
 
              --------------------------- MG4 --------------------------- 
C3_mouse      KTPKFFKPAMPFDLMVFVTNPDGSPASKVLVVTQGSN-AKALTQDDGVAKLSINTPNSRQ 418 
C3_rat        KTPKFFKPAMPFDLMVFVTNPDGSPARRVPVVTQGSD-AQALTQDDGVAKLSVNTPNNRQ 417 
C3_cavpo      KTPKYFKPAMPFEIMVLVTNPDGSPAPHVPVVTQGSN-VQSLTQADGVARLSINTPNTRQ 416 
C3_bovin      KTPKFFKPAMPFDLMVYVTNPDGSPARHIPVVTQGSN-VQSLTQDDGVAKLSINTQNKRD 416 
C3_human      KTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQK 418 
        ****:***.***::** ********* :: *..**.: .::*** ****:**:**  .:. 
 
   ---------- MG4 -------------Æ------------ MG5 ------------- 
C3_mouse      PLTITVRTKKDTLPESRQATKTMEAHPYSTMHNSNNYLHLSVSRMELKPGDNLNVNFHLR 478 
C3_rat        PLTITVSTKKEGIPDARQATRTMQAQPYSTMHNSNNYLHLSVSRVELKPGDNLNVNFHLR 477 
C3_cavpo      PLSVTVQTKKGGIPDARQAINTMQALPYTTMYNSNNYLHLSMPRTELKPGETINVNFHLR 476 
C3_bovin      PLTITVRTKKDNIPEGRQATRTMQALPYNTQGNSNNYLHLSVPRVELKPGETLNVNFHLR 476 
C3_human      PLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLR 478 
        **::** ***  :.:..** .**:* **.*  *********: * **:**:.:**** ** 
 
   -------------------------------- MG5 ----------------------- 
C3_mouse      TDPGHEAKIRYYTYLVMNKGKLLKAGRQVREPGQDLVVLSLPITPEFIPSFRLVAYYTLI 538 
C3_rat        TDAGQEAKIRYYTYLVMNKGKLLKAGRQVREPGQDLVVLSLPITPEFIPSFRLVAYYTLI 537 
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C3_cavpo      SDPNQEAKIRYYTYLIMNKGKLLKVGRQPREPGQALVVLPMPITKELIPSFRLVAYYTLI 536 
C3_bovin      TDPGEQAKIRYYTYMIMNKGKLLKVGRQYREPGQDLVVLPLTITSDFIPSFRLVAYYTLI 536 
C3_human      MDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLI 538 
    *  .:********::****:***.*** ***** ****.:.** ::************* 
 
   ------ MG5 -----Æ------------------- MG6 ------------------ 
C3_mouse      GASGQREVVADSVWVDVKDSCIGTLVVKG----DPRDN--HLAPGQQTTLRIEGNQGARV 592 
C3_rat        GANGQREVVADSVWVDVKDSCVGTLVVKG----DPRDNR-QPAPGHQTTLRIEGNQGARV 592 
C3_cavpo      GASAQREVVADSVWADVRDSCVGTLVVKGGSGKDGQDKRQQHLPRQQMTLRIEGNQGARV 596 
C3_bovin      NAKGQREVVADSVWVDVKDSCMGTLVVKN----GGKEEK-HHRPGQQITLKIEADQGARV 591 
C3_human      GASGQREVVADSVWVDVKDSCVGSLVVKS-----GQSEDRQPVPGQQMTLKIEGDHGARV 593 
        .*..**********.**:***:*:****.   :.:  :  * :* **:**.::**** 
 
   -MG6->----------------- LNK ------------------------------- 
C3_mouse      GLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKNYAGVFMDAGLAFKTS-QGL 651 
C3_rat        GLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKNYAGVFMDAGLTFKTN-QGL 651 
C3_cavpo      GLVAVDKGVFVLNKKHKLTQSKIWDVVEKADIGCTPGSGKDYAGVFTDAGLSFKSSKAGL 656 
C3_bovin      GLVAVDKGVFVLNKKNKLTQRKIWDVVEKADIGCTPGSGRNYAGVFTDAGLTLKTS-QGL 650 
C3_human      VLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSS-SGQ 652 
    **************:**** ******************::***** ****::.:.  *  
 
   --- LNK --Æ-------------------- ANA ----------------------- 
C3_mouse      QTEQRADLECTKPAARRRRSVQLMERRMDKAGQYTDKGLRKCCEDGMRDIPMRYSCQRRA 711 
C3_rat        QTDQREDPECAKPAARRRRSVQLMERRMDKAGQYTDKGLRKCCEDGMRDIPMPYSCQRRA 711 
C3_cavpo      QTAQREGLDCPKPAARRRRSVQLMERRMDKAGKYKSKELRRCCEDGMRENPMQFSCQRRA 716 
C3_bovin      ETQQRADPQCPQPATRRRRSVQLMEKRMDKAGQYSS-DLRKCCEDGMRDNPMKFPCQRRA 709 
C3_human      QTAQRAELQCPQPAARRRRSVQLTEKRMDKVGKYPK-ELRKCCEDGMRENPMRFSCQRRT 711 
        :* **   :*.:**:******** *:****.*:* .  **:*******: ** :.****: 
 
   ---------------- ANA -----------------Æ------- α’NT --Æ---- 
C3_mouse      RLITQGENCIKAFIDCCNHITKLREQHRRDHVLGLARSELEEDIIPEEDIISRSHFPQSW 771 
C3_rat        RLITQGESCLKAFMDCCNYITKLREQHRRDHVLGLARSDVDEDIIPEEDIISRSHFPESW 771 
C3_cavpo      RYVSLGEACVKAFLDCCTYMAQLRQQHRREQNLGLARSDMDEDIIPEEDIISRSQFPESW 776 
C3_bovin      QFILQGDACVKAFLDCCEYITQLRQQHSRDGALELARSDLDDDIIPEEDIISRSQFPESW 769 
C3_human      RFISLGEACKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESW 771 
        : :  *: * *.*:*** ::::**.** *   * ****::::***.**:*:***.**:** 
 
   ---------------------------- MG6 ---------------------Æ---- 
C3_mouse      LWT-IEELKEPEKNGISTKVMNIFLKDSITTWEILAVSLSDKKGICVADPYEIRVMQDFF 830 
C3_rat        LWT-IEELKEPEKNGISTKVMNIFLKDSITTWEILAVSLSDKKGICVADPYEITVMQDFF 830 
C3_cavpo      LWT-IEELKEPERNGISTKTMNIFLKDSITTWEILAVSLSDKKGICVADPFEVTVMQDFF 835 
C3_bovin      LWTVIEDLKQADKNGISTKLMNVFLKDSITTWEILAVSLSDKKGICVADPYEVTVMQDFF 829 
C3_human      LWN-VEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFF 830 
        **. :*:**:. :****** **:***************:***********:*: ****** 
 
   ------------------------- MG7 ----------------------------- 
C3_mouse      IDLRLPYSVVRNEQVEIRAVLFNYREQEELKVRVELLHNPAFCSMATAKNRYFQTIKIPP 890 
C3_rat        IDLRLPYSVVRNEQVEIRAVLFNYREQEKLKVRVELLHNPAFCSMATAKKRYYQTIEIPP 890 
C3_cavpo      IDLRLPYSVVRNEQVEIRAVLYNYREAQSLKVRVELLHNPAFCSLATAKKRHTQTVTIGP 895 
C3_bovin      IDLRLPYSVVRNEQVEIRAILYNYREAENLKVRVELLYNPAFCSLATAKKRHQQTITIPA 889 
C3_human      IDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPP 890 
        *******************:*:***: :.********:******:**:*.*: **: * . 
 
   ------------- MG7 ------------------------Æ------- CUB ---- 
C3_mouse      KSSVAVPYVIVPLKIGQQEVEVKAAVFNHFISDGVKKTLKVVPEGMRINKTVAIHTLDPE 950 
C3_rat        KSSVAVPYVIVPLKIGLQEVEVKAAVFNHFISDGVKKILKVVPEGMRVNKTVAVRTLDPE 950 
C3_cavpo      KSSVAVPYVLVPLKIGLQEVEVKAAVYNYFISDGVKKTLKVVPEGMRVNKTVAIRTLNPE 955 
C3_bovin      RSSVAVPYVIVPLKIGLHEVEVKAAVYNHFISDGVKKTLKVVPEGVRVNKTVAVRTLNPE 949 
C3_human      KSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPE 950 
        :**::****:**** * :********:::******:* *******:*:*****::**:** 
 
 
 
   ---------------- CUB ----------------Æ-------- TED -------- 
C3_mouse      KLGQGGVQKVDVPAADLSDQVPDTDSETRIILQGSPVVQMAEDAVDGERLKHLIVTPAGC 1010 
C3_rat        HLNQGGVQREDVNAADLSDQVPDTDSETRILLQGTPVAQMAEDAVDGERLKHLIVTPSGC 1010 
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C3_cavpo      QLGQGGVQREEIPAADLSDQVPDTDSETKILLQGTPVAQMAEDAVDAERLKHLIITPSGC 1015 
C3_bovin      HLGQGGVQREEVPAADLSDQVPDTESETKILLQGTPVAQMTEDAIDGERLKHLIQTPSGC 1009 
C3_human      RLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGC 1010 
        :*.: ***: :: .**********:***:*:***:**.**:***:*.******* **:** 
 
   --------------------------- TED ---------------------------- 
C3_mouse      GEQNMIGMTPTVIAVHYLDQTEQWEKFGIEKRQEALELIKKGYTQQLAFKQPSSAYAAFN 1070 
C3_rat        GEQNMIGMTPTVIAVHYLDQTEQWEKFGLEKRQEALELIKKGYTQQLAFKQPISAYAAFN 1070 
C3_cavpo      GEQNMIGMTPTVIAVHYLDQTEQWEKFGLEKRQEALNLINRGYTQQLAFKQPNWAYAAFK 1075 
C3_bovin      GEQNMIGMTPTVIAVHYLDSTDQWEKFGLEKRQESLELIRKGYTQQLAFRQKSSAYAAFQ 1069 
C3_human      GEQNMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFV 1070 
        *******************.*:******:**** :*:**.:********:*   *:***  
 
   --------------------------- TED ---------------------------- 
C3_mouse      NRPPSTWLTAYVVKVFSLAANLIAIDSHVLCGAVKWLILEKQKPDGVFQEDGPVIHQEMI 1130 
C3_rat        NRPPSTWLTAMWSRSFSLAANLIAIDSQVLCGAVKWLILEKQKPDGVFQEDGPVIHQEMI 1130 
C3_cavpo      NRASSTWLTAYVVKVFSLAANLIGIDSEVLCGAVKWLILEKQKPDGVFQEDGPVIHQEMI 1135 
C3_bovin      YRPPSTWLTAYVVKVFALAANLIAIDSKDLCETVKWLILEKQKPDGIFQEDGPVIHQEMI 1129 
C3_human      KRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMI 1130 
    *..******   : *:**.***.***. ** :*************:****.******** 
 
   --------------------------- TED ---------------------------- 
C3_mouse      GGFRNAKEADVSLTAFVLIALQEARDICEGQVNSLPGSINKAGEYIEASYMNLQRPYTVA 1190 
C3_rat        GGFRNTKEADVSLTAFVLIALQEARDICEGQVNSLPGSINKAGEYLEASYLNLQRPYTVA 1190 
C3_cavpo      GGVRTAQEADVSLTAFVLIALQEAKDICRAQVNNLEANINKAGDYIESRYADVRRPYTLA 1195 
C3_bovin      GGFRDTREKDVSLTAFVLIALHEAKDICEAQVNSLGRSIAKAGDFLENHYRELRRPYTVA 1189 
C3_human      GGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVA 1190 
        **.*  .* *::*******:*:**:***. ***.*  .* ***:::*  * :::*.**:* 
 
   --------------------------- TED ---------------------------- 
C3_mouse      IAGYALALMNKLEEPYLGKFLNTAKDRNRWEEPDQQLYNVEATSYALLALLLLKDFDSVP 1250 
C3_rat        IAGYALALMNKLEEPYLTKFLNTAKDRNRWEEPGQQLYNVEATSYALLALLLLKDFDSVP 1250 
C3_cavpo      IAGYALALLERLNGATLQKFLNAATEKNRWEEARQKLYSVEATSYALLALLLLKDFDAVP 1255 
C3_bovin      IAAYALALLGKLEGDRLTKFLNTAKEKNRWEEPNQKLYNVEATSYALLALLARKDYDTTP 1249 
C3_human      IAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVP 1250 
        **.**** : :*:   * ***.:*.::****:. ::**.************  **:* .* 
 
   ---------------- TED -----------------Æ----- CUB ---------- 
C3_mouse      PVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQTDVPDHKDLNMDVSFHLPSRSSATTFR 1310 
C3_rat        PVVRWLNDERYYGGGYGSTQATFMVFQALAQYRADVPDHKDLNMDVSLHLPSRSSPTVFR 1310 
C3_cavpo      PVVRWLNEQRYYGRGYGSTQATFMVFQALAQYQTDVPDHKDLNMEVALQLPSRSSPSKFR 1315 
C3_bovin      PVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDVPDHKELNLDVSIQLPSRNSAVRHR 1309 
C3_human      PVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHR 1310 
        *******::**** ******************: *.***::**::*:::****.*   .* 
 
              ------------------ CUB ---------------------Æ-------------- 
C3_mouse      LLWENGNLLRSEETKQNEAFSLTAKGKGRGTLSVVAVYHAKLKSKVTCKKFDLRVSIRPA 1370 
C3_rat        LLWESGSLLRSEETKQNEGFSLTAKGKGQGTLSVVTVYHAKVKGKTTCKKFDLRVTIKPA 1370 
C3_cavpo      LVWEAGSLLRSEATKQNEGFKLTAKGKGQGTLSVVAVYYAKTKRKVVCKNFDLRVTLKPA 1375 
C3_bovin      ILWESASLLRSEETKENERFTVKAEGKGQGTLSVVTVYHAKLKGKVSCKKFDLRVSIRPA 1369 
C3_human      IHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPA 1370 
        : ** ..***** **:** *.:.*:***:******::*:** * :  *::***:*:::** 
 
   ---------------------------- MG8 --------------------------- 
C3_mouse      PETAKKPEEAKNTMFLEICTKYLGDVDATMSILDISMMTGFAPDTKDLELLASGVDRYIS 1430 
C3_rat        PETAKKPQDAKSSMILDICTRYLGDVDATMSILDISMMTGFIPDTNDLELLSSGVDRYIS 1430 
C3_cavpo      PDTVKKPQEAKSTMILGICTRYLGDQDATMSILDISMMTGFIPDTDDLKLLATGVDRYIS 1435 
C3_bovin      PETVKKPQDAKGSMILDICTKYLGDQDATMSILDISMMTGFSPDVEDLKTLSTGVDRYIS 1429 
C3_human      PETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYIS 1430 
        *:* *:*::**.:*:* ***:* ** *************** **..**: *:.******* 
 
 
 
   ---------------------------- MG8 --------------------------- 
C3_mouse      KYEMNKAFSNKNTLIIYLEKISHTEEDCLTFKVHQYFNVGLIQPGSVKVYSYYNLEESCT 1490 
C3_rat        KYEMDKAFSNKNTLIIYLEKISHSEEDCLSFKVHQFFNVGLIQPGSVKVYSYYNLEESCT 1490 
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C3_cavpo      KYEMNKDFS-KNTLIIYLDKVSHSEEECLSFKIHQFFNVGLIQPGSVKVYSYYNLDETCT 1494 
C3_bovin      KYEMNRDSN-KNTLIIYLDKVSHTVEDCLSFKVHQYFNVGLIQPGAVKVYSYYNLDETCI 1488 
C3_human      KYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCT 1490 
        ***:::  . :*******:*:**: ::**:**:**:*** *****:****:****:*:*  
 
   --Æ-------- Anchor ----Æ-------------------- C345c ------- 
C3_mouse      RFYHPEKDDGMLSKLCHSEMCRCAEENCFMQQSQEKINLNVRLDKACEPGVDYVYKTELT 1550 
C3_rat        RFYHPEKDDGMLSKLCHNEMCRCAEENCFMHQSQDQVSLNERLDKACEPGVDYVYKTKLT 1550 
C3_cavpo      QFYHPEKEDGMLNKLCHKDLCRCAEENCFIQLP-EKITLDERLEKACEPGVDYVYKTKLL 1553 
C3_bovin      RFYHPDKEDGMLSKLCHKDTCRCAEENCFMHHTEKEVTLEDRLDKACEPGVDYVYKTRLI 1548 
C3_human      RFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLV 1550 
        :****:*:** *.***:.: *********:: . .::.*: **:*************.*  
 
 
   --------------------------- C345c ------------------------- 
C3_mouse      NIKLLDDFDEYTMTIQQVIKSGSDEVQAGQQRKFISHIKCRNALKLQKGKKYLMWGLSSD 1610 
C3_rat        TIELSDDFDEYIMTIEQVIKSGSDEVQAGQERRFISHVKCRNALKLQKGKQYLMWGLSSD 1610 
C3_cavpo      KMELSDDFDEYIMTIEQVIKSGSDEVQAGKERRFISHIKCRDALHLKEGKHYLMWGLSSD 1613 
C3_bovin      QKKLEDDFDEYIMVIENIIKSGSDEVQVKQERKFISHIKCREALKLKEGAHYLVWGVSSD 1608 
C3_human      KVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSD 1610 
    :* :***** *.*:: *********. ::* *** :***:**:*::  :**:**:*** 
 
 
   --------------------------- C345c ------------------------- 
C3_mouse      LWGEKPNTSYIIGKDTWVEHWPEAEECQDQKYQKQCEELGAFTESMVVYGCPN 1663 
C3_rat        LWGEKPNTSYIIGKDTWVEHWPEAEERQDQKNQKQCEDLGAFTETMVVFGCPN 1663 
C3_cavpo      LWGERPNMSYIIGKDTWVEAWPEAEECQDEENQQQCQDLGTFTENMVVFGCPN 1666 
C3_bovin      LWGEKPKISYIIGKDTWVELWPEAEECQDEENQKQCEDLANFTENMVVFGCPN 1661 
C3_human      FWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN 1663 
              :***:*: *********** *** :* **:: *:**::*. ***.***:**** 
 
 
Figure 1.10 The sequence alignment for C3 from five different species. Sequences were 
aligned using Clustal W (Thompson et al., 1994). The signal peptides are included (before 
MG1). The α-chain includes ANA domain (residue human 665) and onwards. The thioester 
is formed by the side chain of the highlighted red residues in TED domain (Tack et al., 
1980; Thomas et al., 1982). The C3S and C3F variant is highlighted in cyan. The NCBI 
accession numbers are: C3_mouse P01027; C3_rat P01026; C3_cavpo (guinea pig) P12387; 
C3_bovin Q2UVX4 and C3_human P01024. Secondary structure elements refer to human 
C3. 
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human C3/C4 and C3/α2M have ≈29% and ≈23.5% amino acid identity. The anaphylatoxins 
C3a and C4a are very similar; all six cysteine residues are conserved. The sites of activation 
at the COOH termini of C3a and C4a are not conserved in α2M, but the locations of the 
thioester sites are almost identical. This further emphasises the high degree of similarity 
among the three proteins. They have evolved from a common ancestor (De Bruijn & Fey, 
1985). 
 
The crystal structures of human complement components C3 have been determined 
(Janssen et al., 2005). The structure of C3 displays an intricate arrangement of 13 domains. 
The core of C3 is formed by eight homologous macroglobulin (MG) domains, together with 
a thioester-containing domain (TED) domain containing the C3 active site, a C1r/C1s-Uegf-
Bmp1 (CUB, protein module initially found in “complement subcomponents C1r/C1s, Uegf 
and Bone morphogenetic protein-1”) domain that links the TED and MG domains, and the 
C345C, LNK and anaphylatoxin domains. In C3b, the anaphylatoxin domain (C3a) is lost. 
So far, four linkages of disulphide bridge were determined in the C3a part of C3, and a 
single bridge was determined in the β-chain as well as in the C3d part of the α-chain 
(Janssen et al., 2005). The N- and C-terminal regions of the α-chain were found to be 
connected with each other with a disulphide bridge. 
 
The first five domains, MG1-5, are formed by residues of the β-chain, residues 1-
534 (Figure 1.11). MG6 is formed by residues from the intertwined β- and α-chain, where 
residues 535-577 of the β -chain form one half and residues 578 - 642 of the α-chain form 
the other half. An insertion is located in MG6 and is formed by residues 578-745. This 
segment includes the linker region (LNK), the tetra-arginine pro-C3 processing site, the 
anaphylatoxin (ANA) domain and a linker (α’NT) that connects the ANA domain back to 
MG6. The last two MG domains, MG 7-8, on the α–chain, are separated by the CUB 
domain and the thioester-bond containing (TED) domain, and the carboxy-terminal 170 
residues form the ‘anchor region’ and the C345C domain. 
 
The eight MG domains without sequence homology exhibit a fibronectin-type-3-like 
core fold (Figure 1.12). MG8 corresponds to the receptor-binding domain in α2M; as 
expected, the structure of MG8 is homologous to this domain. The MG1-6 domains form 1.5 
turns of helical coil as in a key ring (Figure 1.13). MG7 and MG8 on the α-chain are outside 
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Figure 1.11  Domain sequence and arrangements in C3. Thioester site shows as white 
triangle, disulphide bridges are connected (adapted from Janssen et al., 2005). The first 
residue of β-chain is labelled as “1”. The colours matches Figure 1.10. 
 
 
Figure 1.12 An MG domain (Janssen et al., 2005).  
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Figure 1.13 The crystal structure of C3. INSIGHT II 98.0 molecular graphics software 
(Accelrys, San Diego, CA, USA) was used to create the ribbon structure from PDB entry 
2a73 (Janssen et al., 2005). 
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of the key ring structure. They are close to each other and mismatch slightly in C3.  
 
LNK, ANA and α’NT domains are the insertions between MG6β and MG6α. The 
LNK domain is wedged in between domains MG1, MG4 and MG5. It has three aromatic 
residues from the third helix and a β-strand forms a small hydrophobic core. The ANA 
domain when cleaved off forms the C3a fragment. The structure of this domain in C3 is 
similar to the crystal structure of C3a. Following this, there is a scissile bond Arg 726- Ser 
727 in a disordered loop and an extended loop (residue 730-745) that connects ANA to 
MG6. Loop 727-745 is referred as α’NT. The geometric arrangements of these insertions 
are very interesting. The insert loops completely through the central hole formed by the 
MG1-6 domains. C3 appears as two chains that are intertwined in domain MG6. The C-
terminus of the β-chain and N-terminus of the α-chain are far apart; there is a gap of 5.3 nm 
between the last β residue (Pro-643) and first α residue (Val-651).  
 
Residues 913-1334 form a segment that inserts between domains MG7 and MG8. 
These residues form the CUB domain and the TED domain. The TED domain itself 
(residues 963-1268) is inserted in loop of the CUB domain. Consequently, CUB is an 
intertwined domain consisting of two distinct parts of the polypeptide chain (residues 912-
962 and 1269-1330). The cleavage fragments C3d, C3g and C3f are part of this CUB-TED 
insert. 
 
At the C-terminal end the C345C domain foms a knob-like protrusion (Figure 1.13). 
This is connected to MG8 via a short anchor region. The feature is shared in Complement 
proteins C3, C4 and C5, and not known in any other members of the α2M family. The 
anchor region links the C345C domain both to the MG7 domain, by a disulphide bridge, 
and to the MG8 domain by the polypeptide chain.  
 
 (1.5.3) Function of C3 in complement 
Human C3 in the humoral immune system plays at least three different biological 
functions. Firstly, the activation of C3 leads to target cell lysis through the complement 
activation pathways. The initiation of C3 cleavage leads to covalent C3b deposits onto 
target cell surfaces, thus leading to the membrane-attack complex on target cells. Secondly, 
human C3 is involved in antigen presentation and consequently facilitates cellular immune 
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response. It has been shown that cross-linking of C3b to tetanus toxin reduces the amount 
of antigen required to induce specific T cell responses (Rey-Millet et al., 1994). Thirdly, C3 
functions in cell regulation. During C3 activation, different C3 fragments are generated that 
react with specific cell-surface receptors, such as C3aR, CR1, CR3, CR4 and CR2, 
consequently to trigger regulation of cellular functions. As a result, normal cells or tumour 
target cells against autologous complement lysis by preventing deposition of activated C3b 
on their surface. 
 
(1.5.4) C3 mutations and disease 
Since 1972, inherited C3 deficiency has been described in a variety of ethnic and 
national origins (Singer et al., 1994a, 1994b). Most patients show a heightened 
susceptibility to bacterial infections, thus leading to purulent lesions. C3 deficiency 
normally leads to impaired chemotactic activity, slow response of neutrophils to infectious 
agents and a series of immune complex diseases, such as systemic lupus erythematosus and 
membrane proliferative glomerulonephritis. In patients, defective antibody responses were 
observed, which suggests C3 may be critical in the generation of normal immune response 
(Singer et al., 1994a, 1994b; Bitter-Suermann & Burger, 1990). 
 
Recently, the molecular genetic basis of C3 deficiency has been examined. There 
are at least six types of mutations. Two of the patients show point mutations at 5’-donor 
splice sites in the C3 gene. An English male has a site mutation in intron 18 of C3 gene. 
The mutation generates a 61-nucleotide deletion in the C3 RNA during RNA processing. 
The deletion causes a shift in reading frame of the C3 transcript and a premature stop in 
translation (Botto et al., 1990). The other site mutation described in a Taiwanese aboriginal 
female (Huang & Lin, 1994): a 5’-donor splice site mutation in intron 10 causes exon 10 to 
be skipped during RNA processing, consequently a premature stop codon was generated. A 
third case is from the Afrikaaner population of South Africa (Botto et al., 1992), where an 
inherited C3 deficiency found in a family carries an 800 bp deletion in the C3 gene 
(includes exons 22 and 23). A fourth case is a missense mutation in exon 13 that results in a 
critical amino acid substation in C3 β-chain (Asp549 to Asn). This Asn549 substitution causes 
impaired secretion of the intracellular C3 proteins (Singer et al., 1994a, 1994b). A C3 
deficiency also was found in a Laotian family and results from reduced levels of C3- 
specific mRNA (Singer et al., 1996), although the exact molecular genetic defect for the 
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fifth case is yet to be clarified. The sixth case is reported recently in relation to atypical 
haemolytic uremic syndrome (aHUS) (Frémeaux-Bacchi et al., 2008). Nine mutations were 
found in aHUS patients with low serum C3 level. There were eight heterozygous missense 
mutations, R570W, R570Q, R713W, A1072V, D1093N, C1136W, Q1139K, and H1142D 
and one heterozygous nonsense mutation Y832X. By cofactor activity assay, five of these 
mutations have decreased binding affinity with MCP and two have normal binding affnity, 
therefore C3 could be a susceptibility factor for aHUS. 
 
(1.5.5) C3 fragments  
In three complement pathways, the enzyme complex C3-convertase activates C3 by 
the proteolytic cleavage of C3 into C3a (= ANA) and C3b (remaining 12 domains). C3a is a 
vasoactive peptide and a mediator of inflammation (Hugli, 1975, 1981). The removal of C3a 
induces a conformational change in the C3b portion of molecule. The α’NT domain shifts 
from one face of the protein to the other; as a consequence, the MG8, CUB and TED domain 
undergo a large relocation in relation to the protein core MG1-6 (Janssen et al., 2006). 
Furthermore, relocation leads to the exposure of an internal thioester bond, which is buried 
and quite inaccessible in native C3. By this thioester bond, C3b could covalently bind to the 
cell by an ester or amide bond and thus ultimately lead to formation of the membrane-attack 
complex on target cells, thus inducing inflammation and elimination of self and non-self 
targets. 
  
Without any enzyme present, C3 is also continuously activated at a slow rate in the 
fluid phase to become C3u (C3(H2O)). C3u can be activated by enzyme complexes which 
cleave C3 into anaphylatoxin C3a and the major fragment C3b. It has structural and a 
functional similarity with C3b. C3a consists of the first 77 amino acids of the α-chain of C3 
and mediates inflammation (Bokisch et al., 1969; Figure 1.11). C3b is a 179 kDa protein 
and can covalently attach to antigen surfaces as a component of C3 and C5 convertases, and 
modulate the activities of the C3b as an opsonin for cellular receptors. Subsequent 
proteolysis of C3b results in the formation of the fragments iC3b and C3f, and finally the 
two fragments C3dg and C3c (Figure 1.11). iC3b and C3dg may stimulate B-cells providing 
a link between the innate and adaptive immune response (Caroll, 2004). C3f is a weak 
spasmogen that functions like C3a anaphylotoxin (Ganu et al., 1989). C3d contains the 
thioester-forming residues, and is equivalent to the TED domain (residues 1205-1214) of C3 
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(Figure 1. 11). C3d is less accessible in C3 and C3b, so that these molecules have low 
affinity for CR2. C3d can be covalently attached to an antigen, and has the ability to 
significantly lower the amount of antigen required to elicit an antibody response (Dempsy et 
al., 1996; Green et al., 2003).  
 
(1.5.6) Structure of C3b and C3u 
So far, five C3b crystal structures are available (Janssen et al., 2006; Wiesmann et 
al., 2006; Wu et al., 2009; Rooijakkers et al., 2009; Ajees et al., 2006). In C3b, four crystal 
structures show that the TED and CUB domains are extended along the major axis of the 
MG domains and in contact with these MG domains (Janssen et al., 2006; Wiesmann et al., 
2006; Wu et al., 2009; Rooijakkers et al., 2009), while a fifth deviant crystal structure 
shows that the TED and CUB domains are significantly extended away from the MG 
domains (Ajees et al., 2006). Even though the crystallographic evidence for the fifth C3b 
structure was disputed, the criticisms of this structure were not accepted (Janssen et al., 
2007; Ajees et al., 2007). Most recently, the Ajees et al. crystal structure was reported to be 
falsified (Borrell, 2009). Electron microscopy studies of C3b in vacuo also supported the 
location of the TED and CUB domains seen in the four C3b crystal structures (Nishida et 
al., 2006). H-D exchange rates that were measured in mass spectrometry studies of C3 and 
C3b indicated that a large conformational change occurs between these two proteins, while 
C3u and C3b show similarities with each other except the additional anaphylatoxin domain 
(Schuster et al., 2008). 
 
 An unresolved question in relation to C3b is whether there is any basis for the 
deviant C3b structure. Another involves the structural transition between C3 and C3b. 
Recent developments in X-ray scattering have resulted in considerably improved signal-
noise ratio at the ESRF facility, alongside with constrained modelling methods that result in 
structural determinations that are deposited in the Protein Data Bank (Bonner et al., 2009; 
Perkins et al., 2009). In Chapter 5, I combine analytical ultracentrifugation and X-ray 
scattering to show that conformational and self-association differences exist between C3 and 
C3u, and apply constrained modelling to determine their best-fit solution structures, in order 
to reveal new insights into C3 activation.  
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(1.6) Factor H 
In the alternative pathway, Factor H (FH) has cofactor activity converting C3b to 
iC3b. It is found at the RCA gene cluster (same as CR2) and encoded by a single gene 
(HF1) (Rodriguez de Córdoba et al., 1999). It is a 155 kDa glycoprotein (Fenaille et al., 
2007) that circulates in human plasma at a concentration of 235 – 810 µg/ml (Saunders et 
al., 2006). The polymorphism Tyr402His of FH is a major risk factor for developing age-
related macular degeneration (AMD). AMD is the most common cause of visual 
impairment in the elderly in Western countries. 
 
FH is mainly produced by the liver (Schwaeble et al., 1987) as a single chain 
molecule of 1231 amino acid residues (Ripoche et al., 1988). The first 18 amino acid is the 
signal peptide; after secretion, the mature human FH contains 1213 amino acid residues. 
Like CR2, FH contains multiple SCR domains, with only β-strands and no α-helix in the 
secondary structure (Morikis & Lambris, 2005). There are 20 SCR domains with 19 
flexible linkers (3-8 residues) between domains (Figure 1.14a). SCR domains have 
conserved four Cys and a Trp, with an exception at SCR 10. Two disulphide bonds are 
present in the pattern of Cys1-Cys3 and Cys2-Cys4. There are also glycine, proline and 
tyrosine conserved in the SCR sequences (Aslam & Perkins, 2001; Morikis & Lambris, 
2005; Saunders, et al., 2006). FH is heavily glycosylated including Asn217 in SCR-4, 
Asn529 in SCR-9, Asn718 in SCR-12, Asn802 in SCR-13, Asn822 in SCR-14, Asn882 and 
Asn911 in SCR-15, Asn1029 in SCR-17, and Asn1095 in SCR-18 (Figure 1.14). Except the 
site at Asn217, the other eight sites are proved to be glycosylated by diantennary 
disialylated glycans of 2204 Da by mass spectrometry (Fenaille et al., 2007). 
 
(1.6.1) Self-association of Factor H 
FH oligomerisation in solution was first identified in 1991(Perkins et al., 1991). So 
far several FH fragments have been reported to self-associate. Dimers of fragment SCR 15-
18 and SCR 15-20 have been seen in non-reducing sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and Western blotting analysis (Jokiranta et al., 2000). An 
interaction between the FH N-terminal fragment SCR 1-7 and intact FH was observed by 
SPR (Oppermann et al., 2006). Fragment SCR 6-8 and 16-20 in solution has been found to 
self-associate in AUC analyses (Fernando et al., 2007; Okemefuna et al., 2008). Polyanion  
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Figure 1.14 A schematic diagram of FH binding sites (adapted from Okemefuna, 2009a). 
(a) Schematic view of the 20 SCR domains of FH with different ligands binding sites for 
some C3 fragments. The first region also has decay acceleration and cofactor activity 
(yellow coloured domains). Two heparin-binding sites on SCR-7 and SCR-20 (black), and 
eight putative N-linked glycosylation sites (Y) are shown. (b) FH has flexible beads-on-
string domain arrangement (PDB code 3GAV, Okemefuna et al., 2009a).  
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such as dextran sulphate or heparin was suggested to induce FH to form tetramers on SCR 18-
20 (Pangburn et al., 2009).  
 
The most recent study showed that a reversible monomer-dimer equilibrium of 
intact FH exists up to 1.3 mg/ml, and then more oligomers appear with increased 
concentration (Nan et al., 2008b). Similar studies were carried out in a range of NaCl 
concentrations and pH values. The proportions of FH monomer, dimer and higher oligomers 
in 137 mM NaCl were about 84%, 8% and 8% (Okemefuna et al., 2009a). Both studies 
showed dissociation constant KD value of 16 - 28 µM at pH 7.4, 137 mM NaCl with dimer 
5% to 23% in blood. The FH oligomer formation study indicates that the regulatory role of 
FH will be affected by the local environment and its effect on FH oligomers.  
 
(1.6.2) C3b binding to Factor H 
The partially folded-back arrangement of 20 SCR domains in FH also showed a 
dependence on electrostatic effects (Okemefuna et al., 2009a). This may be important for 
the mechanism of its regulatory action through interaction with C3b. The complement 
amplification step is initiated by the formation of the C3 convertase through the binding of 
factor B to C3b and subsequent proteolytic activation of factor B. FH is the regulation the 
alternative pathway of C3 convertase C3bBb and its C3b component, both in plasma and on 
host cell surface (Pangburn et al., 1977; Whaley & Ruddy, 1976). FH and factor I prevent 
convertase formation and trigger the proteolytic inactivation of C3b. FH regulates surface-
bound C3b activity by recognising charge clusters on the surfaces that are mimicked by 
heparin, then it makes the initial contact with target through the C-terminal SCR-20 
(Oppermann et al., 2006; Ferreira et al., 2006).  
 
There are three C3b binding sites on FH (Figure 1.14a). C3b binds with FH N-
terminal domain SCRs 1-4, where the cofactor and decay accelerating activities of FH are 
located. The second site is on FH SCR-6/10, where it binds to the C3c region of C3b. A 
third site within SCR-16/20 binds to the C3d region of C3b (Lambris et al., 1988; Sharma 
& Pangburn, 1996; Jokiranta et al., 2000; 2001). The known heparin binding sites are SCR 
7, SCR 13 and SCR 20 (Blackmore et al., 1998; Pangburn et al., 1991). It is possible that 
these three binding sites for C3b are not independent of each other but work to bind C3b in 
a synergistic manner. The stoichimetry of C3b and FH may not be a simple 1:1 complex.  
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 In the alternative pathway, SCR 1-4 may compete with fragment Bb to bind to C3b 
on the same region (Wu et al., 2009). A previous study showed that the α’NT and MG7 
regions may be a primary binding site for FH. (Wu et al., 2009). The second main binding 
site may involve a conserved hydrophobic residues surrounded by hydrophilic residues on 
SCR2 that interact with MG6 of C3b. Finally, the hypervariable loop of SCR3 of FH may 
interact with the CUB domain of C3b, because on the crystal structure of SCR 1-4 with 
C3b, the SCR2-SCR3 part of FH bound to C3b, with the hypervariable loop of SCR3 
directly contacting the CUB domain. A molecular understanding of the FH-C3b complex 
requires the dissection of the role of each of these C3b sites on FH. 
 
C3d is similar to the TED part of C3 with a negative surface charge. Surface 
plasmon resonance analysis in 50 mM and 75 mM NaCl indicated that C3d binds weakly to 
FH and the FH-related proteins FHR-3 and FH-4 with dissociation constants KD of 0.09-
0.36 µM (Hellwage et al., 2002). FH-C3d multimers with possible stoichimetries of 1:1, 
2:1 or 2:2 have been seen in both the solution and surface phases using physiologically-
relevant concentrations and different salt concentration buffers (Okemefuna et al., 2008). 
Because FH binds with C3d part of C3b on SCR 19/20, the knowledge of C3d-FH indicates 
that the C3b-FH interaction is comparatively weak. 
 
 From surface plasma resonance, we knew that the interaction between C3b and FH 
is relatively weak (Schmidt et al., 2008). Studies of the complex of C3d-FH will help us 
understand the possibility of how C3b binds with FH in solution. In this thesis, insight into 
C3b interaction with FH was obtained by studying the interaction between C3 and C3u in 
different salt concentration (Chapter 5) and likewise with FH present to alter the strength of 
the C3u-FH interaction in solution (Chapter 6). The effect of ionic strength on these 
interactions provides new insight into complement regulation and host protection. 
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(2.1) Introduction to protein structure determination techniques  
Over the past few decades, much research efforts has been dedicated to protein 
structure determination. It was realised that the structural information for proteins contained 
a wealth of biomedical information, which among other things assists in the development of 
new drugs for all kinds of diseases. Several techniques have been developed to determine 
protein structures.  
 
 Protein amino acid primary structure can be determined directly by mass 
spectrometry, or Edman degradation, Sanger’s reagent or Dansyl chloride methods. It can 
also be determined indirectly through sequencing the protein genes or cDNA.  The secondary 
structure of a protein can be determined by circular dichroism (CD), Fourier transform 
infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy (Latham 
et al., 2005). For protein tertiary structure, there are techniques with low or high structural 
resolution. The low resolution techniques (details of 2-4 nm) include analytical 
ultracentrifugation (AUC), small angle X-ray and neutron scattering (SAXS and SANS; 
Chapter 3) and electron microscopy (EM). The high resolution techniques include nuclear 
magnetic resonance (NMR) and X-ray crystallography. Overall, each structural determination 
technique has its advantages and disadvantages. Usually the one which can provide the 
highest resolution structural information is applied, depending on the system of interest.  
 
AUC, SAXS and SANS are popular methods to study macromolecules in 
solution. AUC has advantages for studying the sizes and shapes of macromolecules, in 
particular the state of oligomerisation. SAXS and SANS can study macromolecules in 
solutions by the diffraction of X-ray or neutrons respectively. The structural resolution 
of AUC, SAXS and SANS can be improved to medium levels (0.5-1.0 nm) if combined 
with biomolecular modelling methods. 
 
EM is a low resolution technique that the operating principles is similar to light 
microscopy, except it uses a beam of electrons and magnetic lense to visualise the 
conformation of protein molecules. The greater resolution of EM compared to light 
microscopy is because of its usage of electron wavelengths about 100,000 times shorter 
than visible light. However, the high level of electron radiation may damage the protein 
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sample.  In addition, samples of hydrated materials have to be prepared in various ways in 
order to stabilise them, and to increase their electron optical contrast (staining) to permit 
visualisation in vacuo. These processes may result in damage to distort the protein 
structures, particularly their structural arrangement in physiological condition. Hence 
structural information obtained under such harsh conditions may not fully represent the 
protein’s native conformation. Furthermore, low signal-to-noise ratio means that structural 
information from several images have to be combined and averaged, thus this creates 
difficulties in presenting highly flexible structures. This is particularly true for flexible 
multiple domain molecules with variable interdomain linkers such FH, CR2 and CR1.  
 
NMR is a field of spectroscopy based on the absorption of electromagnetic radiation 
in the radio-frequency region. It provides information on the topology, dynamic and three-
dimensional structure of molecules in solution. In biology, NMR uses the magnetic 
properties of some nuclei, mostly 1H, 15N and 13C. When a strong magnetic field is applied 
to a protein solution, the net spin aligns in the direction of the field. Then a second 
magnetic field is applied to the sample, and perpendicular to the direction of the first field. 
The nuclei are excited. When the nuclei return to their original alignment, radiation is 
emitted. This dependence of nuclear magnetic energy levels on the local electronic 
environment is known as the chemical shift. NMR experiments apply magnetic fields at 
different radio frequencies to labelled or non-labelled protein samples, and monitor their 
chemical shifts. Currently, multinuclear NMR permits the assignment of chemical shifts to 
specific nuclei, and Nuclear Overhauser effects are used to determine spatial restraints 
between atoms. Informations from them allow three dimensional models to be created for 
the protein structure (Wüthrich, 1986). NMR studies require protein molecules equivalent 
or smaller than 35 kDa, therefore it is an inappropriate technique for studying the intact 
form of relatively large proteins such as FH or CR2. 
 
X-ray crystallography is a technique of determining the arrangement of atoms by 
interpreting the diffraction of X-rays from the repeating unit cells that constitute the crystal 
lattice. Protein crystals are fragile and maintained by weak hydrogen bond and ionic forces. 
Proteins with flexible conformations and many glycosylation sites are sometime hard to 
crystallise. It is difficult to grow intact CR2 and FH crystals for both reasons. Provided the 
protein crystals can be grown, this method can yield high resolution structures (0.1-0.3 nm). 
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Crystals are exposed to a monochromatic, collimated X-ray beam, diffraction data are 
acquired, and electron density maps are calculated, to which the structure is fitted.  
 
(2.2) Introduction on analytical ultracentrifugation 
AUC is a powerful tool to characterise the macromolecules in their native state 
under biological relevant solution conditions (see examples in Cole & Hansen, 1999).  An 
analytical ultracentrifuge combines the functions of an optical detection system and a 
preparative ultracentrifuge. The macromolecular samples are prepared in specially designed 
sample cells and are put into an ultracentrifuge rotor and subjected to a high centrifugal 
force. At the same time, spectroscopic methods, which are based on either absorption or 
refractive index differences between sample and reference buffer in the cell, are applied to 
track the effect of the centrifugal force. AUC monitors sedimentation events in real time. 
By applying the appropriate rotor speed, two types of experiments are performed: 
sedimentation velocity and sedimentation equilibrium. The data obtained are then analysed 
to identify the oligomeric state of the macromolecule and its polydispersity, and model the 
shape of macromolecules.  
 
(2.3) Historical review on analytical ultracentrifugation 
 The use of ultracentrifugation to determine particle structures was first proposed in 
1913 by Dumansky (Serdyuk et al., 2007). Then Svedberg and Nichols constructed the first 
centrifuge with an optical system to follow particle behaviour in a centrifugal field 
(Svedberg & Nichols, 1923).  A year later, Svedberg noted the decrease in absorbance at 
the top of the cell during centrifugation. Between 1926 and 1927, he determined the 
molecular weight of haemoglobin using a combination of sedimentation and diffusion data. 
The behaviour of the moving boundary in the ultracentrifuge was explained by the Lamm 
equation (Lamm, 1929). The equation is an infinite series of integrals, which can be 
computed only by numerical integration. In the 1930s, Schlieren optical systems were 
designed, which allowed a representation of the concentration gradient as a function of 
distance in the centrifuge sample cell. Physicists started to use Perrin’s hydrodynamics 
theories for ellipsoids of revolution to interpret the frictional coefficient in terms of the 
shape and hydration of macromolecules. In this period, important achievements in the field 
of molecular structure included the prediction of the dimensions and shape of tobacco 
mosaic virus, before the rod-like particles were visualised by electron microscopy.  
  43  
 AUC became commercially available from the 1940s. With the increased use of 
sedimentation, many achievements in molecular biology were accomplished with the 
centrifuge. In 1958, Meselson and Stahl use density gradient ultracentrifugation and isotope 
labelling, to prove the semiconservative mechanism of DNA replication. In late 1959, the 
ribosome was discovered (Tissières & Watson, 1958; Schachman, 1959). Following the 
development of the first scanning photoelectric absorption optical system, the 
ultracentrifuge was able to study proteins, ribosomes, DNA and viruses. Williams, van 
Holde, Schachman, Yphantis and Fujita developed the essential theory and practice of AUC 
analysis at this time. In 1970s, the incorporation of a monochromator in the absorption 
optics allowed extremely dilute solutions to be studied. Rayleigh interference optics yielded 
highly accurate data for non-absorbing solutes, and was used mainly for the determination 
of macromolecular mass by sedimentation equilibrium.  In 1978, the development of new 
data analysis methods, which removed the contribution of diffusion from sedimentation 
velocity boundaries, yielded integral distributions of sedimentation coefficients (Van Holde 
& Weischet, 1978). Data analysis was much improved with the appearance of a new 
generation of instruments, which were highly automated for data collection and analysis in 
the 1990s. The Beckman XL-I ultracentrifuge includes two different optical detection 
systems: a UV absorption system that makes it possible to study proteins or nucleic acids at 
very low concentration and a Rayleigh interference optical system, which can detect 
macromolecules with low or no light absorbance (McRorie & Voelker, 1993). Recently, 
AUC can be applied to molecules with molecular weights from several hundreds to tens of 
millions. It can provide accurate determination of the purity, mass, shape, self-association 
and other binding properties of macromolecules in solution. It is now an indispensable 
technique in biological laboratories. 
 
(2.4) Theory of sedimentation 
A particle suspended in a solvent in an analytical ultracentrifuge is subjected to 
three forces (Figure 2.1): the sedimentating, buoyant and frictional force. First, there is a 
sedimenting, or gravitational forces, Fs, proportional to the mass of the particle and the 
acceleration. 
(Eq. 2.1)          Fs = ω2rm = ω2r Mr
                               N 
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where m is the mass in grams of a single particle, Mr is the molar mass of the solute in 
g/mol and N is Avogadro’s number.  
 
Secondly, there is a buoyant force, Fb, which is equal to the weight of fluid displaced: 
(Eq. 2.2)          Fb = -m0ω2r 
 
where m0 is the mass of fluid displaced by the particle: 
 
 (Eq. 2.3)          m0 = m ρ = Mr ρ 
                       N 
 
Here,  is the volume in m that each gram of the solute occupies in solution (the partial 
specific volume; the inverse of its effective density) and ρ is the density of the solvent 
(g/ml).  
 
Provided that the density of the particle is greater than that of the solvent, the particle will 
begin to sediment in a radial direction when gravitational force is applied. As the particle 
begins to move away from the meniscus, its velocity, u, will an increase because of the 
acceleration (a = ω 2r, r is increasing). As a result, the particle will experience an increased 
frictional force, Fƒ, (Figure 2.1) acting in an opposite direction to the sedimentation force:  
(Eq. 2.4)        Fƒ =  -ƒu 
 
ƒ is the frictional coefficient that is proportional to the viscosity of the solvent and the 
linear dimensions of the particle. An elongated molecule has a greater frictional force than 
a small, compact one of the same mass. The frictional, buoyant and sedimenting forces 
reach equilibrium within a short time (less than 10-6 s). So the frictional force is 
equivalent to the difference between the sedimenting and buoyant forces (Serdyuk et 
al., 2007):  
 
(Eq. 2.5)          Fƒ = rω2Mr - Mr ρω2r 
                                     N      N 
 
So 
 
(Eq. 2.6)           ƒu = rω2Mr - Mr ρω2r   
                                       N     N                   
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Figure 2.1 The forces acting on a solute particle during centrifugation. Ff is the 
frictional force. Fb is the buoyant force. Fs is the sedimentating force. Ff  and Fb act in an 
upward direction, while Fs and u act downwards (Ralston, 1993).
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Rearranging, 
 
(Eq. 2.7)       ƒu =  Mr ω2r (1 - ρ)   
                               N          
 
Dividing both side of Equation 2.7 by f ω2r 
 
(Eq. 2.8)              u    =  Mr (1 - ρ) = s  
                          ω2r       Nf          
 
Where u/ω2r, the velocity of the particle per unit gravitational acceleration, is called the 
sedimentation coefficient. The sedimentation coefficient (s) is directly proportional to the 
buoyant effective molar mass of the particle, and inversely proportional to the frictional 
coefficient (ƒ). It has a unit of seconds (s), but is conventionally expressed in terms of Svedberg 
units (S), in recognition of Svedberg’s fundamental pioneering work in AUC (Cole & Hansen, 
1999).  Most sedimentation coefficient values lie between 1 x 10-13 s and 100 x 10-13 s, and one 
Svedberg unit is equivalent to 10-13 s. Therefore a value of 3 S would translate to 3 x10-13 s. 
Equation 2.8 can be alternatively expressed in standard form as the Svedberg equation: 
 
(Eq. 2.9) Mr (1- ρ) =  s 
  RT          D 
 
R is the gas constant and T is the absolute temperature in Kelvin. D is the diffusion coefficient. 
In practice, experimentally-observed s values are often converted to standard conditions (at 
20°C) by correcting for the buffer, temperature conditions and dilution to zero concentration, 
and this is presented as s020,w  (see for example Balbo & Schuck, 2005).  
 
 (2.5) Instruments 
The most popular analytical ultracentrifuges are the Optima™ or Proteomelab™ 
XL-A and XL-I systems, both made by Beckman Coulter Instruments. The XL-A uses UV 
and visible absorbance optics for absorbance measurements, while the XL-I uses integrated 
absorbance and interference optics for both absorbance and interference measurements 
(McRorie & Voekler, 1993). More recently, fluorescence optics have been integrated into 
the XL-I optical system to allow labelled protein in more concentrated solutions to be 
analysed, such as cell lysates, serum and cell culture media (Cole et al., 2008). 
 
The instrument used for my thesis is the Beckman Coulter XL-I analytical  
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ultracentrifuge. It consists of a rotor system (Section 2.5.1) and an optical detection system 
(Section 2.5.2). The centrifugation parameters, such as temperature, rotor speed and data 
acquisition are under computer control. 
 
(2.5.1) The rotor and cells 
A Beckman Coulter XL-I analytical ultracentrifuge uses specialised rotor systems. To 
view the sample, the rotor has holes to hold the sample cells (Figure 2.2a). At high speeds, an 
ultracentrifuge rotor generates a gravitation force in the cell. With a speed of 60,000 r.p.m, a 
mass of 1g would weight 250,000 times of its weight, 250 kg. Therefore, AUC rotors are 
capable of withstanding great gravitational forces, and the ultracentrifuge contains a 
reinforced cylinder chamber in case of rotor breakage. Rotors contains either four or eight 
holes and are capable of holding either three or seven cells together with a reference cell used 
for radial calibration purposes. The multiple cells make possible study of up to seven samples 
in a single experiment.  
 
The centrifuge cells house the sample and reference buffer, and are assembled before 
each experiment from a cell housing, upper and lower plane windows of optical grade 
sapphire or quartz, and a centrepiece (Figure 2.2b). In a sedimentation velocity experiment, a 
double-sector centrepiece is used; while in a sedimentation equilibrium experiment, a six-
sector centrepiece is used. Centrepieces are made out of a variety of tough, inert materials, 
such as epoxy, anodised aluminium or titanium. Aluminium-filled or charcoal-filled epoxies 
are used for biological experiments at speeds up to 42,000 r.p.m., and aluminium cells are 
used for higher speeds (Cole et al., 2008). The use of specialised materials ensures that the 
cell is able to withstand high gravitational forces, does not leak or change shape. 
Sedimentation velocity is observed through a column height of 12 mm, with about 400 µ 
solution in each sector of the cells. Sedimentation equilibrium can employ six sector cells 
with three 100 µl samples and three reference buffers at 100 µl volume each. The equilibrium 
distribution is usually observed across a column height of 2 mm or less (Figure 2.2a; Cole et 
al., 2008). The use of shorter cells enables the quicker attainment of equilibrium.  
 
(2.5.2) The optical systems  
The optical systems track changes in the distribution of protein molecules during the 
spinning of the rotor. There are three commercially available optical detectors for the XL-I 
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 (a) Cells and Rotor 
 
     (b) Assembly of a cell 
 
 
 
Figure 2.2 Cells and rotor. (a) For sedimentation velocity experiment, 2-sectored centrepieces 
are inserted into rotor; while for sedimentation equilibrium experiments, 6-sectored 
centrepieces are usually inserted. (b) Assembly of a cell from different pieces. 
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to measure the concentration distributions: an absorbance spectrophotometer and Rayleigh 
interferometer from Beckman Coulter (Palo Alto USA)and the fluorescence detector from 
Aviv Biomedical (Palo Alto USA). All subsequent analysis of sedimentation data relies on 
the quality of data available from these detectors. The capabilities and characteristics of the 
three optical systems are compared in Table 2.1.  
 
The absorbance optical system of the AUC makes use of a high intensity xenon flash 
lamp and a scanning monochromator. The monochromator measures at wavelengths from 190 
to 800 nm (see, e.g Giebeler, 1992). According to Figure 2.3, the light from the Xenon flash 
lamp passes through the sample and reference sectors and then is detected by a photomultiplier 
tube. The photomultiplier detects the difference between these signals and translates this into an 
absorbance value. When the xenon flash lamp moves radically along the length of the sector, 
different positions of the solute can be scanned. The distribution of protein molecules is 
constantly changing during the experiment, so the light intensities through the sample sector 
and reference sector vary as a function of time. Timing information is provided with the aid of a 
reference magnet at the base of the rotor. Of three optical systems, the absorbance system 
requires the longest time to complete a scan. For sedimentation velocity experiments, the long 
scan times may limit the amount of data that can acquired over the course of an experiment. 
 
Interference optics (Figure 2.4) is an optical system of choice that is available to 
characterise very concentrated or very dilute the samples, due to its sensitivity. It is based on 
the refraction of light as it moves from one medium to another. The signal from the sample 
sector is referenced against that of the buffer sector. If the sample and reference solution are 
the same, refractive index differences will not appear. When the two solutions are different in 
protein concentration, the achromatic fringe will shift, reflecting the difference in the 
refractive indices of the solution. During sedimentation experiments, the camera sends the 
data in digital form to a computer and this will result in a screen image of fringe pattern 
(Figure 2.5). Because the signal does not depend on chromophores, colourless compounds, 
such as polysaccharides and lipids, may be analysed by AUC.  Since any pathlength 
difference between the sample and reference beams contributes to the fringe displacement, 
even tiny optical imperfections (dust, oil or scratches on the lenses) are visible in the signal; 
cells for interference optics have to be cleaned thoroughly. Also, in order to achieve the  
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 Absorbance Interference Fluorescence 
Sensitivitya 0.1 OD 0.1 mg/ml 100 pM 
Rangeb 2-3 logs 3-4 logs 6-8 logs 
Precisionc Good Excellent Good 
Radial 
resolutiond 20-50 10 20-50 
scan timee 60-300    1-10 60-90 
When to usef Selectivity Solvent absorbs light Selectivity 
 Sensitivity 
Solute does not absorb 
light Sensitivity 
 
Non-dialysable 
components Accuracy needed 
Small sample 
quantities 
   Short solution columns 
Non-dialyzable 
components 
            a The sensitivity is the minimum amount of signal needed to obtain good results. 
Sensitivity of the fluorescence system is for fluorescein (molar extinction coefficient 
~65,000 at 488 nm, quantum yield ~0.9) 
b The range refers to the concentration range 
c The precision of the optical system is estimated by comparing the signal to noise 
ratio. 
            d Approximate spacing (in µm) between data points can be considered, independent 
estimate of the concentration 
            e The minimum time (in seconds) required to complete one radial scan. The time 
listed for the fluorescence system is the time needed to scan all of the samples. 
            f Selectivity refers to the ability of absorbance and fluorescence systems to 
discriminate between components based on their spectral properties. Since the Rayleigh 
interference optics relies on differences in the refractive index of the sample and reference 
solutions, it provides no selectivity. The interference optics require that samples are at 
dialysis equilibrium with the reference solution: hence, they should not be used for samples 
containing non-dialyzable component. The greater radial resolution of the interference 
optics allows them to be used with the eight channel “short column” centrepieces. 
 
 
Table 2.1 Capabilities of optical systems (adapted from Cole et al., 2008). 
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Figure 2.3 A schematic diagram of an analytical ultracentrifuge absorbance optical 
system (Ralston, 1993). 
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Figure 2.4 A schematic diagram of an analytical ultracentrifuge interference optical 
system (Beckman XL-I/XL-A Training Guide, 1998). 
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a) 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
Figure 2.5 Schematic and bitmap of fringe shifts  
a) Fringe shifts observed in interference optics of velocity cells. A has no refraction of 
light. The fringe forms after passing through the same solvent. B shows the achromatic 
fringe shift due to the difference in refractive indices of the solvent and solute. C shows 
without diffusion, achromatic fringe shifts; however, XL-I is not able to detect the change. 
D shows clear fringe pattern as significant amounts of diffusion occur.  
b) Formation of achromatic fringe (Beckman XL-I/XL-A Training Guide, 1998). 
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full accuracy of the interference optics, careful alignment and focusing are necessary 
(Richards et al., 1971). Once properly aligned and focused, they remain stable. 
 
 The fluorescence optical system is the most recent addition to the XL-I. A laser light 
source is used to achieve sufficient radial resolution. Currently the AU-FDS laser provides 
excitation at 488 nm. It is likely that more excitation wavelengths will become available in 
the future. The system uses extrinsically labelled compounds. Suitable labels include 
fluorescein, BODIPY, NBD, green fluorescent protein (GFP), and the many derivatives of 
these labels used for fluorescence microscopy. Due to the sensitivity and selectivity of 
fluorescent system, it is possible to characterise the sedimentation behaviour of GFP-labelled 
protein in cell lysates without further purification.   
 
(2.6) Sedimentation velocity 
Sedimentation velocity observes the movement of solute away from the meniscus 
(narrower end of Figure 2.2a) toward the bottom of the cell.  The sample is initially a uniform 
solution (the concentration is constant over the length of the cell). During centrifugation, the 
particles move along gravitational force lines, the meniscus is cleared of solutes, and a 
moving boundary forms between the solvent depleted of solutes and the solvent of finite 
concentration. The different mobilities of macromolecular solutes in a gravitational field are 
exploited to separate the species and have different sedimentation coefficient; however, two 
components of a system may have similar sedimentation coefficient so that they can not be 
easily separated. 
 
The simplest analysis of a sedimentation velocity experiment was done by plotting 
the natural logarithm of the radial position of the boundary mid-point or the second moment 
boundary position versus time (Hansen et al., 1994; Schachman, 1959). The slope of this plot 
is proportional to ω2s, in which s is the average sedimentation coefficient. The methods 
assume the cells contain a single, noninteracting component.  
 
Later softwares were developed to analyse the entire boundary. One of them is the 
time derivative approach (DCDT). It implements the dc/dt method originally developed by 
Walter Stafford, and converts the boundaries into an integral distribution of s, g(s*). The 
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g(s*) distributions are obtained by subtracting pairs of scans, collected over a short time, to 
generate a set of dc/dt data. The differences are then normalised and averaged to enhance the 
signal-noise ratio and subtract time-invariant baseline distortions (Stafford, 1992a, 1994a). 
The results obtained by this method are plotted as g(s*) against s*. Individual peaks in the 
g(s*) distribution can be fitted to Gaussian functions to derive the concentration (from the 
peak area), the sedimentation coefficient (from the centre position) and the diffusion 
coefficient (from the width of the peak) for homogeneous species or non-interacting 
mixtures (Philo, 2006). 
 
In this thesis, another approach is used to analyse the sedimentation boundaries, namely 
SEDFIT software (Schuck, 1998, 2000). It can load all the scans and test these for evidence of 
polydispersity, which is different from the DCDT method. SEDFIT fits the boundaries using 
the Lamm equation (Lamm, 1929), which is derived by combining the law of diffusion and 
centrifugal migration.  The c(s) analysis (Figure 2.6(a,b)) by SEDFIT take into account the 
diffusion of all species by assuming the same frictional ratio for all species. This assumption is 
based on the fact that frictional ratio f/fO is not very sensitive to shape changes, and normally is 
similar for analogous molecules. The c(s) analysis results in c(s) distribution(s) (peaks) that 
reflect the populations of different sedimenting species.  The integration of c(s) peaks gives the 
concentration of the species. If a peak corresponds to a single sedimenting species, the c(s) 
distribution can be transformed to a molar mass distribution c(M). A c(M) distribution presents 
the approximate molecular weight of the species. Whether the model adequately describes the 
experimental data is evaluated by goodness-of-fit analyses. The goodness-of-fit in SEDFIT is 
presented using the residual plot, the grey bitmap image and the r.m.s.d. value. A good fit is 
shown by a monochromatic grey bitmap image and a low r.m.s.d value (< 0.009). 
 
The traditional approach to analyzing an interacting system is to measure the weight 
average sedimentation coefficient, s20,w, as a function of loading concentration (Correia, 
2000; Correia et al., 2005; Schuck, 2003). However, the analysis of reversible interactions 
by sedimentation velocity is a complex problem (Dam and Schuck, 2005; Dam et al., 2005; 
Schuck, 2003; Stafford, 2000; Stafford & Sherwood, 2004). For interacting molecules, the 
peaks cannot be assigned to discrete species, because the species compositions are 
continuously varying due to an equilibrium between them (Dam & Schuck, 2005; Brown & 
Schuck, 2006). Such a mass-action equilibrium can be seen by the peak position shifting to  
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Figure 2.6 Analyses of sedimentation velocity and sedimentation equilibrium by 
SEDFIT and SEPHAT. (a) The boundary movement of a sedimentation velocity 
experiment (b) A c(s) distribution derived from the boundary analysis. (c-d) The analysis of 
sedimentation equilibrium: (c) is the goodness-of-fit shown in residual; (d) is the raw data 
(circle) and fit of the data. 
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higher s* with increasing concentration. There, the peak represents a reaction boundary and 
cannot be treated as an individual species. Reaction boundaries are peaks that correspond to 
the co-sedimentation of both free and complexes (Scott & Schuck, 2005). However, if the 
peaks exhibit moderate or higher stability, the peak positions can give valuable insights into 
the reaction scheme and stoichiometry. 
 
(2.7) Sedimentation equilibrium  
Sedimentation equilibrium (SE) reveals the mass of the macromolecule rather 
than its shape, because the equilibrium distribution depends on the buoyant molecular 
weight and not on the shape of the component in solute. The technique is performed at 
lower speeds and the solute molecules do not completely sediment to the base of the 
cell, due to the diffusion force (Figure 2.7). Increased sedimentation is balanced at 
equilibrium by the reverse flow from diffusion. Thus the rate of sedimentation equals 
the rate of diffusion, and the solute is apparently immobile at equilibrium.  
 
At equilibrium, the concentration distribution is exponential with the square of 
the radial distribution. In polydisperse solution, higher molecular masses dominated 
towards the bottom of the cell, while the lower molecular masses dominate at the top. 
Providing that the values of buffer density ρ and the macromolecular partial specific 
volume  are known, the molecular weight Mr can be calculated from the 
concentration gradient. Standard curve-fit methods using single or multiple species 
exponential function can provide the molecular weight Mr for the solute.  
 
For a single sample, the sedimentation equilibrium needs to be performed at 
multiple speeds and different concentrations of the solute (Figure 2.8). These are used 
to find out the optical speed and concentration for calculation of the molecular weight 
(Perkins et al., 2005). The difference between the experimental data points and the 
corresponding points on the fitted curve which are calculated from the model equation 
is called the residual. The residual is a function of radius. In an accurate presentation, 
the residuals should be randomly distributed around a zero basline (McRorie & 
Voelker, 1993; Beckman Model XL-A/XL-I Analytical Ultracentrifuge OptimaTM 
Series Training Guide, 1998). 
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Figure 2.7 Movement of the boundary in a six-channel centrifuge cell during 
sedimentation equilibrium (Cole & Hansen, 1999). SE data are collected when the protein 
has reached equilibrium between its diffusion and sedimentation in the cell. 
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 Radius (cm) 
 
 
 
Figure 2.8 Sedimentation equilibrium analysis of the single-chain Fv fragment MFE-
23.  The curves were obtained at three concentrations of 1.1, 2.2 and 3.0 mg/ml with three 
speeds of 11, 000, 15, 000 and 19, 000 r.p.m.. The continuous white lines are the result of 
the simultaneous fit using non-linear least-squares regression analysis (Perkins et al., 2005). 
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For an ideal non-interacting simple component system, the following equation applies: 
 
(Eq. 2.10)        cr = cr0 exp[Mr (1-  ρ) ω2 (r2- r02)/2RT]  
 
Where cr is the sample concentration at radial position r, cr0 is the concentration at 
meniscus, Mr is the molecular mass of solute, ρ is the density of the solvent, ω is the 
angular velocity, r is the radial distance from the meniscus, R is the gas constant (equal to 
8.314 x 107 erg K-1mol-1) and T is the absolute temperature (Cole & Hansen, 1999; 
Beckman XL-I/XL-A Training Guide, 1998). Equation 2.10 is not affected by the 
molecular shape. The shape of molecules only affects the rate at which equilibrium is 
reached. An example of single species fit by Equation 2.10 is in Figure 2.6(c-d). 
 
          Sedimentation equilibrium can also be used to characterise oligomerisation of a 
molecules. For self-association systems, the total absorbance at a given radius is the sum of 
absorbance of all species at that radius, and the total concentration distribution can 
described as sum of two species: 
(Eq. 2. 11) 
 
where ctotal(r) is the total concentration of the mixture at the radial position, cm(a) is the 
concentration of monomer at the meniscus, cn(a) is the concentration of oligomer at the 
meniscus, and n is the stoichiometry for the oligomer. Each exponential in the summation 
describes the equilibrium distribution of a species, the first being the monomer and the 
second the n-mer. For the monomer-oligomer equilibrium reaction, the association 
constant, Ka, is defined as: ( )nmna ccK =  (McRorie & Voelker, 1993). 
 
Although the detailed mathematical theories that underlie sedimentation velocity 
and sedimentation equilibrium are complex, many user-friendly data analysis programs 
enable users, with little experience of computer analytical technique, to analyse their AUC 
data with confidence (Table 2.2). In my thesis, I used SEDFIT to analyse the sedimentation 
velocity experiments and SEDPHAT to analyse the sedimentation equilibrium. 
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Table 2.2. Some of the software for analysis of sedimentation data (Cole & Hansen, 
1999). 
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(2.8) Non-ideality in SV and SE experiments 
A solution is considered to be ideal when its enthalpy is zero; the closer to zero the 
enthalpy of solution is, the more “ideal” the solution behaviour becomes (Pusey & Tough, 
1985). Deviations from ideal behaviour are corresponding to non-ideality. In a non-ideal 
solution, there is a tendency of a suspension of particles to remain in solution, to aggregate 
and to overcome phase separation. In SV experiments, non-ideality causes the 
sedimentation coefficient and diffusion coefficient values to vary with concentration. In SE 
experiments, non-ideality causes variation in the point average molecular weight depending 
on concentration or radial position. In this case, the measurement of molecular weight by 
SE over a range of concentrations is necessary followed by an extrapolation to zero 
concentration (Harding & Johnson, 1985).  Biological macromolecules in concentrated 
solutions reflect the effect of macromolecular crowding on biological function (see, e.g., 
Harding & Johnson, 1985). 
 
In SV experiments, sedimentation coefficients from concentration series, s, are 
corrected to be that measured at a temperature of 20oC and to water (solvent environment), 
and labelled as s020,w (Laue et al., 1992). The variation in the sedimentation coefficient with 
concentration may be caused by an increment in the frictional coefficient with 
concentration. The concentration dependence of the diffusion coefficient arises from both 
the thermodynamic nonideality and the hydrodynamic nonideality (Solovyova et al., 2001). 
The driving force for diffusion is the gradient in chemical potential (µ), which is related to 
osmotic pressure (Harding & Johnson, 1985). The shapes of the sedimentation profiles 
generally show steeper boundaries for repulsive non-ideal sedimentation. In SV 
experiments,  
(Eq. 2.12)   c(r,t) = f (f/fo, Mr, kS, KD, r, t );  
where kS is a mass-action parameter that determines hydrodynamic non-ideality. At high 
protein concentrations, repulsive interactions between solute molecules cause a reduction in 
the sedimentation coefficient, which can be expressed by the non-ideality coefficient for 
sedimentation kS (an empirical constant in ml/g) (Schachman, 1959).  A single peak 
distribution seen in c(s) plots does not always mean a single species. Normally low protein 
concentrations under 1 mg/ml are used to avoid non-ideality. The salt concentration in 
buffer should be at least 20-50 mM to shield electrostatic interactions between 
macromolecules that contribute to thermodynamic nonideality (Cole et al., 2008). 
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Thermodynamic non-ideality affects the spatial distribution of macromolecular 
solutes at sedimentation equilibrium. The point average molecular weight depends on the 
concentration or radial position (Wills & Winzor, 1992). Measurement of the relative 
molecular mass of a macromolecule over a concentration range is necessary followed by an 
extrapolation to zero concentration (Harding & Johnson, 1985). The effects of non-ideality 
can be summed up in terms of a “virial expansion” (see, e.g., Scott et al., 2005). In SE 
experiments, 
(Eq. 2.13)   c(r) = f (Mr, B, KD, r);   
the second virial coefficient B (the first coefficient is 1/M) explains thermodynamic non-
ideality (see, e.g., Harding & Johnson, 1985). Sedimentation equilibrium is able to analyse 
non-ideality in polydisperse systems. However, the application of theoretical developments 
to experimental situations is limited by: 1) an inability to accommodate the consequence of 
reactant heterogeneity; 2) a requirement for valency determination to each interacting 
species (Winzor et al., 2004a, 2004b).  
 
Many macromolecular systems give symmetrical Schlieren peaks in a SV 
experiment, or constant point-average molecular weights throughout the solution column in 
a SE experiment. However, such criteria alone are insufficient to prove that a system is 
ideal and homogeneous (see, e.g., Creeth & Knight, 1964; Teller, 1965). 
 
In the experiments of this thesis, non-ideality does not have a significant effect. 
Because the experiments have been done in a low concentration range, any concentration 
effect of protein behaviour becomes standardised when it is converted into s020,w. Salts have 
important effects on the stability and solubility of macromolecules in solution. The 
concentration of salt and valency of ions are only taken into account, when the solution has 
very low (millimolar) salt concentrations (Serdyuk et al., 2007). My experiments have been 
done in both 50 mM NaCl and 137 mM NaCl buffers. The use of 50 mM NaCl increase the 
electrostatic interaction between molecules compared to that of 137 mM NaCl. It is 
possible that the results in 50 mM NaCl buffer induced artificial inter-particle interaction. 
My AUC experiments were validated by X-ray experiments to confirm that even in low 
salt, my results show no notable effects arising from non-ideality (Chapter 4, Chapter 5 and 
Chapter 6).  
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Chapter Three 
Solution Scattering 
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(3.1) Why use solution scattering? 
Solution scattering is a low resolution diffraction technique that is used to study the 
overall structure (length, width and conformation) of biological macromolecules in random 
orientations (Perkins et al., 2008). This method is used for proteins with a molecular mass 
of 10 kDa or upward, with no upper limit. The major strengths of solution scattering are 
that it provides multi-parameter structural information on proteins that are analysed in near-
physiological conditions. X-ray crystallography is able to obtain protein structure at atomic 
resolutions of up to 0.1 nm, but only fixed orientation view. In contrast, solution scattering 
allows structures to be viewed at resolutions of about 2-4 nm, but in various orientations. 
Analytical ultracentrifugation provides structural information through sedimentation or 
diffusion coefficients. This is a single-parameter method, while the related method of 
solution scattering is a multi-parameter method. Solution scattering can analyse multi-
domain protein structures that are not crystallisable for various reasons, such as heavy 
glycosylation or the presence of flexible inter-domain linkers. The concentration of proteins 
required are lower than many other techniques, which minimises the need for non-
physiological high concentrations of sample. Furthermore, solution scattering can be 
combined with X-ray crystallography to validate protein crystal structures in solution, and 
to identify any significant oligomeric or conformational differences between the solution 
and crystal structure (Perkins et al., 2009). Overall, solution scattering overcomes some of 
the limits of other methods of structure determination. It can describe a large 
macromolecule structure in near-physiological condition in less time and model the 
scattering data quantitatively by using known atomic structures. Therefore, solution 
scattering is a useful complementary tool in the research area of protein structures. 
 
(3.2) Types of solution scattering 
There are two common variants of solution scattering: X-ray scattering and neutron 
scattering (diffraction by electrons and nuclei respectively). They share the same physical 
principle. A sample solution is irradiated by a highly collimated (divergent or convergent 
rays converted into parallel rays with minimum divergence or convergence), 
monochromatic (single wavelength) beam of X-rays or neutrons. The diffraction pattern is 
then recorded on an area detector at low scattering angles. X-ray scattering uses a high 
degree of collimation of the main beam and a high positive solute-solvent contrast (Table 
3.1). Neutron scattering differs by the ability to exchange hydrogen by deuterium in the 
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solvent water so that the appearance of the macromolecule can be varied by the contrast 
variation method; and different parts of the sample can be seen in different contrasts. This 
is valuable for protein-DNA complexes. By X-rays, the effect of incoherent scattering 
(where the scattering is out of phase) is negligible; however, it becomes a more noticeable 
issue by neutron scattering. A background level of uniformly scattered neutrons, especially 
at large scattering angles, is created by incoherent scattering. Incoherent scattering from 
hydrogen in the protein requires a flat-background correction to solve the problem in 
neutron scattering analysis (Perkins et al., 2008).  
 
(3.3) Solution scattering experiments 
In a scattering experiment, a solution of the sample is irradiated by a highly 
collimated beam of X-rays (wavelength λ ≈ 0.1 nm) or neutrons (λ ≈ 0.5 nm). As a result 
of coherent scattering and good contrast between the protein and buffer, a circularly-
symmetric diffraction pattern is recorded on a two-dimensional area detector that is placed 
behind the sample. The scattered intensities I(Q) are measured as a function of scattering 
vector Q, where Q = 4π.sinθ /λ (2θ is the angle between the incident and scattered radiation, 
λ = wavelength) (Perkins, 2002; Figure 3.1). The resolution of a scattering experiment is 
usually defined by 2π/Qmax, where Qmax is the largest Q value measured in the experiment. 
(Svergun & Koch, 2003). A typical solution scattering pattern is obtained in a Q range 
between about 0.05 nm-1 to over 2 nm-1. The lowest Q values are not measured due to the 
beam stop to protect the detector camera from the high intensity of the direct main beam. 
Data acquisition times range from seconds to hours. After data have been collected, the I(Q) 
data are analysed by Guinier plots at low Q to extract the RG and Rxs parameters and 
molecular weights. Data are also analysed by indirect transformation to obtain the distance 
distribution function P(r). After satisfactory data analysis, constrained modelling 
calculations are performed to verify and extend the data interpretation in terms of structures. 
 
(3.3.1) The Debye equation 
Diffraction is described by Bragg’s Law according to the equation                        
(Eq. 3.1)  λ = 2d sinθ, 
 
The equation explains the wavelength (λ) in terms of the diffraction spacing (d) and  
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X-ray  Neutron
Studied in high positive solute-solvent 
contrasts; a single contrast measurement  
Contrast variation allow different regions 
within proteins or complexes to be seen 
Instrumental errors caused by wavelength 
polychromicity and beam divergence are 
minimal, no correction required 
Affected by beam divergence, wavelength 
spread and a high uniform incoherent 
scattering background; needs correction 
Radiation damage effects need control ; 
sample cannot be recover after irradiation 
No radiation damage effects; sample can be 
reused  
 A monolayer of water molecules is hydrogen 
bonded to the protein surface. The 
macromolecule appears larger  
No hydration shell is visible, structures 
corresponds to water-free protein coordinates 
Leads to relative Mr values Leads to absolute Mr values 
Buffer background are affected by high salt Buffer background are not affected by high salt
Sample aggregate after radiation damage 
Sample may aggregate in a non-specific 
manner in heavy water solvents 
Table 3.1 Comparison between X-ray and neutron scattering methods.
 
  
 
 
 
 
 
Figure 3.1 Schematic representation of a scattering experiment.  
(a) Scattering from two points p and q in a protein molecule are shown (red circles). The 
scattered angle 2θ and scattering vector Q are also shown. (b) The sample in random 
orientations is irradiation by primary beam and then recorded by an area detector. The 
preliminary image is a scattering pattern about the position of the direct main beam 
(masked by a beam stop). ki is the incident beam, while kS is scattered beam (Perkins et al., 
2008). 
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scattering angle (2θ). In solution scattering, d corresponds to dimensions of 1-100 nm. 
Scattering angles are given in terms of the scattering vector Q (Section 3.3). For any pair 
of scattering electrons or nuclei, if 2θ is equal to zero, the scattered waves are in phase and 
the scattering intensity is at its maximum. In such a situation, the intensity of scattering, 
I(0), is a direct measure of molecular mass, when Q = 0 means at angle zero. When Q and 
2θ are not equal to zero, the intensity of scattering I(Q) is described by the Debye equation 
(Debye, 1915; Guiner & Fournet, 1955):  
 
 (Eq. 3.2) I(Q) = Σ Σ  fp fq   sin(rQ)
              p q            rQ 
 
where the terms fp and fq (or bp and bq for neutrons) are the scattering lengths of the 
electrons (or nuclei; Section 3.3.2) at points p and q in the molecule, and r corresponds to 
the distance between p and q. The scattering length, f, is proportional to the atomic number 
for X-rays, while b for neutrons is roughly similar for different nuclei with the exception of 
1H (Table 3.2a). In solution scattering, macromolecular structures are described in terms of 
scattering power of atoms and the geometrical relationship between the individual atoms 
within the sample. The Debye equation takes account of both factors (Perkins, 1988). A 
limitation of the Debye equation is that it describes particles in vacuo and assumes that the 
scattering patterns are circularly symmetrical. Therefore, the Debye equation is justified for 
two-phase model of aqueous proteins randomised in a solution. 
 
(3.3.2) Contrast variation 
Only when the scattering density of the protein is different from the scattering density 
of the dissolved buffer, can the protein be observed by solution scattering. The scattering 
density of a solute or a buffer is the sum of atomic scattering lengths divided by molecular 
volume V. X-ray scattering is based on electrons. The scattering length f of an electron is 2.81 
fm (or 2.81 × 10-15 m, the classical electron radius). The specific scattering lengths for 
different materials are listed in Table 3.2a. The hydrogen isotopes, 1H and 2H, both have the 
scattering length of an electron of 2.81 fm.  
 
For neutron scattering, b represents the atomic scattering length. It is different from 
X-ray scattering, because neutrons interact directly with the nucleus of the atom. The nuclei  
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 (a)  
  Atomic 
number 
f(2θ = 0º) 
(fm) 
b (fm) 
Hydrogen 1H 
2H 
1 
1 
2.81 
2.81 
-3.742 
6.771 
Carbon 12C 6 16.9 6.651 
Nitrogen 14N 7 19.7 9.40 
Oxygen 16O 8 22.5 5.804 
Phosphorus 31P 15 42.3 5.1 
 
(b) 
Macromolecule X-rays  
(e.nm-3) 
Neutrons 
(% 2H2O) 
H2O 
2H2O 
334 
334 
0 
100 
50 % (w/w) sucrose in H2O 402 13 
Lipids 310-340 10-14 
Detergents 300-430 6-23 
Proteins 410-450 40-45 
Carbohydrates 490 47 
DNA 590 65 
RNA 600 72 
 
 
 
Table 3.2 Scattering lengths and densities for different materials (Perkins, 1988).  
(a) Scattering lengths of biologically important nuclei. (b) Scattering densities of solvents 
and biological macromolecules. “e.nm-3” is the unit for electron density. “% 2H2O” is 
neutron contrast difference between varies materials and 100% heavy water. 
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of all atoms are compact and of comparable size, so neutrons are capable of interacting 
strongly with all atoms with a similar scattering length. 1H has a single proton in its 
nucleus, so the scattered intensity is different from that of 2H where there is a proton and a 
neutron. The atoms 2H, 12C, 14N, 16O, 31P and 32S all have comparable positive b values. 
(Table 3.2a). After dividing the scattering lengths by the molecular volume, it is found that 
the protein scattering density in 2H2O corresponds to 40-45% 2H2O, based on a scale 
ranging from 0% to 100% 2H2O (Table 3.2b). The large difference in the neutron scattering 
properties of the two hydrogen isotopes can be utilised in contrast variation neutron 
scattering experiments. 
 
Solution scattering is a low resolution technique (1-4 nm). Usually, atomic 
scattering lengths in the Debye equation can be replaced by scattering densities ρ(r) of 
small volume elements. The Debye equation is modified to consider the contrast ∆ρ, which 
is the difference between the mean scattering density of the macromolecule ρv and that of 
its buffer ρs:  
(Eq. 3.3)               ∆ρ = ρv – ρs
The terms ρv and ρs are calculated from the total scattering lengths Σfp or Σbp divided 
by the volume V (Eq. 3.2; Perkins, 1988). Larger ∆ρ values give rise to larger signals, and 
this is important for scattering from dilute solutions. Subtracting the scattering of the buffer 
from the sample must be done as precisely as possible to accurately measure differences of 
over three orders of magnitude as Q increases (Putnam et al., 2007).  
 
Scattering density may vary within biological molecules. Proteins, carbohydrates and 
nucleic acids have progressively fewer H atoms and greater proportions of N and O atoms; in 
that order thus their electron densities are greater than that of water; whereas lipids possess a 
great proportion of H and C atoms which are less electron-dense than H2O molecules. Table 
3.2b shows that neutrons have a wider range of solvent contrasts than X-rays. Neutron 
scattering can discriminate between the four macromolecular classes, lipids, proteins, 
carbohydrates and nucleic acids. 
 
Overall, contrast variation is important in both X-ray and neutron scattering. For X-
rays, the protein scattering density is distinguishable from the buffer scattering as it has a 
higher scattering density (positive contrast). For neutrons, the major problem with the 
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contrast is to find suitable solvents with sufficiently different densities that do not alter the 
structure of the dissolved molecules. Neutron scattering is good at this respect, because large 
contrast variation is possible by the simple exchange of H2O by using H2O and 2H2O 
mixtures, and 2H2O is a common solvent.  
 
(3.3.3) Hydration Shell 
SAXS experiments analyse hydration effects during data interpretation. Biological 
molecules have heterogeneous surface chemistry; the interactions between biological surfaces 
and surrounding water are governed by the dipole moment polarisability and hydrogen-
bonding ability of individual water molecules. These interactions modify the structure and 
dynamics of water near the surface of proteins and a distinct hydration shell is formed (Halle, 
2004). Generally the interaction only affects the first hydration shell at about 0-0.3 nm from 
the protein surface (Raschke, 2006). The average density of the first hydration shell is about 
15-22% higher than that of bulk water (Perkins, 2001b). The electron density of the first 
hydration shell is indistinguishable from those of the amino acids, and it will therefore 
contribute to the protein X-ray scattering curve (Perkins, 2001b). The mean volume of a 
water molecule in the hydration shell is 0.0245 nm3, whilst that of bulk water is 0.0299 nm3 
(Perkins, 1986b, 2001b). The volume occupied by a bound water molecule is ~ 20% smaller 
than that of free water, causing this to show a higher density (Svergun et al., 1998). For 
SAXS experiments, an assumption of 0.3 g H2O/g protein leads to a hydration shell volume 
of approximately 33% of that of the protein. 
 
(3.4) Solution scattering methods 
(3.4.1) Sample preparation 
Solution scattering experiments require pure and monodisperse samples. The purity 
of samples can be assessed by reducing and non-reducing SDS-PAGE and AUC. 
Aggregation is another problem. These lead to increased intesities at low Q which mislead 
data interpretation, as the scattering intensities at low Q are proportional to the square of the 
molecular weight. Freezing and thawing cycles promote sample aggregation and are best 
avoided. A trace amount of very large aggregates (compare to the particle that is being 
studied) is better than a monomer and oligomer mixture. In the former case, the scattering 
from aggregates can be removed by removing lowest-q data. In the latter case, the entire 
 73  
  
scattering curve is affected and this is not always detectable. AUC (Chapter 2) can be used 
to detect low levels of aggregation and polydispersity of proteins. Size exclusion gel 
filtration or centrifugation are used to remove aggregation before data collection.  
 
As mentioned in Section 3.3.2, the greater the difference in scattering densities 
between the buffer and the protein, the higher the contrast; therefore signal-noise ratio is 
better. Therefore, buffers for scattering experiments have to be chosen carefully. Salts in 
buffer increase background and decrease the solute-solvent contrast, but these effects are 
often negligible up to about 500 mM salt. The use of 1 M NaCl reduces the X-ray 
transmission to about 10% (Svergun & Koch, 2003). Free radical scavengers sometimes are 
included in the buffer to minimize radiation damage. Common choices are DTT (2-10 mM), 
TCEP (1-2 mM), or glycerol (~5%). Organic buffers containing TRIS or HEPES can also act 
as radical scavengers. Detergents are best avoided unless absolutely necessary, because their 
scattering could be similar to or exceed the protein scattering. Phosphate buffered saline and 
HEPES buffer were used for my X-ray scattering experiments. Samples for neutron 
scattering experiments are prepared similarly as for X-ray scattering experiments, except that 
PBS buffer in 100% 2H2O was used. Each protein sample is dialysed against the 2H2O PBS 
buffer. The buffer was changed four to five times to ensure full 1H-2H exchange.  
 
Preparation of an exactly matching buffer is the most crucial step. Long hours (18- 48 
hours) dialysis works best. In cases when dialysis cannot be done (limited sample stability or 
limited time for preparation), the buffer exchange can be done by passing buffer by 
centrifugation though an appropriate molecular weight cutoff filter. Fresh membrane filter 
normally have organic chemicals on it, so the membrane needs to be washed with the buffer 
before the buffer exchange process. Several cycles of buffer loading will be needed to ensure 
the exact match.  
 
The concentration of sample should be as high as possible to give the best signal, but 
avoiding aggregation or pronounced inter-particle repulsion. For proteins of Mr 200 kDa or 
less, 1-10 mg/ml is a suitable range. For larger proteins, concentrations should be below 2 
mg/ml. Concentration series by dilutions will ensure consistent results. Analysis of I(0)/c (c 
is the sample concentration in mg/ml) should indicate whether concentration effects are 
present (such as oligomerisation with increased concentration), because I(0)/c will be 
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invariant with concentration for monomeric proteins. Protein concentrations are measured 
from the optical densities at 280 nm in a UV spectrophotometer in quartz cells with known 
pathlengths. The concentration is then calculated from the Beer-Lambert law, c =A / εl, 
where c is the protein concentration (mg/ml), A is absorbance at wavelength 280 nm (for 
protein), ε is the protein extinction coefficient (mg/ml/mm) and l is the pathlength (mm). The 
extinction coefficients were calculated from its amino acid and carbohydrate composition 
(Perkins, 1986b).  Sample volumes for X-ray work are 90-150 µl for the ESRF flow-cell. 
When preparing the buffer for X-ray, at least 50 ml of buffer will be needed in order to wash 
the flow cell before the next sample with the same buffer. Neutron experiments need less 
buffer, as no washing process is needed, because of the use of sealed quartz cells. 
 
(3.4.2) X-ray data collection on instrument ID02 in ESRF  
Biological experiments usually involve dilute monodisperse samples. In order to 
obtain good signal-noise ratios, high-flux facilities are required for X-ray scattering. X-ray 
synchrotron radiation sources are more intense than a conventional laboratory anode source. 
They generate high energy electron beams which are maintained in a storage ring for many 
hours. There are about 70 X-ray synchrotron sources in the world. The most powerful “third 
generation” include the 6 GeV European X-ray synchrotron radiation facility (ESRF) in 
France, the 7.0 GeV Advanced Photon Source in the USA and the 8.0 GeV Super Photon 
Ring (Spring8) in Japan (Perkins et al., 2008).  They specialise in either short-wavelength X-
rays (high-energy) or vacuum-ultraviolet and long-wavelength X-rays. 
 
The production of synchrotron radiation is based on the laws of electromagnetism. At 
ESRF, production occurs in several stages. First, electrons are produced by a 100 KeV electron 
triode gun and are accelerated to 200 MeV in a linear accelerator (LINAC, Figure 3.2(a,b)). 
Then the electrons are transferred to a 300 m fast-cycling booster synchrotron in which they 
are accelerated to energies of 6 GeV.  Then the electrons are injected into the 844.4 m diameter 
storage ring to follow a pseudo-circular orbit by bending magnets. The electrons are focused 
by 320 quadrupoles. There are insertion device sources, undulator and wigglers to force the 
electron beam onto a sinusoidal trajectory. Because the electrons in the storage ring travel at 
very high speeds and are constrained in a circular ring trajectory by electromagnets, the 
electrons radiate high energy, including X-rays. The lost energy is replenished by an 
oscillatory radiofrequency electric field which maintains the energy at 6.0 GeV.  
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Figure 3.2 Schematic layout of X-ray solution scattering cameras at beamline ID02 at 
ESRF in France. 
 (a,b) The source is located at the upper section of the storage ring as shown. 
 (c) The undulators U24, U26, and U42 provide high photon flux with a low divergence at 
ID02. Only the central radiation cone of the undulator is used. The beamline operates 
at a fixed wavelength around 0.1 nm (12.4 keV) by a monochromator-mirror optical 
system, and the experiments in this thesis utilised the pinhole SAXS camera EH2 
(adapted from the ESRF Web site http://www.esrf.fr) (PS = primary slits, SS1& SS3 = 
secondary slits, GS = guard slits).  
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The ultimate aim of synchrotron radiation is to produce high quality and high 
brightness beam. Brightness is the measure of how many photons/sec can be imaged on a 
small sample with a small angular divergence. Higher brightness also means that a better 
scattering signal will be obtained. It is affect by the flux and amount of emittance (phase space 
area). For a given wavelength, the total beam power is proportional to the flux. Therefore, high 
flux and more collimated beam produce higher energy beams onto the experimental samples 
(Koch et al., 2003). Figure 3.2c shows the monochromator and focusing mirror used to make 
the beam line more efficient for sample radiation. 
 
 Electrons circulating around the storage ring emit a white beam of all wavelengths 
tangential to the ring. Instrument ID02 will receive this, and transform it into a usable X-
ray beam for experiments (Narayanan et al., 2006; Panine et al., 2006). The beamline use a 
liquid nitrogen cooled Si-111 monochromator and a focusing toroidal mirror (Figure 3.2c) 
to select a wavelength of 0.1 nm and focus the beam on the sample. There are primary, 
secondary and guard slits to reduce parasitic background scattering. These parts of the 
instrument are in a radiation shielded hutch to protect users from lethal X-ray exposure. 
ID02 is composed of two cameras to monitor three types of scatterings. One is the wide 
angle scattering detector, immediately after the guard slit, and outside the vacuum of the ten 
metre long tank within which is a second detector mounted inside the long vacuum tank. 
Alternatively, there is a Bonse-Hart camera for ultra-low angle scattering (not used in this 
thesis).  
 
The samples for small angle scattering are placed between the main beam and the 
detectors (Figure 3.2c). The optimum sample thickness is a trade off between the low 
concentration of the sample (the less it absorbs light, the less radiation damage is observed), 
and the more concentrated sample (better scattering intensity). All samples are translated 
across the beam through a 1 mm wide quartz capillary controlled by a mechanically-operated 
syringe. This means that fresh sample can be continuously exposed during data collection in 
order to eliminated radiation damage effects.  
 
Adjustable sample-detector distance (0.5 to 8 m) is used to obtain the desired Q 
range. The scattered intensity will decrease proportionately to the inverse of the sample-
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detector distance squared. It is necessary to optimise a high signal and large Q range data to 
match the different size of proteins. Two dimensional area detectors in ID02 were used to 
handle the high scattered intensities. There is an image intensifier device to convert the X-ray 
photons into visible photons, and then these are recorded by detector (resolution 2048Х2048 
pixels). The detector is protected from the main beam at zero scattering angle by a beam stop. 
The detector also connects with computers and workstation for data storage and processing. 
During the experiments, automated software convert 2D data set to a 1D curve for display; so 
each sample scattering can be checked quickly to observed and avoid radiation damage. 
 
(3.4.3) Neutron data collection on instruments 
There are about 40 neutron sources in the world at moment. Neutron sources 
include neutron reactor instrumentation and spallation neutron instrumentation. Presently, 
the most powerful one is the 58 MW High Flux Reactor at the ILL in Grenoble, France. 
The ISIS facility adjacent to Diamond, Oxfordshire, UK, is one of the successful spallation 
neutron sources. A neutron camera at a spallation source differs from a reactor-source 
camera, because it does not use a continuous beam, but is based on 50 pulses/sec of 
neutrons that are emitted from a uranium or tantalum target after proton bombardment from 
a synchrotron. In Chapter 5, the ISIS second target station was used for C3 and C3u neutron 
experiments. 
 
(3.5) Data Interpretation 
The data collected through a computer interface at the camera need to be interpreted. 
The structural information is extracted from Guinier and distance distribution analyses. 
 
(3.5.1) Guinier analyses 
Guinier plots are used to analyse experimental data to extract the RG and RXS 
parameters and molecular weights. RG is the radius of gyration which is defined as the root-
mean-square distance of all scattering centres in the macromolecule from its centre of 
gravity. At sufficiently low Q values, the radius of gyration RG (Figure 3.3 and Figure 3.4) 
and the forward scattered intensity I(0) are obtained from the slope - RG2/3 and intercept ln I(0) 
of linear plots :          
(Eq. 3.4)                   ln I(Q) = ln I(0) - RG2Q2/3. 
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Figure 3.3 General features of a solution scattering curve. In solution scattering curve, 
the Guinier region gives information for the overall shape of molecule; in the wide angle 
region secondary and fold (tertiary) structures can be determined. At very low Q, the 
scattering curve is truncated for reason of the beam stop. The scattering curve shown is that 
obtained for C3u (Chapter 5). 
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The X-ray RG value corresponds to a hydrated structure in a highly positive solute-solvent 
contrast, while the neutron RG value corresponds to an unhydrated structure and will 
depend on the solute-solvent contrast. The parameter is analogous to the sedimentation or 
diffusion coefficients of hydrodynamic experiments to characterise the elongation of the 
molecules. The smallest Q required for a RG plot is defined according to Q.Dmax ≤ π, 
where Dmax is the maximum dimension of the protein. The largest Q required depends on 
the protein shape, but normally Q.RG is required to be smaller than 1.5. 
 
For an elongated macromolecule, Guinier analyses of the scattering curve at larger 
Q (Figure 3.3) will give the radius of gyration of the mean cross-section RXS and the cross-
sectional intensity at zero angle [I(Q)Q]QÆ0 . The Q range is larger the one used for the RG 
determination (Figure 3.3): 
       (Eq. 3.5)                    In [I(Q)Q] = In [I(Q)Q]QÆ0 - Rxs
2Q2/2 
RXS is determined by plotting In[I(Q)Q] against Q2 to give a straight line of slope –RXS2/2 
and intercept In[(I(Q)Q)]QÆ0. Sometimes there are two RXS regions for a protein if this has 
two distinct types of folded structures. The results of Guinier plots can be validated by 
analysing the I(0) data. I(0)/c is related with molecular mass of the protein. In X-ray and 
neutron, high I(0)/c values indicates the occurrence of oligomerisation (Figure 3.4). From 
I(0)/c, we can deduce whether the RG and RXS increment depends on oligomerisation of the 
sample or change of the structure. It is important to note that absolute molecular mass 
values cannot be calculated from X-ray experiments, but can be obtained from neutron 
studies. Relative mass values are obtained by X-ray scattering. 
 
(3.5.2) RG and RXS determination of macromolecular dimensions 
From RG and RXS, the maximum length L of a linear model of a protein can be 
determined (Glatter & Kratky, 1982): 
 
(Eq. 3.6)  )(12 22 XSG RRL −⋅=  
Alternatively 
(Eq. 3.7)              [ ] 0→QI(Q)Q
I(0) = L π   
The consistencies of the results are used to validate the presence of rod-like particles. 
 80  
  
 
 
 
 
 
Figure 3.4 Linear relationship between the molar mass and the neutron I(0)/c values 
for glycoproteins in 100% 2H2O buffer (Perkins et al., 2008). 
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(3.5.3) Distance distribution function analyses  
The scattering curve I(Q) is a representation in a reciprocal space of  the 
macromolecule. The experimental I(Q) curve is converted to the distance distribution 
function P(r) by indirect Fourier transformation. P(r) corresponds to the distribution of all 
the distances r between any two volume elements within the macromolecule. It yields the 
shape of proteins. This includes the largest particle dimension that is indicated by the r 
value as the P(r) drops to 0 (Figure 3.5(c,e)) and any notable spatial distributions within the 
molecule, that are observed as peaks in the P(r) curve. The GNOM program is used as a 
semi-automated procedure to evaluate P(r), and the RG value from this can be compared 
with the RG from the Guinier plot. 
 
In conclusion, solution scattering is important for structural analyses. It overcomes 
limitations of using other structural determination methods. Scattering does not only 
provide the solution structures of intact multidomain proteins, but also often provide an 
opportunity to refine and improve the understanding of crystal structures for proteins. In all 
these approaches, other complementary structural detection methods can also be used to 
verify the result of scattering, such as electron microscopy and ultracentrifuge.   
 
(3.6) Biomolecular Modelling 
(3.6.1) Introduction to protein structure 
(3.6.1.1) Amino acids 
 Proteins are composed of amino acids which are linked by peptide chain. Every 
amino acid contains an amino group, a carboxyl group and a side chain (or R group) 
attached to the central Cα atom. If all four groups are different from each other, the amino 
acid is asymmetric. For an asymmetrical amino acid, two distinguishable stereoisomers 
termed L and D forms can co-exist. Only the L-form amino acids are found in proteins. D-
form amino acids are present in nature as peptides. 
 
 The diversity of the amino acid side chains assigns proteins with a great variety of 
structures and properties. The amino acids have been grouped into classes according to its 
side chain (Figure 3.6). Glycine, alanine, isoleucine, leucine, methionine, proline and valine 
all contain straight, branched arrangements of carbon atoms and are aliphatic side chains. As 
these side chains become more elongated, there is a greater tendency to be more hydrophobic. 
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Figure 3.5 Representative X-ray scattering analyses for CR2 and its complex with 
C3d. The filled circles, in the range enclosed by arrows, represent the regions to obtain RG 
and RXS values. (a,d) RG analyses for CR2 and its complex with C3d. (b) RXS for CR2 only. 
(c,e) Distance distribution P(r) analyses. The maximum in P(r) is denoted by M and the 
maximum dimension is denoted by L (taken from Chapter 4). 
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Figure 3.6 The 20 amino acid side chains 
The 20 amino acids are divided into groups based on the chemical properties of their side 
chains (R groups). 
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Although proline is a cyclic amino acid, it shares many aliphatic properties with other 
members of this class. Proline can restrict the flexibility of polypeptide chain. On the other 
side, glycine in this group has no side chain, hence reducing steric collision with other side 
chains and increasing the flexibility of the polypeptide chain, consequently, glycines 
frequently appear at turns in the protein structure. Serine, cysteine, threonine, asparagine 
and glutamine are groups that form hydrogen bonds with water. Serine and threonine have 
hydroxyl groups, while asparagine and glutamine are the amide derivatives of aspartic and 
glutamic acids. Cysteine is important for the formation of disulphide bonds. There is also 
an aromatic group where the members are phenylalanine, tyrosine and tryptophan. 
Phenylalanine is a hydrophobic amino acid, but tyrosine and tryptophan have polar groups. 
In addition to the residues mentioned, the remainder have charged side chains (glutamic 
acid, aspartic acid, histidine, lysine and arginine). 
 
(3.6.1.2) The secondary structure 
When a peptide bond is formed, the movement about the Cα-N bond and the Cα-C 
bond are defined by the phi (Ф) and psi (ψ) angle respectively (Figure 3.7). The 
conformation of protein backbone can be described by dihedral angles around these bonds 
for each residue. The combination of phi and psi angles can be displayed as a 
Ramachandran plot (Figure 3.7b). Most combination of Ф and ψ angles are not allowed 
because of steric collisions between the side chain and the main chain atoms. 
 
 The secondary structures of proteins are α-helices and β-sheets. The α-helices is 
built from a continuous region of polypeptide chain, whereas the β-sheets is formed from 
numerous stretches of five to ten residues that are in different sections of the polypeptide 
chain, but which move into proximity. The allowed Ф and ψ angles for α-helices and β-
sheets are described in the Ramachandran plot (Figure 3.7b).  
 
Within protein structure α-helices and β-strands are combined to from a stable 
hydrophobic core. These compact structure elements are connected by loop regions of 
various lengths and conformations.  The loop regions almost always occur on the surface of 
the molecule. They rarely form hydrogen bonds with each other; instead they form hydrogen 
bonds with water molecules. Surveys of known loop structures are not a random collection of 
possible structures, but a rather limited subset of structure (Sibanda & Thornton, 1985). 
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Figure 3.7 Schematic views of the peptide bonds and a Ramachandran plot. 
(a) Three residues form two peptide bonds. R represents a side chain of any amino acid 
residue. The bonds that defines phi, psi and omega (C-N bond) angles are labelled.  
(b) Ramachandran plot. The light blue, purple and dark cyan represent area of 
generously, additional and most favoured regions of Cα-C bond (Drenth, 1999). 
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A number of combinations of secondary structure elements form with specific 
geometry arrangements known as super secondary structures. The most common form of 
super secondary structure is the βαβ motif which involves two parallel β-strands connected 
by an α-helix. The super secondary structure motifs combine to form compact regions 
called domains. A domain can be folded into a stable tertiary structure independently of the 
rest of the protein. 
 
(3.6.2) Constrained scattering modelling 
Biomolecular modelling is the creation of models that represent the structure of 
biological molecules. The fundamental principle of scattering modelling is to confirm that 
the experimental data has been correctly interpreted. It is useful for multidomain proteins 
that are not crystallisable (while intact) for reason of interdomain flexibility or heavy 
surface glycosylation. A unique structure cannot be determined by this method; however, it 
can identify a group of best-fit conformers that meet well-defined selection criteria (Section 
3.6.2.5). In the absence of a crystal structure, the individual domains are modelled using the 
known structure of homologous domains as templates (Perkins et al., 2008). If an atomic 
structure is available for the domains of the protein, this can be used directly to constrain 
the analysis. An outline of the modelling procedure is shown in Figure 3.8. 
 
(3.6.2.1) Analysis of protein composition 
 In order to model the protein, some elements of the protein need to be understood. 
The program SLUV (Perkins, 1986b) uses the amino acid composition of protein to 
determine essential protein parameters, such as the protein partial specific volume, molar 
mass and the molecular volume before and after hydration. It can also calculates the 
absorption coefficient at a wavelength of 280 nm, which is used for protein concentration 
estimation (Perkins, 1986b).  
 
(3.6.2.2) Creating atomic models 
 Multidomain proteins are created by modelling the domains and flexible linkers. If 
atomic resolution structures for the protein domains are available, then these are used as the 
basis for the models. If crystal or NMR structures are not available, these are created by 
homology modelling using a package such as MODELLER. It greatly improves the value 
of the information provided by structural modelling. For all the models I created, there are  
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Figure 3.8 Overview of the constrained modelling procedure (Perkins et al., 2008). 
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crystallised domains as templates. 
 
 The models were created in randomised arrangements to present all possible 
orientation of domains within the protein. This is achieved by a library of different 
conformational linkers, which are the peptides outside the fixed domain structure. A library 
of thousands of random linker conformations were generated by INSIGHT II 98.0 
molecular graphics software (Accelrys, San Diego, CA, USA). It is generated by fixing the 
temperature of 298K and the linker length, which is measured by the distance between the 
first and last Cα atom, is either allowed to vary at will or restricted to certain values. In the 
automated modelling procedure, linkers are then randomly selected from the linker library 
to join the domains together to generate a series of about 2000-8000 intact models (Figure 
3.8). Usually, even amount of linkers with diverse lengths are the best for creating 
randomised models. 
  
(3.6.2.3) Debye sphere modelling 
 The next stage is to convert the 2000-5000 three-dimensional models into sphere 
models consisting of small non-overlapping spheres of uniform density and with the same 
total sphere volume as the original atomic model (Figure 3.8, Perkins et al., 2002). If the 
atomic coordinate model is available, the coordinates are converted directly to spheres by 
placing all atoms within a three dimensional grid of cubes of side around 0.6 nm. The size 
of the cubes and the number of atoms that each cube contains (namely cut-off level) are 
defined and tested by trial and error. The grid transformation of the resulting sphere model 
needs to have a similar volume as the unhydrated volume of the protein, which is calculated 
from the protein composition (including carbohydrates) by the program SLUV (Section 
3.6.2.1). If residues are missing in the atomic model, the volume discrepancy can be 
compensated by adjustment of the sphere cut-off during sphere generation. For the hydrated 
protein model, a layer of additional spheres is evenly added onto the surface of the dry 
sphere model, where the total number of spheres gives the hydrated volume (Perkins, 
1986b; Ashton et al., 1997; Perkins et al., 2008). Once the sphere size has been determined, 
it is kept constant for the automated curve fit searches.  
 
(3.6.2.4) Debye scattering curve calculation 
Curves are calculated from the sphere models by Debye’s Law (Eq. 3.2) adapted to  
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small spheres (Perkins et al., 1998): 
(Eq. 3.8)        ) 
Qr
Qrsin 
 A 
j
j
j
m
1j=
∑ n2 + n( g(Q) = I(0)I(Q) 2-1-  
(Eq. 3.9)         g(Q) = (3(sin QR – QR cos QR) )2 / Q6R6, 
 
Where g(Q) is the squared form factor for the sphere of radius R, n is the number of spheres 
filling the body, Aj is the number of distances rj for that value of j, rj is the distance between 
the spheres, and m is the number of different distances rj. The equation is modified from 
Debye’s equation (Eq. 3.2) to consider the spheres of the model rather than the electron or 
individual scattering from each nucleus in the molecule. These spheres have to be 
sufficiently small (about 0.6 nm) so that their form factor in the Debye equation is almost 
invariant in the Q scattering range used. The curves generated from this calculation can be 
compared directly with experimental curves to determine best-fit models. 
 
(3.6.2.5) Identification of best-fit models  
The identification of the best-fit models is achieved by the use of four filters: 
(a) Remove the models which have significant steric overlaps between domains or 
subunit, because of the randomisation procedure. Steric overlap means that the number of 
spheres is much reduced compared to that predicted from its composition. Normally any 
models which have spheres less than 95% of the volume calculated from the composition 
needs to be removed. 
(b) The RG and RXS values calculated from each model have to agree with experimental 
Guinier fits in the same Q ranges used (values within 5% of the experimental values are 
good models). 
(c)  An R factor is calculated for a quantitative comparison of each model scattering 
curve I(Q)cal against experimental scattering data I(Q)exp over the whole Q range, where 
I(Q)cal is set as 1000: 
(Eq. 3.10)  R = Σ | I(Q) exp – I( Q) cal | x 100% 
            Σ | I(Q) exp | 
 
The R factor value reflects the goodness-of-fit between the calculated and experimental 
curves. It should be less than 10% for a good fit. With these criteria, the best family of 
structures can be narrowed down. 
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(d) Sedimentation coefficients of the models can be calculated from the hydrated sphere 
models. They were used to compare with the experimental values as an independent 
monitor. 
 
(3.6.2.6) Calculation of hydrodynamic properties 
 
The sedimentation coefficient of all the models can be calculated from the hydrated 
scattering sphere models using the program HYDRO (Garcia de la Torre et al., 1994) and 
also directly from the atomic coordinates in the HYDROPRO using the default value of 
0.31 nm for the atomic element radius for all atoms that includes the hydration shell (Garcia 
de la Torre et al., 2000). Comparison of the sedimentation coefficients of the models with 
that experimentally obtained by SV experiments provides another way to validate the 
scattering modelling. 
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Chapter Four 
 
Solution structure of the complex formed between human complement C3d and 
full length complement receptor Type 2 
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(4.1) Introduction 
Complement receptor type 2 (CR2/CD21), a type I membrane glycoprotein 
found on cell surfaces, belongs to the regulators of complement activation protein 
family (Law & Reid, 1995; Morgan & Harris, 1999). CR2 is comprised of 15 or 16 SCR 
domains depending on alternative splicing (Toothaker et al., 1989; Fujisaku et al., 
1989), a transmembrane region and a short cytoplasmic tail. Cells that express CR2 
include mature B-cells, follicular dendritic cells, epithelial cells, and some T cells. CR2 
has four known ligands: (i) the C3d (Figure 4.1) and iC3b cleavage fragments of C3 
(Lowell et al., 1989; Carel et al., 1990); (ii) the coat glycoprotein gp350 of the Epstein-
Barr virus (Figure 4.1; Fingeroth et al., 1984); (iii) interferon alpha IFNα (Figure 4.1; 
Delcayre et al., 1991; Asokan et al., 2006); and (iv) CD23, a low affinity receptor for 
IgE (Figure 4.1; Aubry et al., 1992). The complement C3d fragment is a 35 kDa 
cleavage product of the central complement protein C3, which is formed by the 
regulatory breakdown of C3b by factor I and factor H; it is derived from the thioester-
containing domain of C3 (Janssen et al., 2005). CR2 is important for B-cell activation 
and the generation of the immune response by linking the innate and adaptive immune 
systems. The prevailing model of CR2 function reveals that binding of C3d to CR2 on 
mature B lymphocytes together with the involvement of CR2 in a complex with CD19, 
CD81 and mIgM reduces the threshold of immune activation. Related activities include 
intracellular reactions, including an increase in intracellular Ca2+ (Carter et al., 1988, 
1991), the activation of MAP kinases (Tooze et al., 1997), and B-cell proliferation 
(Carter & Fearon, 1992).  
 
Diverse structural approaches have clarified CR2 function. Hydrodynamic and 
electron microscopy data on recombinant CR2 showed extended conformations (Moore 
et al., 1989). The binding sites for its four ligands were located to both the SCR 1-2 
domains (and in the case of CD23 to the SCR 5-8 domains as well) (Ahearn et al., 1988; 
Carel et al., 1990; Martin et al., 1991; Aubry et al., 1994). It is of great interest is that 
the compact V-shaped arrangement of the SCR1-2 domains of CR2 in its complex with 
C3d seen in its crystal structure suggested that only the SCR 2 domain interacted with 
C3d (Szakonyi et al., 2001). The unbound CR2 SCR 1-2 domains also showed a similar 
compact V-shaped crystal structure (Prota et al., 2002). In distinction to this, three 
solution structures for unbound CR2 SCR 1-2 in 50 mM NaCl revealed an open V-
shaped structure (Guthridge et al., 2001; Gilbert et al., 2005, 2006a). Unlike the co-
crystal structure, studies of the CR2 SCR 1-2 complex with C3d by constrained  
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Figure 4.1 Views of CR2 SCR 1-15 in comparison with its ligands, namely C3d, the 
C-type lectin domain of CD23, IFN-α and gp350. The SCR domains are numbered 
from 1 to 15 in the CR2 model (red, blue in Figure 4.6). The ligands (blue) are based on 
crystal and NMR structures with the following PDB codes 1GHQ, 1T8D, 1RH2 and 
2H6O (Gilbert et al., 2006b). 
 
 
 
 
 
 
 
 
 
 
 94
scattering modelling in 50 mM NaCl and mutagenesis in 137 mM NaCl, showed that 
both the SCR 1 and SCR 2 domains were bound to the surface of C3d (Gilbert et al., 
2005; Hannan et al., 2005). Hence, in comparison, both crystal structures either 
potentially demonstrate artefactual arrangements of SCR domains, or indicate that SCR 
1-2 exists in alternative structural conformations depending on its biological context. 
The solution structural determination of full length CR2 SCR 1-15 in 137 mM NaCl 
revealed an extended and flexible structure with some regions of folding back, and this 
flexibility is likely to facilitate a broad range of structural interactions between C3d-
antigen complexes and the B-cell receptor (Figure 4.1; Gilbert et al., 2006b).   
 
The interaction of CR2 SCR 1-2 with C3d demonstrates a substantial 
dependence on charge. Surface plasmon resonance studies in 50 mM NaCl that included 
SCR 1-2, SCR 1-4 and SCR 1-15 demonstrated a high affinity for C3d, but in more 
physiological 125 mM NaCl salt, the binding between CR2 and C3d is much weakened 
(Asokan et al., 2006; Moore et al., 1989; Guthridge et al., 2001; Hannan et al., 2005). 
Many earlier binding studies with CR2 and C3d had employed 50 mM NaCl buffers, and a 
broad range of dissociation constants KD had been determined (Moore et al., 1989; 
Guthridge et al., 2001; Hannan et al., 2005; Asokan et al., 2006). Some anomalous 
binding effects had been observed (Asokan et al., 2006; Sarrias et al., 2001).   
 
Knowledge of the solution structure of the CR2-C3d complex is important for 
understanding the role of the 15 SCR domains in CR2 function. It is also important to know 
how the formation and structure of the CR2-C3d complex is modified by electrostatic 
effects. Here, the joint use of analytical ultracentrifugation (AUC) and X-ray solution 
scattering as independent low resolution structural tools suggests that CR2 SCR 1-15 
(denoted as CR2 below unless specified otherwise) is almost unaltered in overall 
conformation between 50 mM and 137 mM NaCl. Unexpectedly, we show that the 
presumed dimerisation of C3d reported in earlier work (Gilbert et al., 2005) is in fact an 
equilibrium between monomers, dimers and trimers in 50 mM NaCl, and that C3d 
becomes monomeric in 137 mM NaCl. The use of both 50 mM and 137 mM NaCl 
buffers to study complex formation between full-length CR2 and C3d shows that the 
CR2 conformation is not affected by C3d binding, but that complex formation is 
detectable only in 50 mM NaCl. This places limits on previously-determined KD values. 
We discuss the implications of these results for biochemical affinity studies and the 
physiological functioning of CR2.  
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(4.2) Results and Discussion 
(4.2.1) Sedimentation velocity of unbound CR2  
Analytical ultracentrifugation studies macromolecular structures in solution by 
following their sedimentation behaviour on subjecting these to a high centrifugal force 
(Cole et al., 2008). By sedimentation velocity, the sedimentation coefficient s020,w 
monitors macromolecular elongation and sample polydispersity. Immediately before 
ultracentrifugation, CR2 was subjected to gel filtration on a Superdex-200 column to 
remove pre-existing aggregates or degradation products. All CR2 samples were checked 
before and after ultracentrifugation experiments by SDS-PAGE.  
 
In order to evaluate the effect of NaCl concentration on CR2, sedimentation 
velocity runs were performed in both PBS buffer (137 mM NaCl) and HEPES buffer (50 
mM NaCl) at three concentrations between 0.12-0.34 mg/ml and four rotor speeds. The 
different rotor speeds established reproducibility and any speed-dependent flexibility in the 
multidomain CR2 structure. Lamm equation fits of up to 200 scans using the continuous 
c(s) distribution model in SEDFIT (Section 4.4.2) resulted in good visual agreements 
between the experimental and fitted CR2 boundaries and satisfactory low root-mean-
square deviations. A single species was observed by both interference and absorption 
optics to confirm its monomeric structure. The c(s) distributions in Figure 4.2 showed that 
the CR2 s020,w value was similar within error at 4.0 S in 137 mM NaCl (Figure 4.2(a,c)) 
and 4.1 S in 50 mM NaCl (Figure 4.2(b,d)). The mean of all the s020,w values in 137 mM 
NaCl was 3.93 ± 0.20 S (11 determinations) and in 50 mM NaCl was 4.03 ± 0.13 S (4 
determinations). The present determinations are in good agreement with the previous 
studies of CR2 in 137 mM NaCl that gave 4.24 ± 0.1 S using DCDT+ software (Gilbert 
et al., 2006b). The similar sedimentation coefficients show that the multidomain 
conformation of CR2 was not altered by ionic strength. If the slight reduction of 0.1 S 
on passing from 50 mM NaCl to 137 mM NaCl is significant, this would correspond to 
a minor lengthening of the CR2 multidomain structure in 137 mM NaCl. 
 
(4.2.2) Sedimentation velocity of unbound C3d 
Recombinant C3d was purified by thrombin cleavage of a C3d-GST construct 
(Section 4.4.2). Previously, C3d purified from a pET15b expression vector was observed to 
undergo what was assumed to be a concentration-dependent monomer-dimer equilibrium 
with a KD value of 40 µM in 10 mM HEPES, 50 mM NaCl (Gilbert et al., 2005). Here,  
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Figure 4.2 (Legend overleaf) 
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 Figure 4.2 Sedimentation velocity data analyses for unbound CR2 and its 1:1 
complex with C3d in PBS (green) and HEPES (red) buffer by Lamm equation fits 
using SEDFIT.  
(a, c) The boundary fits for CR2 SCR1-15 at 0.12 mg/ml in 137 mM NaCl at 30,000 
r.p.m. are from interference data optics. Only every sixth scan of the first 100 scans is 
shown for clarity. The c(s) distribution plot showed one sedimenting species with a s020,w 
value of 4.0 S for 137 mM NaCl. 
(b, d) The boundary fits for CR2 SCR1-15 at 0.15 mg/ml in 50 mM NaCl at 30,000 
r.p.m. are from 280 nm absorbance data optics. Only every seventh scan is shown for 
clarity. The c(s) distribution plot showed one sedimenting species with a s020,w value of 4.1 
S for 50 mM NaCl. 
(e, g) The boundary fit (green) for the complex at 0.72 mg/ml in 137 mM NaCl 
gave two peaks at s020,w values of 2.7 S and 4.1 S as shown. Only every fifth scan of the 
first 65 scans at 42,000 r.p.m. is shown for clarity. 
(b, d) The boundary fit (red) for the complex at 0.46 mg/ml in 50 mM NaCl 
gave only one peak at a s020,w value of 4.6 S. Only every fifth scan of the first 75 scans 
in 50 mM NaCl at 42,000 r.p.m. is shown for clarity. 
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this was reinvestigated by sedimentation velocity at concentrations from 0.3 mg/ml to 
8.3 mg/ml in both 137 mM and 50 mM NaCl buffers at three different rotor speeds 
(Section 4.4.2). Interference optics data were used throughout, together with absorbance 
data below 0.8 mg/ml, due to the saturation of the absorbance optics at C3d 
concentrations above 0.8 mg/ml. Unlike the previous DCDT+ analyses, size-distribution 
c(s) analyses using SEDFIT were now used for data analyses, and resulted in good 
boundary fits (Figure 4.3(a,b)). In 137 mM NaCl, a single predominant species was 
observed at an s020,w value of 3.0 ± 0.1 S between 0.5-7.5 mg/ml (ten determinations) 
(Figure 4.3c). The c(M) size distribution plot showed that this corresponded to a molar 
mass of 39 ± 4 kDa. This was accordingly assigned to C3d monomers with a molecular 
mass of 34.6 kDa calculated from its composition. Trace amounts of higher oligomers were 
visible at higher C3d concentrations (Figure 4.3c). In 50 mM NaCl, the c(s) distributions 
showed a concentration dependence between 0.3mg/ml and 8.3 mg/ml, and three peaks 
indicating three oligomer species were visible (Figure 4.3d). At 0.3 mg/ml, only the 
monomer (M) was present at 2.9 S. The mean value is 3.0 ± 0.3 S (21 determinations). 
Above 0.7 mg/ml, a second peak (D) was observed at 4.3 ± 0.3 S (16 determinations) and 
its intensity increased with concentration. A third peak (T) appeared above 2.1 mg/ml, 
whose s020,w value increased from 5.4 S to 6.8 S as the concentration increased from 2.1 
mg/ml to 8.3 mg/ml. The mean value is 6.0 ± 0.6 S (11 determinations). The c(M) 
distribution plots showed that peaks M, D and T correspond to molecular masses of 34 ± 4 
kDa, 59 ± 10 kDa and 95 ± 18 kDa respectively, assuming that the frictional ratio f/fo 
remained unchanged for these species (Table 4.1). These masses are consistent with the 
formation of C3d dimers and trimers of sizes 70 kDa and 105 kDa. The rate of 
interconversion between the three species was slow enough during the velocity runs for 
these peaks to be visible in the c(s) plots. Our previous study of C3d in 50 mM NaCl buffer 
using DCDT+ fits of 10-20 boundaries gave s020,w values that ranged between 3.26 S to 
4.85 S. (Gilbert et al., 2005). This range of s020,w values is consistent with the range seen 
in Figure 4.3, and reanalyses of the previous data using SEDFIT confirmed the 
occurrence of three species in Figure 4.3d.  
 
Notably, in Figure 4.3d, at 8.3 mg/ml; the third peak which is labelled as “T” 
may be a mixture of trimer and tetramer. C3d is a globular protein. It is known for 
globular proteins that the sedimentation coefficient ratios between monomer-dimer, 
monomer-trimer and monomer-tetramer can be fitted by the rule of: (1) The 
sedimentation coefficient of the dimer is 41/3 times that of the monomer. (2) The 
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(a) The boundary fits for C3d at 1.1 mg/ml in 137 mM NaCl at 32,000 r.p.m. are 
from interference data. Only every sixth scan in a total of 200 scans is shown for clarity.  
 
(d) The concentration dependence of the c(s) size distributions for 0.3 mg/ml, 0.7 
mg/ml, 0.8 mg/ml, 1.2 mg/ml (red), 2.1 mg/ml, 2.8 mg/ml and 8.3 mg/ml of C3d in 50 mM 
NaCl is shown. The peaks are labelled as M (monomer), D (dimer) and T (possible trimer) 
in increasing order of S values, where the values shown correspond to 8.3 mg/ml.  
(c) The concentration dependence of the c(s) size distributions for 0.6 mg/ml, 1.1 
mg/ml (green), 3.6 mg/ml and 7.4 mg/ml of C3d in 137 mM NaCl is shown. A single 
species is observed at 2.9 S and labelled M (monomer).  
(b) The boundary fits for C3d at 1.2 mg/ml in 50 mM NaCl at 40,000 r.p.m. are 
from interference data. Only every fourth scan of the first 80 scans is shown for clarity. 
Figure 4.3 Concentration dependence of the sedimentation velocity data for free 
C3d in PBS (green) and HEPES (red) buffers. Figure (b) and (d) are used with 
permission from Dr A. I. Okemefuna (Okemefuna, 2009). 
 
 
100
101
   Protein  Buffer Experimental
s020,w (S) 
Frictional ratio f/fo Calculated s020,w (S) 
C3d monomer  10 mM HEPES, 50 mM NaCl, pH 7.4 3.0 ± 0.3 1.066 3.1, 2.9 ** 
C3d monomer  9.6 mM phosphate, 137 mM NaCl, pH 7.4 3.0 ± 0.1   
C3d dimer  10 mM HEPES, 50 mM NaCl, pH 7.4 4.3 ± 0.3 1.181 4.7, 4.5 ** 
C3d trimer  10 mM HEPES, 50 mM NaCl, pH 7.4 6.0 ± 0.6 1.106 5.9, 5.8 **  
CR2 10 mM HEPES, 50 mM NaCl, pH 7.4 4.03 ± 0.13 1.99 ± 0.15* 3.94 
CR2  9.6 mM phosphate, 137 mM NaCl, pH 7.4 3.93 ± 0.20 2.06 ± 0.27* 3.89 
CR2-C3d complex 10 mM HEPES, 50 mM NaCl, pH 7.4 4.52 ± 0.11 2.11 ± 0.27* 4.57 ± 0.04 
CR2-C3d complex 9.6 mM phosphate, 137 mM NaCl, pH 7.4 2.52 ± 0.40, 4.07 ± 
0.14 
n.a.  n.a.
Table 4.1 Sedimentation coefficients for CR2, C3d and their complex. 
*   The frictional ratio was floated in the SEDFIT analyses for CR2 and the CR2-C3d complex. 
** The first value is from HYDRO; the second is from HYDROPRO 
n.a. – not available 
 
 
 
 
 
 
 
 
 
 
 
 
 
sedimentation coefficient of the trimer is 91/3 times that of the monomer. (3) The 
sedimentation coefficient of the tetramer is 161/3 times that of the monomer (Cőlfen & 
Vőlkel, 2003). If the C3d monomer has a sedimentation coefficient of 2.9 S, the 
predicted dimer, trimer and tetramer sedimentation coefficients will be 4.6 S, 6.03 S and 
7.31 S respectively. In 50 mM NaCl buffer (Figure 4.3d), the observed dimer value of 
4.6 S for C3d agrees with the calculated value of 4.6 S. At 8.3 mg/ml, the observed s 
value of 6.8 S is intermediate between that calculated for the trimer of 6.03 S and that 
for the tetramer of 7.31 S. The c(M) distribution plots showed that peak T correspond to a 
molecular mass of 95 ± 18 kDa, which is close to that of 102 kDa for a trimer; therefore, 
we cannot state if C3d above 2.8 mg/ml is a tetramer or trimer only or a mixture of 
tetramer and trimer. 
 
(4.2.3) Sedimentation equilibrium of unbound C3d  
Sedimentation equilibrium experiments in both 137 mM NaCl and 50 mM NaCl 
were performed to explore C3d oligomer formation over a ten-fold concentration range. 
Absorbance data were not fitted because of the saturation of the optics above 0.8 mg/ml. 
The individual fits of the equilibrium curves at different speeds and concentrations gave 
the molecular weights shown in Figure 4.4c. Thus C3d in 50 mM NaCl showed a 
concentration dependent mass, while this was not seen in 137 mM NaCl buffer. The 
final global fit of each multispeed experiment was done at rotor speeds of 19,000, 
28,000 and 35,000 r.p.m. (Section 4.4.2). 
 
For C3d in 137 mM NaCl, the mass was determined using a global fit of 15 
curves at five concentrations (Figure 4.4a) on the basis of a monomer-dimer-trimer 
model (Figure 4.3). Low random residuals, a low reduced χ2 value of 8.0, and good 
visual fits were obtained. A C3d monomer mass of 34.1 ± 1.6 kDa was determined, in 
good agreement with the composition-determined value of 34.6 kDa. The monomer-
dimer and monomer-trimer dissociation constants KD were high at 61 mM and 1.4 mM2 
respectively, indicating that no dimer or trimer had formed. This outcome was 
confirmed by a global fit based on a single species only, which gave a similar mass of 
35.1 ± 0.3 kDa and an almost unchanged reduced χ2 value of 9.7 (fits not shown). 
Hence, like CR2, C3d was concluded to be monomeric in physiological buffer.  
 
For C3d in 50 mM NaCl buffer, the same rotor speeds and concentration range 
also gave good fits to a monomer-dimer-trimer association model. This fit required that 
 102
 
 
Figure 4.4 (Legend overleaf). 
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Figure 4.4 Multispeed global fit sedimentation equilibrium analyses of C3d in 137 
mM NaCl (green) and 50 mM NaCl (red). The fit residuals are shown above each 
panel. Figure (b) is used with permission from Dr A. I. Okemefuna (Okemefuna, 2009). 
(a) The five panels show the multispeed global fit analysis of interference data 
for C3d (fitted line in green) at five concentrations (0.64 mg/ml, 1.20 mg/ml, 3.63 
mg/ml, 4.20 mg/ml and 7.01 mg/ml). Within each panel, the rotor speeds were 19k 
r.p.m. (○), 28k r.p.m (∆) and 35k r.p.m (□). The global fits gave a monomer mass of 
34.1 kDa.  
(b) The six panels show the multispeed global fit analysis of interference data 
for C3d (fitted line in red) at six concentrations (0.26 mg/ml, 0.81 mg/ml, 1.77 mg/ml, 
2.84 mg/ml, 3.63 mg/ml and 5.50 mg/ml). The rotor speeds are the same as in (a).  
(c) Concentration dependence of the molecular mass of C3d in 137 mM (green) 
and 50 mM (red) NaCl buffers. For 137 mM NaCl, the green line corresponds to a mass 
of 35 kDa. For 50 mM NaCl, the red line corresponds to the regression line drawn using 
data from 0.11 mg/ml, 0.26 mg/ml, 0.81 mg/ml, 1.77 mg/ml, 2.84 mg/ml, 3.63 mg/ml, 
4.49 mg/ml and 5.5 mg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 104
equilibrium had been reached, and this was confirmed using overlays of runs (Section 
4.4.3). The global fit based on a monomer-dimer-trimer association model of 18 curves 
at six concentrations with a fixed monomer mass of 34.6 kDa gave low residuals 
(Figure 4.4b) and a global reduced χ2 value of 3.5. The KD values of the monomer-dimer 
and monomer-trimer equilibria were determined to be 360 ± 0.01 µM and 0.070 ± 0.003 
µM2 respectively. Global fits based on a single species gave much worsened reduced χ2 
values of 60 to 223. A monomer-dimer model gave a poorer reduced χ2 value of 12.9 
but gave a KD value of 210 µM, which was comparable with the previous estimate of 40 
µM (Gilbert et al., 2005). Overall, C3d at 8.3 mg/ml in low salt will form more trimer 
than dimer, and this agrees with the c(s) analyses of the sedimentation velocity data 
(Figure 4.3d).  
 
(4.2.4) Sedimentation velocity of the CR2-C3d complex  
  Previous studies by surface plasmon resonance and mutagenesis studies showed that 
the CR2-C3d complex is formed with a KD of 22-27 nM in 50 mM NaCl, and that this 
association is weakened as [NaCl] is increased (Guthridge et al., 2001; Hannan et al., 
2005). Accordingly the CR2-C3d complex was studied by sedimentation velocity in both 
50 mM NaCl and 137 mM NaCl using a 1:1 molar ratio of CR2 and C3d.  
 
In 50 mM NaCl, the boundary fits for the complex in c(s) plots in a dilution series 
starting from 0.54 mg/ml (a range of 0.28-3.5 µM) showed a single peak at a s020,w value 
of 4.52 ± 0.11 S (4 determinations) (Figure 4.2(f,h)). As this peak has shifted from a 
value of 4.0-4.1 S for unbound CR2 (Figure 4.2(c,d)), this single peak indicated that full 
complex formation in the fluid phase had occurred between 0.28 µM and 3.5 µM, and 
therefore that its KD value is below 0.28 µM. The c(M) plot from Figure 4.2(f,h) 
indicated a molecular mass of 140 ± 17 kDa, which is close to the expected value of 155 
kDa calculated from its composition. The fits showed that the frictional ratios of CR2 
and the CR2-C3d complex were similar (Table 4.1). This indicates that no 
conformational change in CR2 had occurred with complex formation, and that the peak 
shift arises as the result of the change in molecular mass.  
 
In 137 mM NaCl, the corresponding c(s) fit for the complex in a dilution series 
starting from 1.08 mg/ml (a range of 0.42-6.9 µM) consistently showed two peaks at s020,w 
values of 2.7 S and 4.1 S at all concentrations (Figure 4.2(e,g)). The average s020,w values 
from all speeds and concentrations were 2.52 ± 0.40 S and 4.07 ± 0.14 S (seven 
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determinations). These values agree with that for monomeric C3d at 3.0 ± 0.1 S and that 
for unbound CR2 at 3.93 ± 0.20 S, both in 137 mM NaCl (Table 4.1). Integration of the 
two c(s) peaks compared to the total peak area revealed 14 ± 6% for the C3d peak and 85 
± 6% for the CR2 peak in the concentration range from 0.06-1.08 mg/ml. This is at the 
limit of error of the expected ratio of 23%-77% C3d-CR2 calculated according to the 
masses of the two free proteins. It was concluded that the non-appearance of a c(s) peak at 
4.6 S and the lack of change in signal areas in the two peaks are both consistent with little 
or weak complex formation in a fast chemical equilibrium on the time scale of the 
velocity experiment. The KD value is therefore above 6.9 µM. The use of c(s, f/fo) 
distribution fits showed that two frictional ratio values represented the sedimentation 
profiles at all concentrations (fits not shown). This indicated that any possible weak 
complex formation did not alter the frictional ratio of CR2 when unbound or bound, i.e. 
that no conformational change had occurred during complex formation in 137 mM NaCl.  
 
(4.2.5) X-ray scattering of CR2 and the CR2-C3d complex  
Solution scattering is a diffraction technique that studies the overall structure of 
biological macromolecules in random orientations in solution (Perkins et al., 2008). 
Immediately following size-exclusion chromatography, CR2 was successfully studied 
by X-ray scattering at three concentrations between 0.4 mg/ml and 1.5 mg/ml in 137 
mM NaCl. These experiments differ from previous (Gilbert et al., 2006b) in that (i) a 
flow cell was now used, meaning that possible radiation damage effects were more 
precisely eliminated, and (ii) a new detector had been installed, and enabling lower CR2 
concentrations to be studied (Section 4.4.3). However, in contrast to the X-ray 
experiments performed with 137 mM NaCl, X-ray experiments in 50 mM NaCl were 
unsuccessful for reason of persistent trace aggregates of CR2 that were visible at the 
lowest Q values (where Q = 4π sin θ /λ ; 2θ = scattering angle; λ = wavelength). These 
aggregates were not visible in the sedimentation experiments because they rapidly 
sediment out at the start of the velocity runs.   
 
In Guinier plots at low Q values, linear radius of gyration RG fits in an 
appropriate Q.RG range between 0.8 and 1.4 were again obtained (Figure 4.5a). The 
lowest Q values in Figure 4.5a were not used in order to exclude the effect of 
unavoidable trace aggregates. The mean X-ray RG value of CR2 in PBS was 10.8 ± 0.7 
nm (11 determinations), which is within error of the previously-reported value of 11.5 ± 
0.9 nm (Gilbert et al., 2006b). The cross-sectional radius of gyration RXS monitors the  
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Figure 4.5 X-ray scattering analyses for CR2 and its complex with C3d in 137 mM 
NaCl.  
(a) Guinier RG analyses, where the filled circles correspond to the data points 
used to obtain RG values and the straight lines correspond to the best fit through these 
points using a Q range of 0.09-0.14 nm-1 (top) and 0.08-0.13 nm-1 (middle and bottom). 
The Q.RG fit range is arrowed. Concentrations of 1.5 mg/ml, 0.8 mg/ml and 0.4 mg/ml 
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were used (top, middle and bottom respectively). 
(b) Guinier RXS analyses, using a Q range of 0.30 - 0.70 nm-1. Other details are 
as in (a).  
(c) Distance distribution P(r) analyses. The intensity of the four P(r) curves are 
normalised using the maximum of the P(r) curve at M at 6 nm (arrowed). The maximum 
dimension at 38 nm is denoted by L. The thin dots, line and dashes correspond to 1.5 
mg/ml, 0.8 mg/ml and 0.4 mg/ml. The thick dots correspond to 1.84 mg/ml, taken from 
Gilbert et al., 2006b.  
(d) Guinier RG fit analyses were performed in a Q range of 0.09-0.14nm-1.  
(e) Distance distribution P(r) analyses. The maximum in P(r) is denoted by M at 
3.2 nm and the maximum dimension is denoted by L at 36 nm. The continuous line 
corresponds to the CR2 and C3d mixture. The upper pair of dotted lines corresponds to 
CR2 at 0.8 mg/ml and 0.4 mg/ml from (c). The lowest dotted line corresponds to 
monomeric C3d in 50 mM NaCl. 
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shorter axes of an elongated macromolecule. The RXS value monitors the averaged short-
range and long-range orientation between adjacent SCR domains. Unlike two other 
related SCR proteins, factor H and complement receptor type 1, where two linear RXS 
regions of fit were observed (Aslam & Perkins, 2001; Furtado et al., 2008) only one fit 
range was seen for CR2 (Gilbert et al., 2006b). Here, the Q ranges used previously for 
CR2, factor H and complement receptor type 1 were re-assessed with the new CR2 data at 
lower concentrations. This reconfirmed the existence of a single RXS region in CR2, and 
the mean X-ray RXS value of CR2 was determined as 1.5 ± 0.1 nm (nine determinations) 
(Figure 4.5b), which is similar to the previous value of 1.8 ± 0.1 nm for CR2 (Gilbert et 
al., 2006b) and other RXS values for SCR proteins (Furtado et al., 2008).  
 
The indirect transformation of the scattering curve I(Q) measured in reciprocal 
space gives the distance distribution function P(r) in real space. The P(r) curve 
represents all the distance vectors between pairs of atoms within CR2 in PBS. The 
comparison of the three P(r) curves at 0.4-1.5 mg/ml with that obtained previously at 
1.84 mg/ml suggested small concentration dependence in Figure 4.5c that is attributable 
to trace aggregates at higher concentrations, although the P(r) maximum at M is 
unchanged at 6 nm and the maximum dimension at L is unchanged at 38 nm.Beyond the 
small concentration dependence, the finer detail in Figure 4.5c between 5 nm and 35 nm 
is comparable to the statistical error bars of the P(r) curves, and is not considered 
significant. However the previously-observed P(r) peak M2 at 22 nm is not now 
observed. The mean RG value of 11 ± 1 nm (3 determinations) calculated from the P(r) 
curves agrees well with those from the Guinier fits. 
 
The new X-ray data for CR2 was compared with that for the CR2-C3d complex 
in 137 mM NaCl at three concentrations, for which the sedimentation data in Figure 
4.2g shows little or no complex formation had occurred. The mean X-ray RG value of 
CR2-C3d was determined to be 11.0 ± 0.2 nm (four determinations) using the same Q 
range from 0.08 nm-1 to 0.14 nm-1 (Figure 4.5d). If no complex formation occurs, the 
weighted mean of the RG values of 10.8 nm for CR2 and 1.8 nm for monomeric C3d 
gives 10.4 nm (Gilbert et al., 2005; Perkins et al., 1985). This value sets the lower limit 
for the RG value of a non-interacting mixture of CR2 and C3d. Its similarity with the 
observed value of 11.0 nm indicates that no or only weak complex formation was 
detectable. The P(r) curve for CR2-C3d (cotinuous line in Figure 4.5e) corresponds to 
the sum of those for unbound CR2 at 0.4-0.8 mg/ml and C3 at 0.5 mg/ml (Figure 4.5b in 
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Gilbert et al., 2005). The main peak denoted as M at 3.2 nm is similar to that for C3d, 
and indicated the presence of unbound C3d. More importantly, the overall length L is 
unchanged at 38 nm, indicating that any weak interaction between CR2 and C3d does 
not result in a lengthening of CR2.   
 
(4.2.6) Sedimentation coefficient modelling of CR2, C3d and their complex  
The sedimentation coefficients s020,w of CR2, C3d and their complex were 
calculated from their atomic coordinates in order to confirm the interpretation of the 
sedimentation and X-ray data. The construction of C3d dimers and trimers is necessarily 
arbitrary as the intermolecular contacts are not known, although two-fold and three-fold 
symmetry respectively will be present. The compact oligomer arrangements exemplified 
in Figure 4.6 resulted in calculated s020,w values of 2.9-3.1 S, 4.5-4.7 S and 5.8-5.9 S for 
the monomer, dimer and trimer respectively using the HYDRO and HYDRPRO 
programs (Section 4.4.2). These calculations agreed well with the experimental values of 
3.0 ± 0.1 S, 4.3 ± 0.3 S and 6.0 ± 0.6 S (Table 4.1), and verified the existence of these 
three forms. The best-fit CR2 model from earlier work (Gilbert et al., 2006b) gave 
calculated s020,W values of 3.89-3.94 S, which agreed well with the experimental values 
of 3.93-4.03 S (Table 4.1). The superimposition of the solution structure of six CR2 
SCR 1-2 complexes with C3d (Gilbert et al., 2005) onto this best-fit CR2 model using 
the SCR 2 domain as template gave a calculated s020,W value of 4.57 ± 0.04 S for the 
CR2-C3d complex. This agreed well with the experimental value of 4.52 ± 0.11 S 
(Table 4.1). The modelling confirmed that no detectable conformational change in 
unbound CR2 takes place in its complex with C3d. 
 
No X-ray modelling of the CR2-C3d complex was done because this complex 
did not form in the 137 mM NaCl condition that resulted in good scattering data. 
 
(4.3) Conclusions 
We have determined the solution structure for intact CR2 bound to its main 
physiological ligand C3d to clarify the way in which CR2 interacts with C3d-coated 
antigens on the B-cell receptors to enhance the antibody response to antigen. To our 
knowledge, this is the first solution structure for a large multidomain SCR protein 
bound to its physiological ligand. This study extends our recent CR2 structure which 
showed that this has an extended and flexible structure, but with evidence of some  
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Figure 4.6 Modelling of the CR2-C3d complex using the experimental 
sedimentation coefficients in 50 mM NaCl. Schematic views of the putative 
monomer, dimer and trimer forms of C3d are shown in red. The orientation of the 
monomers within the dimer and trimer is unknown, and is arbitrary as shown. The 
complex between C3d (red) and CR2 (blue) is shown in both front and back views, in 
which the 15 SCR domains are numbered from 1 to 15. The sedimentation coefficients 
calculated from these models are shown in Table 4.1.
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bending-back or folding-back of the SCR domains (Gilbert et al., 2006b). Our strategy 
used 50 mM NaCl to clarify molecular details of how the complex was formed, given 
that no complex was detectable in 137 mM NaCl. Three lines of evidence based on 
sedimentation coefficients, X-ray scattering, and molecular modelling showed that little 
conformational alteration, if any, occurs in the 15 SCR domains of CR2 after binding to 
C3d. This result argues against any allosteric mechanism involving the intact CR2 
structure when bound to C3d. Both the unbound and liganded forms of CR2 possess 
extended and flexible arrangements of SCR domains. This concurs with the 
proportionately longest set of inter-SCR linker lengths that are present in CR2 when 
compared with other SCR-containing proteins (discussed more fully elsewhere (Gilbert 
et al., 2006b; Furtado et al., 2008). There are six long linkers of lengths seven or eight 
residues in CR2. The inter-domain angle between SCR 1-2 is as low as 37o-40o in its 
crystal structure while solution structures by scattering report angles of 63o-121o 
(Gilbert et al., 2005). This difference is a measure of how much the orientation can vary 
between two SCR domains in CR2, and results in a flexible SCR arrangement in full-
length CR2. Interestingly, our present study indicates no change in the SCR domain 
arrangement within CR2 with change of ionic strength, showing that this is not 
influenced by electrostatic interactions between SCR domains. 
 
The present study has extended our understanding of how to study the CR2-C3d 
interaction. Most notably, C3d in 50 mM NaCl at concentrations above 0.7 mg/ml (20 
µM) undergoes two slow monomer-dimer and monomer-trimer associations (possible 
monomer-tetramer also), both of which disappear in physiological 137 mM NaCl 
(Figure 4.3). This will hinder any NMR studies of unbound C3d in 50 mM NaCl. If C3d 
oligomer formation is circumvented for NMR studies by working in 137 mM NaCl, 
C3d will not form a complex with CR2. Fortunately both types of C3d self-association 
are blocked when the complex is formed with CR2 in 50 mM NaCl (Gilbert et al., 
2005). C3d oligomers therefore have no practical consequences on the previous 
structural analysis of the CR2 SCR 1-2 complex with C3d by constrained X-ray 
scattering modelling. However, there are further implications for determining the 
affinity of C3d for CR2 in low salt conditions, as C3d will compete for self-association 
with itself as well as with CR2. Thus KD values that are measured in 50 mM NaCl in the 
absence of an explicit consideration of multiple C3d equilibria should be interpreted 
with caution. An early binding study of C3d to CR2 in 75 mM NaCl did not fit a simple 
1:1 interaction (Sarrias et al., 2001). When the interaction between chip-bound CR2 and 
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fluid phase C3d was studied by surface plasmon resonance, the data suggested one high 
affinity site and a second much lower affinity site (Asokan et al., 2006). Both 
observations may be explained by the occurrence of C3d dimer and trimer formation. In 
addition, it cannot be ruled out that earlier C3d-CR2 mutagenesis work that modified 
C3d may have affected C3d dimer and trimer formation, rather than the direct C3d 
interaction with CR2. In distinction to these single-molecule studies, comparison with 
cell systems shows a detectable interaction between CR2 and C3d at physiological ionic 
strength. Thus flow cytometry using tetrameric C3dg-biotin in solution bound to CR2-
transfected cells bind the C3dg ligand in PBS buffer in a dose-dependent manner 
(Hannan et al., 2005). This difference is attributable to the involvement of a large 
number of CR2 molecules at the cell surface, and shows that solution results based on 
single molecule interactions do not necessarily correspond to in vivo conditions.  
 
The loss of the CR2-C3d interaction in 137 mM NaCl (Figure 4.2) may be 
explained by the masking of electrostatic interactions that mediate complex formation in 
50 mM NaCl. As noted above, possible salt-dependent conformational changes within 
the SCR domains that might inhibit the CR2 interaction with C3d have been ruled out. 
This key observation must be added to determinations of the dissociation constant KD 
for the CR2-C3d complex in five earlier studies by surface plasmon resonance (Table 
4.2). It should be noted that the ultracentrifugation data provide an independent method 
for determining associations, as this corresponds to a fluid phase measurement, not one 
based on binding to a chip surface. In low salt conditions of 75 mM NaCl and less, only 
two of the five studies report KD values below 100 nM (Guthridge et al., 2001; Hannan 
et al., 2005). The ultracentrifugation data in Figure 4.2h clearly show that a KD of less 
than 280 nM will account for the c(s) plot, and these support the lowest KD values in 
Table 4.2. Given that the largest KD values in low NaCl in Table 4.2 mostly involve 
CR2 SCR 1-15, it is possible that these larger KD values may be explained by a lack of 
steric access to the SCR 1-2 binding site in CR2 caused by the high flexibility of the 
SCR 3-15 domains. In contrast, using high salt conditions, all three surface plasmon 
resonance studies and the present ultracentrifugation study show that the KD values are 
significantly higher at 600 nM and above (Table 4.2). All four studies confirm the same 
weakening of C3d binding when the [NaCl] is increased.   
 
The molecular basis of NaCl effects on the CR2-C3d association is informed using 
crystal and solution structures. The CR2 SCR 1-2 structure was obtained in 100 mM MgCl2, 
CR2 protein         Ligands                         Buffer      Experimental KD            Reference 
Low NaCl (~50 mM)     
CR2 SCR 1-15 C3dg 10 mM phosphate, 50 mM NaCl 400-1600 nM (Moore et al., 1989)  
CR2  SCR 1-15 BCCP C3d 20 mM Phosphate, 50 mM NaCl 4300 nM (Sarrias et al., 2001) 
CR2  SCR 1-15 BCCP C3d 20 mM Phosphate, 75 mM NaCl 2800 nM (Sarrias et al., 2001) 
CR2 SCR 1-2 C3dg-biotin 10 mM HEPES, 50 mM NaCl 22.4 nM* (Guthridge et al., 2001) 
CR2  SCR 1-15 C3dg-biotin 10 mM HEPES, 50 mM NaCl 27.1 nM (Guthridge et al., 2001) 
CR2 SCR 1-2  C3d 10 mM HEPES, 50 mM NaCl 67.2 nM (Hannan et al., 2005) 
CR2 SCR 1-4 biotin C3d 10 mM HEPES, 50 mM NaCl 314 nM (Asokan et al., 2006) 
CR2  SCR 1-2  C3d-biotin 10 mM HEPES, 50 mM NaCl 179 nM (Asokan et al., 2006) 
CR2  SCR 1-4  C3d-biotin 10 mM HEPES, 50 mM NaCl 617 nM (Asokan et al., 2006) 
CR2  SCR 1-15  C3d-biotin 10 mM HEPES, 50 mM NaCl 2200 nM (Asokan et al., 2006) 
CR2 SCR 1-15 C3d 10 mM HEPES, 50 mM NaCl Below 280 nM  Present study 
 (Figure 4.2h) 
High NaCl (> 100 mM)     
CR2 SCR 1-15 C3dg 10 mM phosphate, 100 mM NaCl 3200 nM (Moore et al., 1989) 
CR2 SCR 1-2 C3dg-biotin 10 mM HEPES, 125 mM NaCl 620 nM** (Guthridge et al., 2001) 
CR2 SCR 1-2  C3dg 10 mM HEPES, 125 mM NaCl 658 nM (Hannan et al., 2005) 
CR2 SCR 1-15 C3d 9.6 mM phosphate, 137 mM NaCl Above 6900 nM  Present study  
(Figure 4.2g) 
** Precise values in 125 mM NaCl could not be obtained for reason of signal-noise issues at high [NaCl]. 
 Table 4.2 Dissociation constants KD for the CR2-C3d complex. 
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* No change in KD was observed between 25 mM NaCl to 85 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 mM CsCl, 100 mM HEPES (Prota et al., 2002). The co-crystal structure was obtained 
using 200 mM zinc acetate, 100 mM sodium cacodylate (Szakonyi et al., 2001). These 
buffers are probably sufficient to dissociate SCR1 from C3d according to our data (Figure 
4.2). A recent study of the effect of zinc ions on the binding of CR2-IgG to plate-bound 
C3dg showed that the interaction is abrogated in the presence of 0.2 M zinc acetate 
(Isenman et al., 2010). In the co-crystal, only SCR2 associates with C3d through the 
hydrogen bonding of the R83 side chain with a pocket of main-chain carbonyl groups, as 
well as through two lysines. The importance of R83 on C3d for binding with CR2 was 
indicated in a mutation study (Hannan et al., 2005) and a chemical shift perturbation study 
(Kovacs et al., 2009); however, the hydrogen bonds were disputed as an artefact in view of 
an alanine mutagenic scan (Clemenza & Isenman, 2000, see also Isenman et al., 2010). In 
the solution state, constrained scattering modelling shows that both SCR structures in 
uncomplexed CR2 SCR1-2 are opened out in 10 mM HEPES, 50 mM NaCl. This 
approach, as well as mutagenesis studies in 50 mM NaCl and 137 mM NaCl, also showed 
that both SCR 1 and SCR 2 make contact with the surface of C3d in this complex (Gilbert 
et al., 2005; Hannan et al., 2005; Young et al., 2007; Isenman et al., 2009). Thus a single 
SCR2-C3d interaction on its own in 137 mM NaCl appears to be too weak to lead to 
complex formation (Figure 4.2), and both SCR domains appear to be needed for binding. 
 
Electrostatic calculations have been reported for the CR2-C3d complex 
(Morikos & Lambris, 2004; Zhang et al., 2007), but their utility appears limited by the 
consideration of only the C3d-SCR2 interaction in the complex. Interestingly the 
calculations do not explain the absence of CR2-C3d complex formation in 137 mM 
NaCl, e.g. through the prediction of pK changes that would lead to the loss of charges 
that would lead to the loss of charges at the CR2-C3d interface. The calculations show 
that C3d has an excess charge of -4, while CR2 SCR 1-2 has an excess charge of +8. 
The calculations postulate that long-range electrostatic interactions have a role in 
complex formation, and it is possible that their masking in physiological salt is 
responsible for complex dissociation. Electrostatic maps for CR2 SCR 1-2 show a 
preponderance of positive charge on its surface (Hannan et al., 2005; Young et al., 
2007). In C3d two separate clusters of residues on opposite sides of the acidic pocket, 
specifically D37/D39 and E160/D163/I164/E166 are found to be important for binding 
with CR2 (Clemenza & Isenman, 2000; Isenman et al., 2010). Unlike the crystal 
complex of CR2-C3d, CR2 mutations targeting R13, R28, R36, K41, K50 and K57 on 
SCR1 confirm that SCR1 interacts with C3d, probably with at least some of E117, 
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D122, D128 and D147, which form a negatively-charged groove on C3d adjacent to the 
SCR2 site (Hannan et al., 2005). This interaction is supported by the scattering 
modelling of this complex (Gilbert et al., 2005). These short range interactions stabilise 
the complex, but are not sufficient on their own to be effective in 137 mM NaCl to 
enable the complex to be formed on the basis of a 1: 1 single molecule interaction. It 
may be relevant that the mutagenesis work used a tetrameric form of C3dg-biotin 
ligated to streptavidin, suggesting that the aggregation of CR2 and C3d will promote 
these interactions in physiological salt. 
 
 The understanding of the solution structures of CR2 and the CR2-C3d complex 
is related to its involvement with the B-cell receptor as a coreceptor that links innate and 
adaptive immunity (Fearon & Carroll, 2000; Tolnay & Tsokos, 1998). Our previous 
study (Gilbert et al., 2006b) was focussed on the determination of a highly flexible CR2 
structure that is well designed to interact with a variety of differently-sized locations for 
C3d bound to antigens. This CR2 structure is conserved across different mammalian 
species. The present study has focussed on the solution-phase structure of the CR2-C3d 
complex and its reduced stability in physiological salt. Here and earlier (Moore et al., 
1989; Guthridge et al., 2001) no interaction was detected between C3d and CR2 in 
physiological pH and ionic strength. Nonetheless, the use of a tetravalent C3dg ligand 
bound to surface-bound CR2 shows that this interaction must take place. Our main 
results show that B-cell activation must result from the combination of (i) a flexible 
CR2 domain structure that is able to position SCR 1-2 in conformations appropriate to 
interact with antigens, and (ii) the accumulation of weak interactions between CR2 and 
C3d. For the latter to contribute as an immunologically significant trigger, these weak 
CR2–C3d interactions must be multiplied several times over by the presence of a 
sufficiently large number of C3d-bound ligands on the antigen(s)-coated pathogen and a 
sufficiently large number of CR2 molecules on the B-cell surface. This interaction will 
be amplified by increased local concentration effects at the B-cell surface, because CR2 
is already positioned on this surface ready for interaction with C3d ligands. Such an 
interaction in physiological salt appears to be a good way for B-cells to respond only to 
antigens that present multimeric C3d molecules in a manner that clustered surface-
bound CR2 molecules. This is similar to the CR1 interaction with C3b/C4b molecules 
on neutrophils, which is also strongly promoted by the polymerization or 
multimerization of the ligand and the clustering of receptors.  
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(4.4) Materials and Methods.  
(4.4.1) Purification of CR2, C3d and their complex 
Human CR2 SCR 1-15 was expressed in Sf9 insect cells as a soluble 
recombinant protein in the baculovirus expression system as described previously 
(Guthridge et al., 2001; Gilbert et al., 2006b). This protein was kindly provided by Dr 
Asokan (Denver, U.S.A). This product (Ile21 to Arg971) possessed a stop codon prior 
to the transmembrane domain to create a soluble secreted form of the receptor. 
Immediately prior to scattering and ultracentrifugation data acquisition, the concentrate 
was dialysed against Dulbecco’s phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 
mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.5) made 0.5 mM in EDTA. Non-
specific aggregates were removed by size exclusion chromatography on a Superdex 200 
HiLoad 16/60 column (Amersham Pharmacia Biotech).  
 
Human C3d (sequence 994-AVDAE… to …QLPSR-1303 of the mature protein 
C3 with SWISSPROT accession code P01024) was expressed in E. coli BL21 
transformed with the PGEX-2T vector for purification by an affinity column binding 
GST-tag using standard protocols. The construct was provided by Prof. V. M. Holers 
and Dr. J. P. Hannan of the University of Colorado School Of Medicine, Denver, 
Colorado, U.S.A. Previously C3d was purified using a pET15b-C3d plasmid (Szakonyi 
et al., 2001; Guthridge et al., 2001; Gilbert et al., 2005). Ampicillin-resistant colonies 
were used to produce starter cultures, which were then expanded to five litres and 
grown at 37°C until an absorbance at 600 nm of 0.3 was attained, then cooled to 23°C 
and incubated to an absorbance of 0.4. Samples were then induced with 0.5 mM IPTG 
and shaken overnight at 25°C. The culture was lysed in the presence of protease 
inhibitors by sonication, and after clarification applied to a GSTrap FF column 
equilibrated in 25 mM Tris, 0.5 M NaCl, 1 mM EDTA, 1 mM DTT, pH 8.0. After 
washing to remove unbound protein, thrombin was added to the column. After an 
overnight incubation at 4ºC, the thrombin was inactivated and the cleaved C3d was eluted 
by further washing. Reduced glutathione was added to the buffer in further washes to elute 
GST and uncleaved GST-C3d. The C3d was concentrated using Amicon® Ultra-15 
centrifugal filter devices with a molecular mass cut-off of 10 kDa at 4500 g, and size 
exclusion chromatography using a Superdex-200 Prep Grade XK 16/60 column resulted in 
the C3d samples used for data acquisition.  
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The CR2 and C3d samples were extensively dialysed into PBS or HEPES (10 
mM HEPES, 50 mM NaCl, pH 7.4) buffers for data acquisition. Samples were routinely 
analysed by SDS-PAGE before and after scattering and ultracentrifugation to confirm 
their integrity. CR2 and C3d concentrations were determined using absorption 
coefficients of 12.7 and 13.1, respectively (1%, 280 nm, 1 cm path length), which was 
calculated from their compositions (Perkins, 1986). For the CR2 composition, eleven 
high mannose type oligosaccharides GlcNAc2Man7 were assumed. Following dialysis 
into PBS or HEPES buffer as required, the CR2-C3d complexes were prepared by 
mixture in a 1:1 molar ratio according to the sample absorbances. 
 
(4.4.2) Analytical ultracentrifugation data and analyses  
Analytical ultracentrifugation was done at 20ºC with two Beckman XL-I 
instruments equipped with An50Ti and An60Ti rotors as described (Gilbert et al., 
2006b). Sedimentation velocity experiments were used for shape and size analysis. New 
sedimentation velocity data for CR2 were acquired in both PBS and Hepes buffers at 
rotor speeds of 25,000, 30,000, 35,000, 40,000 and 42,000 r.p.m in a concentration 
series of 0.12 – 0.34 mg/ml. New sedimentation velocity data for C3d were acquired in 
both PBS and Hepes buffers. The PBS data utilised sample concentrations of 0.54 – 
7.48 mg/ml, while the Hepes data utilised concentrations of 0.32 – 8.29 mg/ml, with 
rotor speeds of 32,000, 40,000 and 50,000 r.p.m. This work included reanalysis of the 
previous C3d velocity data in Hepes buffer (Gilbert et al., 2005). Sedimentation 
velocity experiments for the CR2–C3d complex were performed with rotor speeds of 
30,000, 40,000 and 42,000 r.p.m. in PBS and Hepes buffers. The PBS data used a total 
concentration of complex of 1.08 mg/ml, prepared by mixing 1.07 mg/ml CR2 and 1.13 
mg/ml C3d in a 1:1 molar ratio. The Hepes data used a total concentration of 0.54 
mg/ml, prepared by mixing 0.67 mg/ml CR2 and 0.33 mg/ml C3d in a 1:1 molar ratio. 
Each complex was studied in a dilution series from 100% to 10%. Data analyses used 
direct boundary Lamm fits of up to 200 scans using SEDFIT (Schuck, 1998, 2000), 
which was used for size-distribution analysis c(s) that assumed that all species have the 
same frictional ratio f/fo. The final c(s) fits were determined using a resolution of 200 
and by floating the meniscus, frictional ratio, and baseline and holding the cell bottom, 
partial specific volume and solvent density fixed until the overall root-mean-square 
deviations and visual appearance of the fits were satisfactory (Figure 4.2 and 4.3). For 
C3d, the frictional ratio was floated to result in a realistic range of values of 1.10 ± 0.08 
(Table 4.1). For CR2 and the CR2–C3d complex, floating the frictional ratio resulted in 
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ranges of 1.99 – 2.11 (Table 4.1). The buffer density of 137 mM NaCl in PBS and 50 
mM NaCl in Hepes was 1.00541 g/ml and 1.00117 g/ml, respectively, as measured with 
an Anton Paar DMA 5000 density meter, to be compared with 1.00534 ml/g and 
1.00030 ml/g, respectively, calculated from SEDNTERP (Gilbert et al., 2005). The 
partial specific volume v for CR2 and C3d was calculated to be 0.716 ml/g and 0.746 
ml/g from its amino acid and carbohydrate content calculated from its sequence, 
respectively (Perkins, 1986). 
 
Sedimentation equilibrium experiments resulted in molecular weight and 
dissociation constant KD. C3d data were obtained in PBS and HEPES buffers at 20ºC over 
30 h at each speed using six-sector cells with column heights of 2 mm and rotor speeds of 
19,000 r.p.m., 24,000 r.p.m., 28,000 r.p.m., 30,000 r.p.m. and 35,000 r.p.m. The existence 
of equilibrium conditions after at least 10 h in PBS buffer and at the lowest 
concentrations, after at least 30 h at the highest concentrations in HEPES buffer was 
confirmed using overlays of runs measured at 3 h intervals in SEDFIT. In PBS buffer, 
nine concentrations between 0.04 mg/ml to 7.01 mg/ml were used, while in HEPES 
buffer, nine concentrations between 0.11 mg/ml to 5.50 mg/ml were used. Data analyses 
utilised SEDPHAT version 5.01 (Schuck, 2003). First, multispeed fits assuming a single 
species were performed individually. Next, the best interference optics fits from 19,000 
r.p.m., 28,000 r.p.m., and 35,000 r.p.m. were used for global fits using the monomer-‘m-
mer’-‘n-mer self-association model with m = 2 (dimer) and n = 3 (trimer) in SEDPHAT 
(Figure 4.4). The global fits utilised a common baseline, meniscus, cell bottom, extinction 
coefficient, and loading concentration. Fits used the M and s, simplex and Marquardt-
Levenberg fitting routines, while floating the baseline and the cell bottom of the cell. 
Statistical error analyses employed the Monte-Carlo approach.  
 
(4.4.3) X-ray scattering data and analyses  
X-ray scattering data were collected in three sessions on the camera at the ID02 
high brilliance beamline at the European Synchrotron Radiation Facility in Grenoble, 
France, operating at a ring energy of 6.03 GeV (Narayanan et al., 2001). Data prior to 
September 2006 (Gilbert et al., 2005, 2006a, 2006b) were acquired using an image-
intensified FReLoN CCD detector, which involved an additional correction step for the 
point spread function of the image intensifier. This detector has been replaced by a fibre 
optically coupled high sensitivity and dynamic range CCD detector (FReLoN). Using a 
smaller beamstop, this enabled data to be recorded at a shorter sample-to-detector 
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distance of 2.0 m, thereby improving the signal-to-noise ratio. For CR2 in PBS buffer, 
storage ring currents ranged between 167-168 mA (uniform fill mode) and 79-81 mA 
(16 bunch mode) in two sessions. For the CR2-C3d complex in PBS buffer, the ring 
current ranged from 56 mA to 82 mA (16 bunch mode in one beam session). Flow cells 
were used to eliminate radiation damage in conjunction with on-line checks for the 
absence of radiation damage by optimisation of the exposure times in sets of ten time 
frames. The flow cell utilised fresh 100 µl samples that move in the X-ray beam, in 
distinction to the static samples in Perspex cells used previously (Gilbert et al., 2005, 
2006a, 2006b). Each sample was measured in four sets of ten time frames of length 0.1, 
0.15 and 0.2 sec for CR2 and 1, 1.5 and 2 sec for the CR2-C3d complex, both in PBS. 
Sample temperature corresponded to ambient conditions at 23ºC for CR2 and 20ºC for 
the CR2-C3d complex. Unbound CR2 was studied at concentrations of 0.4 mg/ml, 0.8 
mg/ml and 1.5 mg/ml. The CR2-C3d complex was studied at 0.7 mg/ml, 1.0 mg/ml and 
1.3 mg/ml. Buffers were measured using the same exposure times in alternation with the 
samples to eliminate background subtraction errors.  
 
For a given solute-solvent contrast, the radius of gyration RG characterises the 
degree of elongation provided that the internal inhomogeneity of scattering densities has 
no effect. Guinier analyses at sufficiently low Q give the RG and I(0) parameters 
(Glatter & Kratky, 1982): 
    lnI(Q) = lnI(0) – RG2Q2/3 
This equation is valid in a Q.RG range of up to 1.5. The relative I(0)/c values (where c is 
sample concentration) for samples measured in the same buffer gives the relative 
molecular mass of the proteins when referenced against a suitable standard. For 
elongated structures, the mean radius of gyration of cross-sectional structure RXS and the 
mean cross-sectional intensity at zero angle [I(Q)Q]Q→0 is obtained from: 
ln [I(Q)Q] = [I(Q)Q]Q→0 - RXS2Q2/2. 
 
Combination of the RXS and RG analyses gives the length of the macromolecule 
if the structure can be represented by an elliptical cylinder, where L = √ 12(RG2 - RXS2) 
(Glatter & Kratky, 1982). The Guinier analyses were done with a PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics O2 
Workstations. Indirect transformation of the reciprocal space scattering data into real 
space to give the distance distribution function P(r) was implemented using the program 
GNOM (Semenyuk & Svergun, 1991; Svergun, 1992). The P(r) curve represents the 
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distribution of distance vectors r between pairs of atoms within a molecule, and 
provides another calculation of the RG and I(0) values as well as giving the maximum 
dimension of the macromolecule, L. The CR2 X-ray curve used the Q range between 
0.08 nm-1 and 1.75 nm-1 at 0.40 mg/ml (Figure 4.5c), supplemented by that between 
0.09 nm-1 and 1.34 nm-1 at 0.80 mg/ml and between 0.09 nm-1 and 1.69 nm-1 at 1.5 
mg/ml. The CR2-C3d complex X-ray curves use the Q range between 0.12 nm-1 and 1.45 
nm-1 at 1.32 mg/ml (Figure 4.5e), and Dmax was set as 36 nm. 
 
(4.4.4) Modelling of the CR2-C3d complex 
The CR2 SCR 1-15 model was taken from the overall best-fit solution structure of 
CR2 which gave good agreement for both the RG and RXS values (PDB code 2gsx) (Gilbert et 
al., 2006b). That for the complex between CR2 SCR1-2 and C3d was taken from the six best-
fit solution structures for this (PDB code 1w2s) (Gilbert et al., 2005). Insight II 98.0 
(Accelrys, San Diego, CA) software on Silicon Graphics workstations was used for 
manipulations. Thus the C3d oligomers were created by juxtapositions of the C3d crystal 
structure (PDB code 1C3d) (Nagar et al., 1998) in arbitrary contacts but showing two-fold or 
three-fold symmetry. SCR2 in the six CR2-C3d complexes was superimposed upon SCR2 in 
the SCR1-15 model, after which the SCR1 and SCR2 domains in the SCR 1-15 model were 
deleted. Minor steric overlap between the C3d fragment and SCR3-15 in these models was 
removed by a torsion angle rotation in the linker peptide between SCR2 and SCR3. Sphere 
models for C3d were calculated as described for use with the HYDRO software (Gilbert et 
al., 2005; Garcia de la Torre et al., 1994). Sedimentation coefficients for CR2, C3d and their 
complex were calculated from atomic models using HYDROPRO software with a default 
value of 0.31 nm to represent the hydration shell (Garcia de la Torre et al., 2000).
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       Chapter Five 
 
 
                      Self-association and domain rearrangements between 
complement C3 and C3u provide insight into 
the activation mechanism of C3 
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(5.1) Introduction 
The complement system of innate immunity plays a major role in the 
recognition and elimination of microbial intruders and other pathogenic cells (Walport, 
2001; Law & Reid, 1995). Complement is activated by three pathways, the classical, 
alternative and lectin pathways, each of which leads to the activation of C3, the so-
named third component of complement. C3 is the most abundant complement 
component in plasma at about 1.0 mg/ml, and its level can be elevated considerably 
during inflammation and infection. The three pathways lead to a C3 convertase enzyme 
complex that activates C3 by proteolytic cleavage to yield the small anaphylatoxin C3a 
and active C3b (Walport, 2001; Law & Reid, 1995). The removal of C3a induces a 
major conformational change in C3b to expose an internal thioester bond, which is 
inaccessible in C3 (Janssen et al., 2005; Fredslund et al., 2006, 2008; Janssen et al., 
2006; Wiesmann et al., 2006; Wu et al., 2009; Rooijakkers et al., 2009; Ajees et al., 
2006). The thioester forms covalent bridges with antigenic surfaces. C3 is also 
continuously activated at a slow “tick-over” rate in plasma to form C3u, sometimes 
named C3H2O. C3u also participates in convertase enzyme complexes that cleave C3 
into C3a and C3b, and triggers the rapid activation of C3 to C3b, but C3u is unable to 
attach covalently to surfaces because its thioester bond has been hydrolysed. 
 
C3 is synthesised as a single chain pre-pro-molecule in which the α- and β-
chains are linked by a tetra-Arg sequence that is enzymatically removed during post-
translational processing. The α- and β-chains (molecular masses 115 kDa and 75 kDa 
respectively) are linked by a single disulphide bond and non-covalent interactions. 
Major aspects of complement activation have been revealed by three C3 and C5 crystal 
structures (where C5 is a homologue of C3) and five C3b crystal structures (Janssen et 
al., 2005; Fredslund et al., 2006, 2008; Janssen et al., 2006; Wiesmann et al., 2006; Wu 
et al., 2009; Rooijakkers et al., 2009; Ajees et al., 2006). C3 is formed from a 
compacted arrangement of eight macroglobulin (MG) domains, to which are added the 
thioester-containing domain (TED) domain containing the C3 active site, a C1r/C1s-
Uegf-Bmp1 (CUB) domain that links the TED and MG domains, and three additional 
C345C, L and C3a domains. In C3, the TED and CUB domains are positioned near the 
C345C domain and the thioester is buried (Janssen et al., 2005; Fredslund et al., 2006, 
2008). In C3b, four similar crystal structures show that the TED and CUB domains are 
extended along the major axis of C3b to make contact with the MG1 domain at the base 
of the structure (Janssen et al., 2006; Wiesmann et al., 2006; Wu et al., 2009; 
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Rooijakkers et al., 2009). A fifth deviant crystal structure suggested that the TED and 
CUB domains are significantly extended away from the MG domains (Ajees et al., 
2006), however the crystallographic evidence for the fifth C3b structure was disputed 
(Janssen et al., 2007; Ajees et al., 2007; Borrell, 2009). Electron microscopy studies of 
C3b in vacuo supported the location of the TED and CUB domains seen in the four C3b 
crystal structures (Nishida et al., 2006). H-D exchange rates that were measured in mass 
spectrometry studies of C3, C3u and C3b indicated that large conformational changes 
occur between the three different protein forms (Winters et al., 2005; Schuster et al., 
2008). 
 
            Knowledge of the solution properties of C3 and C3u will clarify the initial stage 
of the mechanism of the conversion of C3 to C3b. A notable aspect of these crystal 
structures is that many were crystallised in buffers with low salt, and it is not known if 
these crystallographically-observed C3 structures or their properties are maintained in 
near-physiological buffers. A two-segmented structure for C3 and its homologues C4 
and C5 had been identified from low resolution solution scattering modelling, in which 
large conformational differences between C4 and C4b were detectable (Perkins & Sim, 
1986; Perkins et al., 1990a; 1990b).  Because the smaller segment seen by scattering 
resembles the distinct TED-CUB domains seen in recent crystal structures, this 
indicates that scattering modelling is able to monitor the positions of the TED-CUB 
domains in C3 and C3u (Figure 5.1). In recent years, X-ray scattering has benefitted 
from improved signal-noise ratios at the ESRF facility, alongside with new constrained 
modelling methods that result in molecular structural determinations that are deposited 
in the Protein Data Bank (Bonner et al., 2009; Perkins et al., 2009). Analytical 
ultracentrifugation has been much improved by the use of size-distribution c(s) analyses 
to analyse self-association (Cole et al., 2008). Here, we combine both methods to show 
that both self-association and conformational differences exist between C3 and C3u. We 
show that C3 and C3u are principally monomeric, however the monomer exists in 
equilibria with two different types of dimers. One of these offers an explanation for the 
mechanism of inhibition of C3b by the bacterial protein SCIN (Rooijakkers et al., 2009).  
Constrained scattering modelling demonstrated that the position of the TED-CUB 
domains relative to the MG1-MG8 domains is significantly altered between C3 and C3u. 
We conclude that the conformational properties of the TED-CUB domains are more 
variable than believed from crystallography. This variability would enable activated C3  
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Figure 5.1 Comparison between the low resolution Debye sphere models for C3, 
C4 and C5 in 1990 and the crystal structure of C3 (PDB code 2A73).  
(a) The two side views correspond to orthogonal views of the long axis of the C3 
structure. The long axis of the C3c segment (tangerine) in the C3 crystal structure 
corresponds to the major segment of the C3 sphere model. 
(b) The top end of the two views in (a) is rotated by 90o towards the reader. The TED-
CUB domains (red) correspond to the minor segment of the C3 Debye sphere model.  
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and its homologues to bind to a broad range of antigenic targets and provides insight for 
the mechanism of C3 regulation by complement factor H and other inhibitors.  
 
(5.2) Results  
(5.2.1) Sedimentation velocity data analysis for C3 and C3u  
Immediately prior to ultracentrifugation and scattering experiments, purified C3 
and C3u (Section 5.4.1) were subjected to gel filtration on Superose 6 column to 
remove potential pre-existing aggregates or degradation products. Both proteins eluted 
as single symmetric peaks in 137 mM NaCl and 50 mM NaCl (Figures 5.2(a,b)). Here 
and below, the buffer is denoted as 137 mM NaCl or 50 mM NaCl, even though 
phosphate is also present (Section 5.4). C3u (and less so with C3) eluted earlier in 50 
mM NaCl than in 137 mM NaCl, suggesting that C3u underwent self-association in 
reduced salt. C3 and C3u before and after experiments revealed a single band in non-
reduced SDS-PAGE and two bands corresponding to the α- and β-chains in reduced 
SDS-PAGE (Figure 5.2(c)).  
 
Analytical ultracentrifugation studies macromolecular structures in solution by 
monitoring the time-course of sedimentation under high centrifugal force (Cole et al., 
2008). The peaks in size distribution analyses c(s) plots monitor the extent of sample 
monodispersity, and macromolecular elongation is monitored through the sedimentation 
coefficient s20,w values of the observed peaks. Using SEDFIT, good boundary fits were 
obtained for the sedimentation profiles for each of C3 and C3u in 50 mM and 137 mM 
NaCl buffer (Figure 5.3(a-d)). While a major c(s) peak was visible in all runs, 
differences between the two buffers were seen:  
(i) In 137 mM NaCl, the interference and absorbance data sets for C3 gave an 
s020,w value of 7.85 ± 0.05 S, and both data sets for C3u gave an s020,w value of 7.44 ± 
0.07 S (Figure 5.4). No concentration dependence was seen, showing that both the 
shape and size of C3 and C3u were each unchanged with concentration, and the 
molecular weights from the c(s) peaks corresponded to 192 ± 8 kDa and 172 ± 16 kDa 
for C3 and C3u respectively, in good agreement with their sequence-predicted 
molecular weight of 189.0 kDa. Accordingly the change in s20,w values showed that C3u 
is more elongated in solution than C3. The frictional ratios f/fo (where fO is the frictional 
coefficient of the sphere with the same volume as the hydrated glycoprotein) for C3 and 
C3u were 1.37 ± 0.10 and 1.40 ± 0.10. 
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Figure 5.2 Size-exclusion gel filtration and SDS-PAGE analyses of C3 and C3u.   
(a,b) The elution of C3 (dashed line) and C3u (continuous line) are labelled as shown. 
The elution positions of four standards are shown in kDa. In 137 mM NaCl buffer 
(black), C3 and C3u eluted as a single peak at approximately the same position. In 50 
mM NaCl buffer (red), C3u eluted slightly earlier than C3, and both eluted earlier 
compared to 137 mM NaCl buffer. 
(c) Non-reducing and reducing SDS-PAGE analyses of C3 and C3u from the 137 mM 
NaCl buffer. The protein markers are labelled at the right side in kDa. 
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Figure 5.3 (figure legend overleaf) 
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Figure 5.3 Sedimentation velocity size distribution analyses c(s) of C3 and C3u.  
(a-d) Representative interference boundary fits for C3 and C3u at about 2 mg/ml in 137 
mM NaCl (black) and 50 mM NaCl (red) buffers. Only every sixth or tenth scan of the 
fitted boundaries are shown for clarity. 
(e) The c(s) distributions for C3 in 137 mM (black) and 50 mM (red) NaCl buffers. In 
137 mM NaCl, C3 concentrations ranged from 0.5 mg/ml to 2.2 mg/ml. In 50 mM NaCl, 
C3 concentrations ranged from 0.3 mg/ml to 2.3 mg/ml. Here and in (f), the dotted lines 
indicate the movement of s20,w with change of concentration. 
(f) The c(s) distributions for C3u in 137 mM (black) and 50 mM (red) NaCl buffers. In 
137 mM NaCl, C3u concentrations range from 0.3 mg/ml to 2.4 mg/ml. In 50 mM NaCl, 
C3u concentrations range from 0.4 mg/ml to 2.1 mg/ml.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) The corresponding s20,w values for C3u in 50 mM (red) and 137 mM (black) were fitted by linear regression to result in s020,w values at zero 
concentration of 7.47 ± 0.07 S in 137 mM NaCl and 7.66 ± 0.19 S in 50 mM NaCl.  
(a) The s20,w values for C3 in 50 mM (red) and 137 mM (black) were fitted by linear regression to result in s020,w values at zero concentration of 7.85 ± 
0.05 S in 137 mM NaCl and 8.02 ± 0.12 S in 50 mM NaCl. Statistical error bars are shown where visible. 
  
Figure 5.4 Concentration dependence of the sedimentation coefficients s20,w for C3 and C3u.  
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(ii) In 50 mM NaCl, the major c(s) peak for C3 and C3u both showed a clear 
concentration dependence (Figure 5.3(e,f)). The molecular weight and f/fo values for C3 
were 190 ± 18 kDa and 1.38 ± 0.09 respectively; those for C3u were 175 ± 20 and 1.37 
± 0.12 respectively. The s20,w values for C3 ranged from 8.04 S to 8.25 S, while those 
for C3u increased by a larger proportion from 7.59 S to 8.02 S for C3u. The 
extrapolated s020,w values for C3 and C3u were 8.02 ± 0.12 S and 7.66 ± 0.19 S 
respectively, being within error of the corresponding values in 137 mM NaCl. It is of 
interest that these values are slightly increased in 50 mM compared to 137 mM, because 
this implies that both proteins became more compact in 50 mM NaCl. 
 
The concentration dependence in 50 mM NaCl resembles that seen for the C3d 
fragment of C3, which gave a single s20,w value that was unchanged at 3.0 S in 137 mM 
NaCl, but gave three c(s) peaks at s20,w values of 3.0 S, 4.3 S and 6.0 S in 50 mM NaCl 
(Gilbert et al., 2005; Li et al., 2008; Chapter 4). Further inspection of the c(s) analyses 
for C3 and C3u revealed that a second minor s20,w peak at 11.2 ± 1.0 S and 11.5 ± 1.3 S 
respectively was consistently observed for both proteins (Figure 5.5(a)). The molecular 
weights from the c(s) peaks corresponded to 330 ± 36 kDa and 305 ± 36 kDa for C3 and 
C3u respectively; this is less than double the sequence-predicted molecular weight of 
378 kDa. This lower-than-expected molecular mass indicate that this peak is not a stable 
C3 or C3u dimer but is instead a reaction boundary corresponding to a rapid equilibrium 
between monomeric and dimeric protein on the time scale of sedimentation (Dam & 
Schuck, 2005). Reaction boundaries are peaks that correspond to the co-sedimentation 
of two different species, and exhibit well-defined sedimentation coefficients between 
the values of the two different species. Peak integrations showed that the estimated 
proportion of dimer is low at 6 ± 3% for C3 and 8 ± 2% for C3u in 137 mM NaCl, and 5 
± 3% for C3, but increases up to 23% for C3u in 50 mM NaCl (Figure 5.5(b,c)). The 
existence of dimer in rapid equilibrium with monomer accounts for the concentration 
dependences for C3 and C3u in 50 mM (Figure 5.4). Given the knowledge that C3d 
itself self-associates in 50 mM NaCl, the greater salt dependence seen for C3u in 50 
mM NaCl compared to 137 mM NaCl indicated that the C3d region is significantly 
more exposed in C3u than in C3.  
 
Previous analytical ultracentrifugation experiments reported s020,w values for C3 
of 9.5 S (Bokisch et al., 1969), 8.3 ± 0.1 S (Molenaar et al., 1973), 7.3 ± 0.4 S (Paques, 
1980), and 7.3 ± 0.3 S (Perkins & Sim, 1986). While the earlier work gave variable 
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Figure 5.5 Dimer formation in C3 and C3u from size distribution analyses c(s). 
(a) C3u in 50 mM NaCl buffer is shown at 0.7 mg/ml, 1.4 mg/ml and 2.1 mg/ml. The 
monomer peak is labelled as 1 (Figure 5.3(e,f) and the dimer peak is labelled as 2).  
(b) The concentration dependence of the percentage C3u dimer formation in 50 mM 
NaCl (red) and 137 mM NaCl buffers (black) by linear regression. 
(c) The concentration dependence of the percentage C3 dimer formation in 50 mM 
NaCl and 137 mM NaCl buffers. The mean values are shown by the lines.  
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results, their mean value is close to the C3 value of 7.85 ± 0.06 S measured in 137 mM 
NaCl in the present study.  
 
(5.2.2) X-ray solution scattering data for C3 and C3u  
Solution scattering is a diffraction technique that studies the overall structure of 
macromolecules in solution (Perkins et al., 2008, 2009). Freshly prepared C3 and C3u 
were studied in 50 mM and 137 mM NaCl buffer. The domain arrangement and self-
association of C3 and C3u were assessed by Guinier analyses of the X-ray I(Q) data in 
two different Q ranges (Q = 4 π sin θ /λ; 2θ = scattering angle; λ = wavelength). The 
overall radius of gyration RG monitors the degree of elongation of C3 and C3u, while 
that for its cross-section RXS monitors the elongation of its cross-section shape along its 
longest axis. The I(0)/c value is proportional to the molecular mass. All four sets of 
Guinier RG analyses showed linear fits within satisfactory Q.RG and Q.RXS limits (Figure 
5.6). The concentration dependence of the RG values again reflected the buffer in use:  
(i) In 137 mM NaCl, the RG values for C3 and C3u were unchanged at 4.52 ± 
0.08 nm and 4.88 ± 0.23 nm with protein concentration (Figure 5.7(a,c)). The larger 
value for C3u reflected its more elongated structure, in agreement with the s020,w values. 
The I(0)/c values were similar at 0.0186 ± 0.0009 and 0.0196 ± 0.0013 (Figure 5.7(b,d)), 
showing that both C3 and C3u were similar in mass as expected. The RXS values were 
the same at 2.54 ± 0.06 nm and 2.55 ± 0.16 nm for C3 and C3u (Figure 5.7(e,f)).  
(ii) In 50 mM NaCl, the RG values for C3 and C3u increased linearly with 
concentration. At zero concentration, the RG values were 4.87 ± 0.26 nm and 5.16 ± 
0.22 nm respectively. That these values are slightly larger than those at 137 mM is 
attributed to the increased proportion of dimeric species in reduced salt conditions, 
meaning that the mean RG value corresponds to an average of monomer and a small 
amount of dimer. The I(0)/c values were similar at 0.0199 ± 0.0016 and 0.0178 ± 
0.0011, and agree with those at 137 mM NaCl when extrapolated to zero concentration. 
This shows that the I(0)/c values correspond to similar masses and that the monomer-
dimer equilibrium is reversible. The RXS values also became the same at 2.50 ± 0.17 nm 
and 2.56 ± 0.03 nm for C3 and C3u when extrapolated to zero concentration.  
 
 The distance distribution function P(r) leads to the determination of overall 
lengths L following an assumption of the value of the maximum dimension Dmax. The 
RG values calculated from the P(r) analyses agree with those from the Guinier analyses 
(Table 5.1). In 137 mM NaCl, the length L of C3 and C3u in 137 mM NaCl is 16 nm  
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Figure 5.6 Experimental X-ray Guinier RG and cross-section RXS analyses of C3 
and C3u. The Q ranges used for the RG fits were 0.13 to 0.30 nm-1 for C3, and 0.16 to 
0.30 nm-1 for C3u. . The Q ranges used for the RXS fits were 0.35 to 0.50 nm-1 for C3 
and C3u. The data points are denoted by open circles; the filled circles were used to 
determine the RG (a-d) and RXS (e-h) values based on the best fit lines as shown. 
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(a,e) C3 concentrations between 0.5 mg/ml to 1.2 mg/ml in 137 mM NaCl (black) from 
bottom to top.  
(b,f) C3 concentrations between 0.2 mg/ml to 2.0 mg/ml in 50 mM NaCl (red).  
(c,g) C3u concentrations between 0.5 mg/ml to 1.1 mg/ml in 137 mM NaCl.  
(d,h) C3u concentrations between 0.5 mg/ml to 1.7 mg/ml in 50 mM NaCl.  
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Figure 5.7 Concentration dependence of the Guinier RG, I(0)/c and RXS values for 
C3 and C3u. Each value was measured in quadruplicate and averaged for linear 
regression fits. Statistical error bars are shown where visible.  
(a, c) The RG values are shown for 137 mM NaCl (black) and 50 mM NaCl buffer (red).  
(b, d) The corresponding I(0)/c values are shown for 137 mM and 50 mM NaCl buffer. 
The fitted line shown for 137 mM NaCl buffer is the mean value.  
(e, f) The RXS values are shown for 137 mM NaCl and 50 mM NaCl buffer. 
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Figure 5.8 X-ray distance distribution function P(r) analyses for C3 and C3u. For 
C3 and C3u in 137 mM NaCl, the peak maximum M is observed at 5.0 nm. For C3 and 
C3u in 50 mM NaCl, M is observed at 5.0 to 5.4 nm for C3 and 5.0 to 5.2 for C3u.  
 
 
 
 
 
 
 
(d) C3u in 50 mM NaCl buffer showed L values of 16 nm (0.5 mg/ml), 17 nm (1.0 
mg/ml) and 20 nm (1.7 mg/ml).  
(c) C3u between 0.5 mg/ml to 1.1 mg/ml in 137 mM NaCl buffer showed an unchanged 
L value of 16 nm. 
(b) C3 in 50 mM NaCl buffer showed L values of 15 nm (0.6 mg/ml), 17 nm (0.7 
mg/ml) and 20 nm (0.9 mg/ml).  
(a) C3 between 0.5 mg/ml to 1.2 mg/ml in 137 mM NaCl buffer showed an unchanged 
maximum length L of 16 nm.  
 
Table 5.1 X-ray scattering and sedimentation coefficient values from the C3 and C3u experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a The experimental values are extrapolated to zero concentration. The first value is from the Guinier RG analyses (Figure 5.6 and 5.7) and the second 
value is from the GNOM P(r) analyses (Figure 5.8). 
 
b The Dmax values in here are from P(r) analyses, while the values in Table 5.2 and Table 5.3 are calculated using HYDROPRO. 
  RG (nm) a RXS (nm) Dmax (nm) b s020,w (S) 
Experimental      
C3 (50 mM NaCl) 4.87 ± 0.26  2.50 ± 0.17 15-20 8.02 ± 0.12 
 4.80 ± 0.18    
C3 (137 mM NaCl) 4.52 ± 0.08 2.54 ± 0.04 16 7.85 ± 0.05 
 4.67 ± 0.19    
C3u (50 mM NaCl) 5.16 ± 0.22 2.56 ± 0.03 16-20 7.66 ± 0.19 
 5.35 ± 0.16    
C3u (137 mM NaCl) 4.88 ± 0.23 2.55 ± 0.10 16 7.44 ± 0.07 
 5.07 ± 0.21     
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(Figure 5.8(a,c)). In 50 mM NaCl, the L values increase from 15-16 nm at the lowest 
concentrations of 0.5-0.6 mg/ml up to 20 nm at 1.0-1.7 mg/ml. This concentration 
dependence is consistent with Figure 5.7.  
 
Previous X-ray scattering experiments were performed in different buffers (50 
mM potassium phosphate, 100 mM KC1, 5 mM EDTA, pH 7.0, or 12.4 mM sodium 
phosphate, 200 mM NaC1, 0.5 mM EDTA, pH 7.0) (Perkins & Sim, 1986). The 
previous RG values for C3 in 200 mM NaCl (Perkins & Sim, 1986) were 5.2 ± 0.1 nm, 
which is larger than the present C3 RG values (Table 5.1). The difference is attributable 
to improvements in sample purifications in the present study, most notably the 
avoidance of protein aggregation by gel filtration immediately prior to beam time, and 
instrumental improvements at the ESRF compared to those at DESY Hamburg and SRS 
Daresbury, most notably in terms of better detector sensitivities, and a larger Q range. 
The previous RXS value for C3 in 200 mM NaCl (Perkins & Sim, 1986) of 2.6 ± 0.1 nm 
agrees with the current C3 RXS value of 2.54 nm (Table 5.1).  
  
(5.2.3) Constrained modelling of the C3 and C3u solution structures 
C3 is converted to C3b by the removal of its anaphylatoxin C3a domain. 
Comparatively large conformational changes in several MG domains occur during the 
conversion of inactive C3 to active C3b. C3b has 12 domains, namely the MG1-MG8, 
LNK, and C345C domains within the C3c region and the CUB and TED domains 
outside this region (Figure 5.9(a)). The CUB and TED domains are connected by linker 
peptides of length seven to ten residues to the MG7 and MG8 domains, denoted by 1-4 
in Figure 5.9(a). These peptides are significantly altered in conformation during the 
large movement of the CUB and TED domains from their location proximate to the 
C345C domain in C3 to their location adjacent to the MG1 domain in four C3b crystal 
structures.  
 
The crystal structures were tested for their agreement with the sedimentation 
data. The C3 crystal structure gave a calculated s020,w value of 8.11 S (Table 5.2), which 
agreed well with the experimental values of 8.02 S and 7.85 S in two buffers (Table 5.1), 
given that the accuracy of the method is ± 0.21 S (Perkins et al., 2009). The four similar 
C3b crystal structures gave calculated s020,w values in a range of 7.51-7.69 S, which 
agrees well with the experimental value of 7.66 S for C3u in 50 mM NaCl. Interestingly, 
the deviant C3b crystal structure gave a calculated s020,w value of 7.37 S, which agrees 
Table 5.2 Single models fit for the solution structures of C3 and C3u.  
 
 
 
 
 
 
 
 
 
 
 
a The RG values are calculated from individual models by Debye equation adapted to spheres using the same Q range as the X-ray scattering 
experiments. 
  Models 
Hydrated 
spheres N RG (nm) a RXS (nm) Dmax (nm) b
R-factor 
(%) s020,w (S) 
Crystal structure               
C3 (PDB 2a73)  1 1863 4.35 2.45 16.4 3.1 8.11 
C3b (PDB 2i07) 1 1845 4.64 2.48 17.7 4.8 7.69 
C3b (PDB 2icf) 1 1895 4.58 2.52 17.5 4.5 7.56 
C3b (PDB 2win) 4 1804-1856 4.59-4.62 2.46-2.50 17.3-17.6 4.6-5.1 7.51-7.59 
C3b (PDB 2wii) 1 1856 4.50 2.56 16.0 4.5 7.62 
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b The values in here are calculated using HYDROPRO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
well with the experimental value of 7.47 S for C3u in 137 mM NaCl. It is concluded 
that, if the TED/CUB domains become extended away from the eight MG domains in 
C3b in 137 mM NaCl, this movement will account for the difference in s020,w values 
seen between 50 mM and 137 mM NaCl.  
 
The crystal structures were next tested for their agreement with the scattering 
data. The experimental RG values of 4.52 - 4.87 nm for C3 were similar to the calculated 
RG value of 4.35 nm for C3 within error (Table 5.1, Table 5.2). The experimental RG 
values of 4.88 - 5.16 nm for C3u were also similar to the calculated RG values of 4.50-
4.64 nm for the four C3b crystal structures within error. That the experimental values 
were slightly larger than the calculated values is attributed to the sensitivity of the 
scattering experiment to small amounts of dimers. A good curve fit was obtained 
between the C3 crystal structure and C3 in 137 mM NaCl with a low R-factor of 3.1%. 
The four similar C3b crystal structures gave larger R-factors of 4.5-5.1% with C3u in 
137 mM NaCl. An improved R-factor of 3.9% was obtained with the deviant C3b 
crystal structure. This showed again that, if the TED/CUB domains became extended 
away from the MG domains, slightly improved agreement between the solution and 
crystal structures was obtained.  
 
The location of the CUB and TED domains is crucial to the biological function of 
C3, C3u and C3b. Solution structures for C3 and C3u in 137 mM NaCl were determined 
by constrained scattering modelling, in which the C3 and C3b crystal structures were used 
as the starting constraints (Section 5.4.5). The scattering modelling of C3u assumed that 
the functional similarity between C3u and C3b meant that the C3b crystal structure (PDB 
code 2I07) should be used to model this. A range of different searches was used to show 
that the C3u solution structure did not depend on the modelling strategy in use. To 
determine the CUB/TED location in the solution structure of C3u, the four linkers were 
each individually conformationally randomised in four searches in order to create up to 
8,000 different trial structures per search in which the CUB and TED domains were 
distributed in all orientations relative to the MG1-MG8 domains. That a sufficiently wide 
range of C3u conformations was generated in each search by the modelling procedure is 
shown by the superimposition of the first 100 models created from the linker 2 
randomisation (Figure 5.10). The side and top views show a full degree of conformational 
variability in the position of the CUB-TED domains (blue). The best fit model from the 
linker 2 search (green circle from Figure 5.9c) is shown by the pink ribbon denoting the 
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Figure 5.9 (figure legend overleaf) 
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Figure 5.9 Constrained modelling analyses of the C3u solution structure.  
(a) Cartoon of the 12 domains in C3b, with the CUB and TED domains shown in pink, 
and the other domains (MG1- MG8, C345C and L) comprising the C3c segment of C3b 
shown in tangerine. The interdomain linkers varied in the modelling are labelled as 1, 2, 
3 and 4. 
(b) The R factor values for 6,000 trial models of C3u in which linker 1 was varied are 
compared with the corresponding RG values. The vertical dashed line corresponds to the 
experimental RG value. The 13 good fit models are shown by pink circles, of which the 
best-fit model with the lowest R factor is denoted by the green circle.  
(c) The linker 2 search was based on 4,650 trial models. The five good fit models and 
single best fit best-fit model are denoted by pink and green circles respectively.  
(d) The linker 3 search was based on 6,000 models. The six good fit models and single 
best fit best-fit model are denoted by pink and green circles respectively.  
(e) The linker 4 search was based on 4,200 models. The 15 good fit models and single 
best fit best-fit model are denoted by pink and green circles respectively.  
(f) The linker 1 and 3 search was based on 8,000 models. The 13 good fit 
models and single best fit model are denoted by pink and green circles respectively. 
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Figure 5.10 Superimposition of 100 randomised C3u models created from the 
linker 2 search. The models were superimposed on the invariant C3c segment of C3b 
shown in tangerine (PDB code 2I07). The best fit TED-CUB model is highlighted as a 
pink ribbon. The positions of the TED-CUB domains from the first 100 models from the 
4,650 used in this search are shown in blue. The views in (a) and (b) correspond to the 
side and top views in which the side view is rotated by 90o as arrowed. 
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CUB and TED domains, with the remaining domains (MG1- MG8, C345C, LNK) 
shown in tangerine.  
 
The predicted X-ray curves calculated from the models after conversion to 
Debye spheres in the five searches of Figure 5.9 were compared with the experimental 
C3u curve in PBS 137 mM NaCl buffer. The graphs of R-factor (goodness-of-fit) vs. the 
RG values showed that the R-factors ranged between 3.6% to 17.6% and the RG values 
ranged from 3.8 nm to 5.6 nm (Figure 5.9(b-f)). The experimental RG value of 4.97 nm 
is close to the minimum R-factor values. By applying filters based on the total number 
of Debye spheres (a monitor of whether the CUB and TED domains sterically overlap 
with the MG domains), and the requirement that the RG and RXS values were within ± 
5 % of the experimental values, and sorting the output in order of lowest R-factors, 5-15 
best fit C3u models were identified from each conformational search (pink circles in 
Figure 5.9(b-f), of which the best-fit model is denoted by the green circle. The best fit 
C3u model with an R-factor of 3.6% was determined from the Linker 2 search. 
Comparison of the calculated and experimental C3u I(Q) curves showed good visual 
agreement (Figure 5.11(b)). Likewise the modelled P(r) curve showed a major peak at r 
= 5.45 nm and L of 16 nm, indicating good agreement with Figure 5.8(b).  
 
The best-fit C3u models from the four Linker 1-4 searches consistently showed 
that the TED domain was well separated from the MG1 domain, unlike in the C3b 
crystal structures (Figure 5.12). The ribbon models in green correspond to the best fit 
with the lowest R-factor. The different types of searches meant that the RG values 
showed a reduced range of values in Figures 5.9(d,e) compared to Figures 5.9(b,c). The 
randomisation of either Linker 1 or 2 moved the rigid CUB-TED domain pair into one 
set of similar best-fit locations, while the randomisation of either Linker 3 or 4 moved 
the TED domain away from the MG domains. The overall best-fit C3u models with the 
lowest R-factors resulted from the Linker 2 search. There, the separation of 6.0 ± 0.9 
nm between the TED and the MG1 domains in the best-fit C3u models is significantly 
wider than that of 3.1 ± 0.1 nm seen in the other four crystal structures for C3b (PDB 
codes 2I07, 2ICF, 2WIN, 2WII) (Janssen et al., 2006; Wiesmann et al., 2006; Wu et al., 
2009; Rooijakkers et al., 2009). The deviant C3b crystal structure (PDB code 2HR0) 
(Ajees et al., 2006) showed a separation of 7.1 nm, this being more similar to our best-
fit C3u structure. 
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Figure 5.11 (figure legend overleaf). 
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Figure 5.11 X-ray scattering curve fits for C3 and C3u. The experimental data for 
C3 and C3u in 137 mM NaCl buffer correspond to 1.2 mg/ml and 1.1 mg/ml 
respectively.   
(a) The experimental I(Q) and P(r) curves for C3 are shown in green. The modelled 
curves based on the C3 crystal structure (PDB code 2A73) are shown in black.  
(b) The experimental I(Q) and P(r) curves for C3u are shown in red. The curves for the 
best-fit C3u model are shown in black. The experimental I(Q) curves for C3 (green) and 
C3u (red) are also shown superimposed upon each other, where the main difference 
between the curves is highlighted by a black bar 
(c) A ribbon view of the C3 crystal structure, with the TED and CUB domains 
highlighted in red. Here and in (d), the interdomain linker peptides are highlighted in 
blue.  
(d) A ribbon view of the C3u best fit model, with the TED and CUB domains 
highlighted in red.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3 X-ray scattering and sedimentation coefficient modelling fits for the solution structures of C3 and C3u.  
 
 
  Filter Models 
Hydrated 
spheres N RG (nm)  RXS (nm) Dmax (nm) a
R-factor 
(%) s020,w (S)  
C3u modelling                 
Linker 1 search None 6000 1553-1895 4.15-5.38 1.67-2.83 n. a. 3.8-14.7 n. a. 
 
N, RG, RXS and 
R factor 13 
 
1853-1877 4.75-4.88 2.56-2.65 
 
17.1-18.2 
 
3.8-4.5 7.27-7.53 
    
    
    
   
   
Best fit 1 1867 4.78 2.59 18.6 3.8 7.46
Linker 2 search None 4650 1526-1902 4.08-5.55 1.66-2.90 n. a. 3.6-15.8 n. a. 
 
N, RG, RXS and 
R factor 5 1870-1886 4.73-4.81 2.55-2.68 
 
18.0-19.0 
 
3.6-3.8 7.33-7.53 
 Best fit 1 1877 4.78 2.55 19.0 3.6 7.48
Linker 3 search None 6000 1622-1894 3.97-5.01 1.97-2.85 n. a. 3.7-14.1 n. a. 
 
N, RG, RXS and 
R factor 6 1864-1883 4.77-4.82 2.54-2.58 
 
17.9-18.2 
 
3.9-4.1 7.33-7.46 
 Best fit 1 1871 4.77 2.55 17.9 4.1 7.44
Linker 4 search None 4200 1623-1881 3.96-4.82 1.97-2.78 n. a. 3.8-14.2 n. a. 
 
N, RG, RXS and 
R factor 15 
 
1851-1873 4.74-4.77 2.55-2.67 
 
17.3-18.4 
 
3.9-4.0 7.33-7.59 
 Best fit 1 1860 4.74 2.59 18.0 3.9 7.46
Linker 1 and 3 search None 8000 1453-1890 3.93-5.45 1.52-2.90 n. a. 3.8-17.6 n. a. 
 
N, RG, RXS and 
R factor 13 
 
1853-1888 4.71-4.91 2.50-2.69 
 
16.1-18.9 
 
3.9-4.7 7.29-7.55 
 Best fit 1 1878 4.76 2.50 18.9 4.1 7.48
 148 
n. a. Not available. 
 
a The values in here are calculated using HYDROPRO. 
 
  
 
 
Figure 5.12 Comparisons of the best fit models for C3u generated from each of the 
linker 1-4 searches. The best-fit model with the lowest R-factor is shown in green, and 
the remaining 5-15 good fit models are shown in pink. The TED-CUB and MG1-MG8 
domains are in pink.   
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As one control of the modelling procedure, the I(Q) and P(r) curves calculated 
from the C3 crystal structure were compared with the experimental C3 curves in 137 
mM NaCl at 1.2 mg/ml (Figure 5.11a). A good visual match was observed, in which the 
major peak at r = 5.0 nm in the crystallographic P(r) curve reproduced the experimental 
P(r) curve of Figure 5.8a. It was concluded that the crystal and solution structures of C3 
are similar. As a second control, the significance of the structural difference between C3 
and C3u is shown by the comparison of their X-ray scattering curves, where clear 
intensity differences are seen in the Q range between 0.1-0.6 nm-1 (Figure 5.11b) as well 
as the neutron scattering curves (Figure 5.13). Models were created from a new double 
Linker 1 and 3 search performed using the experimental curve of C3 in PBS 137 mM 
NaCl buffer with 8,000 trial C3b models. In Figure 5.14, the resulting R-factor vs. RG 
analysis for C3 differed significantly from the same double Linker 1 and 3 search 
performed for C3u. The minimum is shifted to lower RG values, and interestingly 
showed lower R-factors than the C3u analysis. The superimposition of the 15 best-fit 
C3b structures using the fit with the C3 scattering curve showed that seven of these 
resembled the C3 crystal structure itself, while the other eight showed a broad range of 
other conformations. Even though this search based on a C3b crystal structure had not 
allowed for the significant shifts of the MG domains between C3b and C3, this fit 
outcome for C3 validated the modelling procedure for C3u.  
 
(5.3) Discussion 
C3, C3u and C3b are important for the initiation, amplification and effector 
functions of complement (Walport, 2001; Law & Reid, 1995). The “tick-over” 
conversion of C3 to C3u leads to alternative pathway activation, because C3u exhibits 
C3b-like function and forms an initial convertase with the Bb fragment of Factor B to 
enable the rapid generation of active C3b. We have determined solution structures for 
C3 and C3u by constrained scattering modelling. The high quality of the curve fits are 
similar to those obtained for other complement proteins and antibodies (Furtado et al., 
2008; Bonner et al., 2009). While the C3 solution structure corresponded well with its 
crystal structure, the C3u solution structure is distinct to that of four similar C3b crystal 
structures (Figures 5.15(a,b)). The TED domain in C3u is significantly extended away 
from the MG1-MG8 domains in solution, and is not proximate to the MG1 domain. 
This is different from the four C3b crystal structures that show that the TED and MG1 
domains are in contact with each other. A small variability in the four C3b crystal 
structures suggests that the TED and MG1 domains do not form a precise interaction. A 
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Figure 5.13 Neutron scattering curve for C3 and C3u. This was recorded on 
instrument SANS2D at ISIS TS2. The experimental data for C3 (green) and C3u (red) 
in 137 mM NaCl, 2H2O PBS buffer corresponding to 2.1 mg/ml and 1.7 mg/ml 
respectively. The experimental I(Q) curves for C3 (green) and C3u (red) in neutron are 
shown superimposed upon each other, where the main difference between the curves is 
highlighted by a black bar. 
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Figure 5.14 Comparison of the constrained modelling fits for the Linker 1 and 3 
search with 8,000 models with the experimental I(Q) curves for C3 and C3u. The 
vertical dashed lines indicate the experimental RG value for C3 in (a) and C3u in (b) in 
137 mM NaCl. 
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(b) The 8,000 models were compared against the experimental C3u curve; this is 
identical with Figure 5.9(f). The best-fit model is shown as a green ribbon structure at 
the right.  
(a) The 8,000 models were compared against the experimental C3 curve, giving 15 
good-fit models. Seven of the 15 good-fit models resemble the C3 crystal structure, and 
these seven are shown in pink at the right, with the best-fit model shown in green. 
  
Figure 5.15 Comparison of ribbon views of the solution and crystal structures for C3u, C3b and C3. The TED and CUB domains are shown in 
red and pink respectively, the linkers are shown in blue, and the remaining C3c segment is tangerine.  
 
(b) Superimposition of four C3b crystal structures (PDB codes 2I07, 2ICF, 2WII and 2WIN);  
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(c) The C3 crystal structure (PDB code 2A73). 
(a) The best-fit C3u solution structure model;  
 
 
 
weak interaction between the TED and MG1 domains would explain why the C3b 
crystal and C3u solution structures differ. Electron microscopy images are viewed in 
two-dimensions in comparatively harsh conditions. While shape differences between C3 
and C3u were detected by electron microscopy (Nishida et al., 2006), their structures 
could not be defined in more detail. Hydrogen/deuterium exchange studies also revealed 
differences between C3 and C3u, and showed that C3u possessed a more open structure 
(Winters et al., 2005). Our results indicate that the arrangement of the TED and CUB 
domains relative to the eight MG domains exhibit previously unrecognised 
conformational flexibility.  
 
Mechanistic insights are obtained by this study. Our results show that C3u 
represents a structure that is intermediate between those of C3 and C3b. Functionally, 
the ability of the TED domain to move independently from the MG domains in the C3 
proteins will facilitate the attachment of C3b to an antigenic surface in a broad range of 
conformations independent of the remaining C3b structure. The four similar C3b crystal 
structures do not show that the TED domain is optimally positioned for antigen 
interactions, because the MG domains can potentially block steric access to one half of 
this. Versatile TED arrangements in the C3 proteins would permit a more efficient 
innate immune response by C3 and also its complement C4 and C5 homologues. 
Functionally also, the mobility of the TED domain relative to the fixed MG domains 
clarifies the need for Factor H to act as a cofactor for the Factor I-mediated cleavage of 
C3b. The Factor H SCR-4 domain is seen to link together the MG1 and TED domains in 
the crystal structure (Wu et al., 2009). It is deduced that Factor H restricts what would 
otherwise be a high conformational variability of the TED domain in order to provide 
an appropriate rigid template at the CUB domain for Factor I-mediated cleavage of C3.  
 
The existence of both C3 and C3u monomer and dimer in solution was 
previously unrecognised. The C3 concentration in serum ranges between 1 and 1.5 
mg/ml (5.3 µM to 7.9 µM) in 137 mM NaCl (Law & Reid, 1995). Given that C3 is an 
acute-phase reactant, its concentration is increased during inflammation, and any 
localised production could also result in higher C3 levels at inflammatory sites. By size-
exclusion chromatography, no dimer peak was visible, however both C3 and C3u eluted 
earlier in 50 mM NaCl than in 137 mM NaCl buffer (Figure 5.2). Our results explain 
this in terms of reversible greater self-association in lower salt from our c(s) size-
distribution analyses and X-ray scattering data, and explains previous similar data for 
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C3 (Nishida et al., 2006). While our analysis of reversible systems has been achieved 
using sedimention boundary analysis, it is not rigorous. Even though there are good 
indications that dimerisation is occurring and differs with salt, the possible effects of 
conformational change, different hydration levels and non-ideality may require 
consideration. Concentration studies by sedimentation equilibrium and surface plasmon 
resonance experiments will clarify the association kinetics between each of the C3 and 
C3u dimers. In summary, both C3 and C3u are largely monomeric up to 2.3 mg/ml in 
137 mM NaCl, in agreement with the observation of monomeric C3d in this buffer (Li 
et al., 2008). In 50 mM NaCl, greater amounts of dimer are seen, especially for C3u, in 
a reversible self-association with monomer (Figures 5.3-5.5). Self-association was also 
observed with C3d in this buffer, which is equivalent to the TED domain (Li et al., 
2008). The interaction between factor H and C3d is seen to be strengthened in 50 mM 
NaCl compared to 137 mM NaCl buffer, even though this interaction is complicated by 
its multimeric nature (Okemefuna et al., 2009a). It is expected that the factor H-C3u 
interaction will be likewise increased in 50 mM NaCl, however an understanding of this 
will require dissociation constant KD determinations for both C3u dimerisation and the 
factor H-C3u interaction. The larger dimerisation change seen with C3u, but not C3, is 
explained by the existence of a more exposed TED domain in the C3u solution structure 
(Figure 5.15(a)). Relatively low amounts of C3 and C3u dimer are also seen (Figure 
5.5). A different second dimerisation site in C3 and C3u is suggested from the crystal 
structure of the C3b-SCIN complex (where SCIN is a bacterial Staphylococcus aureus 
protein that inhibits C3b) (Rooijakkers et al., 2009). SCIN induced the formation of a 
non-covalent C3b dimer through interactions between the MG4-MG5 domains that is 
stabilised by SCIN at this dimer interface. The modelling of our sedimentation data for 
the dimer based on this crystal structure account for the low amount of dimer in 137 
mM NaCl. We speculate that SCIN promotes inhibitory C3b dimers starting from low 
amounts of dimer as part of its pathogenic inhibitory mechanism. It is possible that C3 
and C3u dimerisation may offer opportunities for therapeutic interventions to reduce 
unwanted C3 activation.  
 
Many C3 and C3b crystal structures were crystallised from low salt buffers 
(Table 5.4) using a diverse range of additives. Here, we have shown that alterations in 
buffer conditions affect the spatial arrangement of the 13 domains in the structures of 
C3 and C3u. Interestingly, examination of the crystallisation buffers for all four similar 
C3b crystal structures showed that comparatively low NaCl concentrations up to 50 mM 
Protein species 
PDB 
code Buffer before crystalisation Crystallisation Authors 
C3 Human 2A73 10 mM Tris, pH 7.4 
hanging drops from mother liquor containing 18% w/v 
PEG-3000 and 200 mM LiNO3 at 20oC Janssen et al., 2005 
C3 Bos 2B39 20 mM Hepes (pH 7.2),100 mM NaCl 
heavy-atom-containing 100 mM HEPES (pH 7.7) 
40 % (w/v) PEG 400 
Fredslund et al., 
2006 
C3b Human 2I07 10 mM Tris, pH 7.4 
sitting drops from mother liquor containing 9% w/v 
PEG-monomethylether 2000, 100 mM sodium acetate, 
10 mM taurine and 50 mM Bis-Tris propane pH 7.8 at 
30 oC Janssen et al., 2006 
C3b Human 2ICF 25 mM Hepes, 50 mM NaCl, pH 7.2.  12% PEG 20000, 0.1 M MES, pH 6.0 
Wiesmann et al., 
2006 
C3b 
(BbSCIN)  Human 2WIN 
500 mM imidazole in 10 mM Tris, 40 
mM NaCl and 5 mM MgCl2, pH 8.0 
75 mM sodium-potassium tartrate, 8.0% (w/v) PEG 
3350 and 50 mM Bis-Tris propane, pH 6.5. 
Rooijakkers et al., 
2009 
C3b Human 2WII 10 mM Tris, 50 mM NaCl, pH 7.4 
7.0% (wt/vol) PEG 3,350 and 70 mM ammonium 
acetate, pH 7.1 Wu et al., 2009 
C3b human 2HR0 
20 mM Tris-HCl pH 7.5, and a protein 
inhibitor cocktail 
200 mM Tris-HCl pH 7.5, 100 mM NaCl, 20 mM 
LiCl and 15% PEG 6000. Ajees et al., 2006 
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Table 5.4 C3 and C3b crystal buffers.
 
were used, while the deviant C3b crystal structure was determined using 100 mM NaCl. 
Even though the deviant crystal structure is disputed (Ajees et al., 2006; Janssen et al., 
2007; Ajees et al., 2007; Borrell, 2009), the higher NaCl concentration used for these 
crystals apparently resulted in a more extended TED/CUB domain arrangement that 
gave a better account of the C3u scattering and ultracentrifugation data in 137 mM NaCl. 
The resolution of separate monomer and dimer peaks by ultracentrifugation showed that 
the arrangement of 13 domains in both the C3 and C3u monomers is slightly more 
compact in 50 mM NaCl than in 137 mM NaCl. Functionally-related proteins such as 
Factor H with 20 SCR domains also demonstrated conformational changes with change 
of salt concentration (Okemefuna et al., 2009a). Accordingly functional studies 
performed in 50 mM NaCl buffer should be interpreted with caution. Buffers containing 
137 mM NaCl will maintain C3 and C3u as largely monomeric proteins in 
physiologically-appropriate concentrations.  
 
Conformational and self-association variability will also apply to C3 
homologues, most notably C4 and C5, where this may have significant roles in 
complement mechanisms during their activation, and the formation of the C5 convertase 
by the covalent attachment of a C3b molecule to the C3bBb complex (Walport, 2001; 
Law & Reid, 1995). Thus the degree of self-association of C3 and C3u and 
conformational changes in these is important for both physiological function and 
laboratory investigations. The appropriate choice of buffer will be crucial to study their 
interactions with physiological ligands or pathogenic proteins. 
 
(5.4) Materials and methods 
(5.4.1) Purification of C3 and C3u  
Wild-type C3 was purified from fresh human plasma essentially as described 
previously with slight modifications (Dodds, 1993). 50 ml fresh human plasma was 
centrifuged after adding 5% (w/v) polyethylene glycol (PEG 3500 molecular weight, 
Sigma Chem. Corp), and again after adding 12% PEG 3500 MWCO to the supernatant. 
The final pellet was resuspended in the starting buffer, formed from 95% of Buffer A 
(20 mM HEPES, 50 mM ε-aminocaproic acid, 5 mM EDTA, 0.5 mM Pefabloc-SC, pH 
7.5) and 5% of Buffer B (as buffer A, but with the addition of 1 M NaCl). 5 ml of the 
filtered suspension was loaded onto a 20 ml Q-Sepharose fast flow anion-exchange 
column (Amersham Biosciences, GE Healthcare, Uppsala, Sweden). This column binds 
to proteins according to their net surface charge, and proteins are eluted according to 
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their isoelectric point (pI). After washing unbound proteins using 60 ml (3 column 
volumes) of 92% buffer A and 8% buffer B, C3 was eluted using a 120 ml (6 column 
volumes) linear salt gradient to 300 mM NaCl. Reduced SDS-PAGE on the C3 fractions 
(3.5 ml each) confirmed the α chain (115 kDa) and β chain (75 kDa). The C3 fractions 
from 210 mM NaCl to 250 mM NaCl were pooled to approximately 14 ml, then this 
was diluted 2.5 fold with Buffer A to reduce the NaCl level to 100 mM. C3 was applied 
onto a MonoQ 5/50 GL column (Pharmacia GE Healthcare, Uppsala, Sweden) in four to 
six separated batches to avoid overloading, where the column was pre-equilibrated in 
90% Buffer A and 10% Buffer B. Using a salt gradient from 100 mM NaCl to 300 mM 
NaCl, C3 was eluted at 28 ml about 210 mM NaCl to 240 mM NaCl and checked by 
reducing SDS-PAGE.  
 
For all ultracentrifugation and scattering experiments, C3 was dialysed into 
phosphate buffer saline (PBS: 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, 50 
mM or 137 mM NaCl, pH 7.4) overnight at 4ºC, and concentrated using Amicon® 
Ultra-15 centrifugal filter devices with a molecular weight cut-off of 50 kDa at a speed 
of 2,500 g. The C3 concentrations were determined using an absorption coefficient of 
9.4 (1%, 280 nm, 1 cm path length) calculated from its composition (SWISSPROT code 
P01024) assuming the presence of three high mannose type oligosaccharides at Asn63, 
Asn917 and Asn1597 (Perkins & Sim, 1986; Hase et al., 1985; Hirani et al., 1986). The 
sequence-predicted molecular mass of C3 and C3u was 189,000 Da (2.3% 
carbohydrate), to be compared with that of 179.3 kDa for C3b. A partial specific 
volume of 0.739 ml/g was calculated for C3 and C3u from its composition (Perkins, 
1986).The buffer density of 137 mM NaCl and 50 mM NaCl PBS were measured at 
20oC using an Anton-Paar DMA5000 density meter to be 1.00542 g/ml and 1.00171 
g/ml, in good agreement with the predicted values of 1.00543 g/ml and 1.00175 g/ml 
from SEDNTERP (Laue et al., 1992).  
 
 Haemolytically inactive C3 (C3u, also known as C3(H2O)) was produced by 
incubating C3 with 100 mM hydrazine at 37ºC for 1 hr (Sim et al., 1981), and then left at 
4 ºC overnight. To separate C3u from any unconverted C3, C3u in 90% Buffer A and 
10% Buffer B was applied to the MonoQ column, and eluted using the same procedure 
described for C3. C3u eluted earlier than native C3 at about 190 to 200 mM NaCl. C3u 
but not C3 was active in functional assays using factor I and factor H (Nan et al., 2008a).  
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(5.4.2) Analytical ultracentrifugation data for C3 and C3u  
Sedimentation velocity experiments were performed at 20°C using two Beckman 
 XL-I analytical ultracentrifuges (Beckman-Coulter Inc, Palo Alto, CA) at rotor speeds 
of 40,000 r.p.m. and 50,000 r.p.m.. An eight-hole AnTi50 rotor was used with standard 
double-sector cells with column heights of 12 mm at 20ºC, monitoring sedimentation 
using absorbance optics at 280 nm and interference optics. C3 was studied in a 
concentration series of 0.26 mg/ml to 2.28 mg/ml (PBS 50 mM NaCl) and 0.48 mg/ml 
to 2.20 mg/ml (PBS 137 mM NaCl). C3u was studied between 0.35 mg/ml to 2.13 
mg/ml (PBS 50 mM NaCl) and 0.27 mg/ml to 2.36 mg/ml (PBS 137 mM NaCl). The 
continuous c(s) analysis method was used to determine the s20,w values of C3 and C3u 
using SEDFIT software (version 11.7) (Dam & Schuck, 2004; Schuck, 2000). The final 
c(s) fits were determined using a resolution of 200 and by floating the meniscus, 
frictional ratio, and baseline and holding the cell bottom, partial specific volume and 
solvent density fixed until the overall root-mean-square deviations and visual 
appearance of the fits were satisfactory (Figure 5.3).  
 
(5.4.3) X-ray scattering data for C3 and C3u 
X-ray solution scattering data for C3 and C3u were collected in five sessions on the 
camera at the ID02 high brilliance beamline at the European Synchrotron Radiation Facility 
(ESRF) at Grenoble, France with a ring energy of 6.0 GeV (Narayanan et al., 2001). In the 
first and second sessions, data were collected for C3 in 16-bunch mode using beam currents 
of 67-77 mA and 68-86 mA. In the third, fourth and fifth sessions, data were collected for 
C3 and C3u using beam currents of 30-37 mA (4-bunch mode), 69-83 mA (16-bunch 
mode) and 30-43 mA (4-bunch mode). Data were acquired using an improved fibre 
optically-coupled high sensitivity and dynamic range CCD detector (FReLoN) with a 
smaller beamstop. The sample-to-detector distance was 2.0 m. Sample flow cells were used 
to eliminate radiation damage in conjunction with on-line checks to confirm the absence of 
radiation damage by optimisation of the exposure times. Each sample was measured using 
four sets of ten time frames, each of length 0.05, 0.08, 0.1, 0.15, 0.2 or 0.5 sec for C3 and 
0.05, 0.08, 0.1, 0.15, 0.2 or 0.25s for C3u, then these were averaged. The sample 
temperature was 20°C. C3 in PBS 50 mM NaCl was studied at seven concentrations 
between 0.18 mg/ml and 0.98 mg/ml. C3 in PBS 137 mM NaCl was studied at 18 
concentrations between 0.21 mg/ml and 1.95 mg/ml. C3u in PBS 50 mM NaCl was studied 
at seven concentrations between 0.32 mg/ml and 1.67 mg/ml. C3u in PBS 137 mM NaCl 
was studied at seven concentrations between 0.28 mg/ml and 1.12 mg/ml. 
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In a given solute-solvent contrast, the radius of gyration RG is a measure of 
structural elongation if the internal inhomogeneity of scattering densities within the 
protein has no effect. Guiner plot at low Q values gives the RG and scattering at zero 
angle I(0) (Glatter & Kratky, 1982):   
ln I(Q) = ln I(0) - RG2 Q2/3 
This expression is valid in a Q.RG range up to 1.5. For elongated structure, at larger Q 
values than those used for the RG analysis, the radius of gyration of the cross-sectional 
structure RXS and the mean cross-sectional intensity at zero angle [I(Q).Q]Q→0 
parameters are obtained from:  
ln [I(Q).Q] = ln [I(Q).Q]Q→ 0  - RXS2 Q2/2 
The RG and RXS analyses were performed using an interactive PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics 
OCTANE Workstations. Indirect Fourier transformation of the full scattering curve I(Q) 
in reciprocal space gives the distance distribution function P(r) in real space. This yields 
the maximum dimension of the macromolecule L and its most commonly occurring 
distance vector M in real space:  
dQ (Qr) Qr I(Q)  
2
1 = P(r)
o
2
sin∫∞π  
The transformation was implemented using GNOM software (Semenyuk & Svergun, 
1982). For C3, up to 345 data points were used for Q values between 0.13 nm-1 and 1.73 
nm-1, while for C3u, up to 373 data points were used for Q values between 0.16 nm-1 
and 1.85 nm-1.  
 
(5.4.4) Neutron scattering data for C3 and C3u 
 Neutron scattering data for C3 and C3u were collected in one session on the 
SANS2D instrument at the pulsed neutron source at ISIS at Rutherford Appleton 
Laboratory (RAL) in Didcot, U.K (Heenan et al., 2006). Time-averaged flux is over 106 
cm-2 s-1 (at 10Hz, 40 uA 800 MeV proton beam). Data acquisition were measured at 
20°C for C3 at 2.1 mg/ml and C3u at 1.7 mg/ml.  
 
(5.4.5) Constrained scattering and sedimentation coefficient modelling for C3 and 
C3u 
The scattering modelling of human C3 was based on its unmodified crystal 
structure (PDB code 2A73) (Jansen et al., 2005). The constrained scattering modelling 
of C3u was based on four crystal structures for human C3b (PDB codes 2I07, 2ICF, 
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2WIN, 2WII) (Janssen et al., 2006; Wiesmann et al., 2006; Wu et al., 2009; 
Rooijakkers et al., 2009). Inspection of these six crystal structures indicated that C3 and 
C3b could be considered as three subunits, namely the C3c region and the CUB and 
TED domains. These were joined by two pairs of linker peptides (1-4 in Figure 5.9(a)). 
Linkers 1 and 2 connect the MG7 and MG8 domains respectively in C3c with the CUB 
domain. Linkers 3 and 4 connect the CUB and TED domains. Their sequences are as 
follows: linker 1, 908-KVVPEGI-914; linker 2, 1328-AKAKDQLTC-1336; linker 3, 
964-PVAQMTEDAV-973; linker 4, 1263-DAPDHQEL-1270 (C3 sequence numbering 
(Janssen et al., 2005)). Each linker was created as an extended β-strand structure, then 
the residues within each linker were conformationally randomised, using INSIGHT II 
98.0 molecular graphics software (Accelrys, San Diego, CA, USA) on Silicon Graphics 
OCTANE Workstations, following Method 2 used for modelling human IgA1 (Boehm 
et al., 1999). For linker 1, 6,000 conformers were created in which the distance between 
the first and last α-carbon atoms ranged between 1.21 nm to 2.27 nm (Figure 5.16a). For 
linker 2, the 4,650 conformers ranged in length between 0.59 nm to 2.72 nm (Figure 
5.16b). For linker 3, the 6,000 conformers ranged in length between 1.35 nm to 3.38 nm 
(Figure 5.16c). For linker 4, the 4,200 conformers ranged in length between 0.86 nm to 
2.89 nm (Figure 5.16d). Five types of conformationally randomised C3u models were 
formed by combining the linkers and domain structures (Figure 5.9). In the first of these, 
the crystallographically-observed linkers 2, 3 and 4 were fixed, the connection between 
linker 2 and the MG8 domain was severed, and the 6,000 linker 1 conformations was 
used to join the TED and CUB domains to the C3c region in randomised orientations to 
create the C3u models. The second set of 4,650 models employed the linker 2 
conformations to assemble C3u models. The third and fourth sets of models varied the 
position of the TED domain relative to the CUB and C3c regions by employing the 
6,000 linker 3 or 4,200 linker 4 conformations respectively. A fifth set of 8,000 models 
was created from a randomised selection of linkers 1 and 3 conformations while holding 
linkers 2 and 4 fixed.   
 
Each full C3 or C3u molecular model was used to calculate its X-ray scattering 
curve for comparison with the experimental C3u curve in PBS 137 mM NaCl (Table 5.3) 
using Debye sphere models (Perkins & Weiss, 1983). A cube side length of 0.540 nm in 
combination with a cutoff of 4 atoms was used to convert the atomic coordinates into 
Debye sphere models with 1557 spheres (C3) or 1478 spheres (C3b) that corresponded to 
the unhydrated structure. The hydration shell corresponding to 0.3 g H2O/ g protein was
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Figure 5.16 Linkers are created with the different lengths. The linkers were created 
and the distributions of linker lengths were checked to ensure that a sufficient range of 
lengths had been studied. The frequency is the number of linkers that were created for 
each linker length. 
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created using HYPRO (Ashton et al., 1997), where the optimal total of hydrated spheres 
in the C3 or C3u model is 2047 (C3) or 1943 (C3b) (Table 5.3). The X-ray scattering 
curve I(Q) was calculated using the Debye equation adapted to spheres (Perkins & 
Weiss, 1983). No instrumental corrections were applied because these are considered to 
be negligible for the pinhole optics in use. No ad-hoc assumptions were required in 
relation to hydration effects, and details are given elsewhere (Perkins, 2001b). Steric 
overlap between the TED, CUB and C3c regions in the models was assessed using the 
number of spheres N in the models after grid transformation, where models showing 
less than 95% of the required total of 1557 or 1478 spheres were discarded. Over 54% 
of the 10,000 models met this “absence of steric overlap” criterion Next, the X-ray RG 
and RXS values were calculated from the modelled curves in the same Q ranges used for 
the experimental Guinier fits. This allowed for any approximations inherent in the use 
of the Q.RG fit range up to 1.5. Models that passed RG and RXS filters of ± 5% were then 
ranked using a goodness-of-fit R factor defined by analogy with protein crystallography 
and based on the experimental curves in the Q range extending to 1.73 nm-1 (C3) or 
1.85 nm-1 (C3u) (Table 5.3; Figure 5.8).  
 
Sedimentation coefficients s0 20,w were calculated directly from the hydrated 
Debye sphere models using the program HYDRO as a confirmation of the GENDIA 
analysis. (Garcia de la Torre et al., 1994). They were also calculated from the atomic 
coordinates in the HYDROPRO shell modelling program using the default value of 0.31 
nm for the atomic element radius for all atoms to represent the hydration shell (Garcia 
de la Torre et al., 2000). Previous applications of these calculations to proteins are 
reviewed elsewhere (Perkins et al., 2009).  
 
(5.5) Protein Data Bank accession number 
 The five best-fit C3u models for 137 mM NaCl PBS were deposited in the 
Protein Data Bank with the accession code 3MMQ.  
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       Chapter Six 
 
Solution structures reveal that complement C3u interacts 
   independently with complement Factor H at two sites: 
implications for complement regulation 
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(6.1) Introduction 
C3 is the central protein of the complement system of innate immunity (Law & 
Reid, 1995). In the tick-over mechanism of the complement alternative pathway, C3 is 
slowly hydrolysed into C3u (also known as C3H2O) through hydrolysis of its thioester 
group within its thioester domain (TED). C3u shows functional similarities to C3b, the 
immunologically active form of C3 in which a small C3a domain is removed by 
cleavage. Thus C3u is able to form a C3 convertase by interactions with the Bb 
fragment of factor B, and this triggers the uncontrolled formation of C3b. The C3-to-
C3b conversion is controlled by several regulators including factor H (FH) in order to 
ensure appropriate targeting against pathogens while minimising damage to host cells. 
FH regulates the activation of the alternative pathway by competing with factor B for 
binding to C3b, enhancing the dissociation of the C3bBb complex, and acting as a 
cofactor for the protease factor I, which leads to the irreversible proteolytic inactivation 
of C3b through the formation of the iC3b, C3d (the TED domain) and C3c fragments 
(Weiler et al., 1976; Pangburn et al., 1977).  
 
C3 circulates in plasma at 1.0-1.5 mg/ml and FH circulates at 0.235 – 0.81 
mg/ml (Law & Reid, 1995; Saunders et al., 2006). C3 is constructed from eight 
macroglobulin (MG) domains, together with the TED and C3a anaphylatoxin (ANA) 
domains and three other domains termed CUB, LNK and C345C (Figure 6.1(a)), while 
FH consists of 20 short complement regulator (SCR) domains, each containing about 60 
amino acid residues (Figure 6.1(b)). Multiple functional sites exist in both C3 and FH 
(Alsenz et al., 1984, 1985; Sharma & Pangburn, 1996; Pangburn et al., 1991; Gordon et 
al., 1995; Ram et al., 1998a). Three binding sites for FH on C3b have been identified 
(Jokiranta et al., 2000). The first site is illustrated by the crystal structure of intact C3b 
with FH SCR-1/4, which showed that these four SCR domains bind in the crevice 
between the TED/CUB and the MG domains, with the SCR-1 and SCR-4 domains 
positioned adjacent to the C345C and MG1 domains respectively (Wu et al., 2009). 
This location is consistent with biochemical data where SCR-1/4 displayed decay-
accelerating activity and this interaction is destroyed by the cleavage of C3b to C3c and 
C3d (Alsenz et al., 1984; Kühn & Zipfel, 1996). The second site involves FH binding to 
the C3c region (Jokiranta et al., 2000). This site is weaker than the other two and may 
correspond to SCR-6/8, and its existence has been disputed (Schmidt et al., 2008). The 
third site corresponds to the C-terminal SCR-19/20 domains which interact with the C3d 
fragment (TED domain) (Sharma & Pangburn, 1996; Jokiranta et al., 2000;  
 
165
  
 
 
 
Figure 6.1 Schematic cartoon of C3u and FH. In C3u, the CUB and TED domains are 
shown in pink, while the remaining 11 domains (MG1-MG8, ANA (A), LNK (L) and 
C345C) are shown in orange (Chapter 5). In FH, the 20 SCR domains are shown in 
orange, with those that bind to C3b denoted in blue (SCR-1/4 and SCR-19/20).  
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Hellwage et al., 2002; Bhattacharjee et al., 2010). The third binding site was initially 
revealed by the deletion of residues 1187-1214 in C3d, which partially inhibited the FH-
C3b interaction (Lambris et al., 1988). Residues involved in the SCR-19/20 interaction 
with C3d have been identified (Hellwage et al., 2002; Sánchez-Corral et al., 2002; 
Manuelian et al., 2003; Jozsi et al., 2006; Lehtinen et al., 2009; Jokiranta et al., 2006). 
The affinity of FH for C3b is stronger at SCR-19/20 than at SCR-1/4 (Schmidt et al., 
2008). SCR-20 has other roles. It enables FH to adhere to glycosaminoglycan 
polyanionic markers on host cell surfaces (Pangburn et al., 1991; Blackmore et al., 
1996, 1998; Prodinger et al., 1998; Ram et al., 1998b). These functions are reflected by 
the distribution of mutations, where SCR-1/4 and SCR-19/20 present most of the 
disease-linked sequence variations reported so far in FH (Saunders et al., 2007).  
 
A molecular mechanism for the interaction between C3b and FH will clarify 
how the alternative pathway is regulated. In 150 mM NaCl buffer, the dissociation 
constant KD is 0.59-1.6 µM for the C3b-FH interaction (Schmidt et al., 2008). The KD 
value is 11 µM and 9.8-13.5 µM for the C3b interaction with SCR-1/4 (Wu et al., 2009; 
Schmidt et al., 2008), 3.5-4.5 µM and 5.4 µM for the C3b interaction with SCR-19/20 
(Schmidt et al., 2008; Jokiranta et al., 2000, 2006), and 29 µM for the SCR-16/20 
interaction with C3d (Okemefuna et al., 2009b). Binding between C3b and FH is 
dependent on ionic strength and pH (Soames & Sim, 1997). These micromolar KD 
values in physiological salt indicate that the C3b-FH interaction is comparatively weak. 
Only 63% complex formation will be achieved, even with the strongest KD value of 0.59 
µM in the presence of the highest reported plasma concentrations of 1.5 mg/ml (C3b) 
and 0.81 mg/ml (FH) (8.4 µM and 5.3 µM respectively). This is a characteristic feature 
of the interactions between the complement proteins (Perkins et al., 2010a, 2010b), and 
makes structural studies of the C3b-FH complex more difficult to achieve. Recently we 
have described the solution structures for C3u and FH by analytical ultracentrifugation 
(AUC) and constrained small-angle X-ray scattering (SAXS) modelling, and identified 
dimeric and higher oligomeric forms of C3u and FH (Li et al., 2010; Chapter 5; Nan et 
al., 2010). These two studies enable the C3u-FH interaction to be studied. Even though 
full complex formation was not achieved, the joint use of AUC and SAXS 
unambiguously identified a 1:1 complex between C3u and FH, and we propose a 
solution structure for this complex in which there are no major conformational changes 
in FH. In addition, a higher oligomer of the C3u-FH complex with a 2:1 stoichiometry 
was identified, showing that C3u binds independently to two different sites on FH. In 
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combination with the multimeric C3d-FH complexes identified previously (Okemefuna 
et al., 2009b), these results provide novel insights into a molecular mechanism for the 
C3u-FH interaction as well as that for the C3b-FH interaction.  
 
(6.2) Results and Discussion 
Following our studies of the interactions between recombinant complement 
receptor type 2 SCR-1/2 and SCR-1/15 with recombinant C3d, and that between plasma 
FH and recombinant C3d (Gilbert et al., 2005; Li et al., 2008; Chapter 4; Okemefuna et 
al., 2009b), size-exclusion chromatography was first performed in order to characterise 
the C3u-FH complexes formed in 137 mM and 50 mM NaCl phosphate buffers. Next, 
AUC and SAXS were performed in order to define these mixtures quantitatively in 
terms of free and complexed proteins. Finally, constrained sedimentation and scattering 
modelling was performed in order to define the structures and KD values for the C3u-FH 
complexes (Li et al., 2010; Chapter 5; Nan et al., 2010).  
 
(6.2.1) Size exclusion chromatography of C3-FH and C3u-FH mixtures  
Native FH, C3 and C3u were purified from plasma (Materials & Methods). C3, 
C3u and FH were checked by SDS-PAGE. While all proteins ran as single bands, FH at 
130 kDa migrated faster than C3 or C3u at 180 kDa on a non-reducing gel (Figure 
6.2(c)). The observed mass of 130 kDa is less than the expected mass of 154 kDa, and 
this difference is attributed to the high carbohydrate content of FH. For both the C3-FH 
and C3u-FH mixtures, only two bands from C3 or C3u and FH were observed in the 
non-reducing gel. Because no third band was observed at a mass of about 300 kDa, the 
interaction between C3u-FH was inferred to be weak. On a reducing gel, FH at 170 kDa 
migrated slower than the α-chain and β-chain of C3 and C3u at 110 kDa and 70 kDa. 
Weak bands for free FH at 120 kDa and 40 kDa indicated trace amounts of a 
previously-characterized proteolytic cleavage of FH within the disulphide-bridged 
region of SCR-5 (Perkins et al., 1991). 
 
When the three proteins and the C3-FH and C3u-FH mixtures were analysed by 
size-exclusion chromatography, weak complex formation was observed for C3u-FH but 
not for C3-FH. Accordingly the C3-FH mixtures were used as controls for complex 
formation observed with the C3u-FH mixtures: 
(i) In 137 mM NaCl (Figure 6.2(a)), C3 (red dashed line) and C3u (red solid line) 
each eluted as single homogeneous peaks at 77 ml (Li et al., 2010; Chapter 5). FH (blue line)  
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Figure 6.2 Size-exclusion chromatography and SDS-PAGE analyses of C3, C3u, 
FH and their mixtures. In (a,b) the elution positions of four molecular mass standards 
are shown in kDa, and the elution positions of C3 and FH are indicated by vertical 
dashed lines.  
(a) In 137 mM NaCl buffer, FH (blue), C3 (red dashed) and C3u (red) are each 
eluted as single peaks. The C3u-FH mixture eluted as three peaks that correspond to the 
C3u-FH complex, free FH and partially-complexed C3u (green), while the C3-FH 
mixture eluted as two peaks that correspond to free FH and free C3 (green dashed).  
(b) In 50 mM NaCl buffer, FH (blue), C3 (red dashed) and C3u (red) are each 
eluted as single peaks. The C3u-FH mixture eluted as three peaks (green), while the C3-
FH mixture eluted as two peaks (green dashed).   
 (c) Non-reducing and reducing SDS-PAGE analyses of C3, C3u, FH and their 
mixtures in 50 mM NaCl and 137 mM NaCl as labelled. A precast 3-8% Tris-acetate 
gradient gel was used for the non-reduced analysis and a 4-12% Bis-Tris gradient gel 
was used for the reduced analysis (Invitrogen). The molecular mass standards are 
indicated in kDa at the right hand side. 
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eluted as a single peak at 70 ml, followed by a minor peak assigned to residual traces of 
human serum albumin (Nan et al., 2008). The equimolar C3-FH mixture eluted as two 
peaks in 137 mM NaCl at the positions of unbound C3 and FH (green dashed line), thus 
no complex formation was observed. The equimolar C3u-FH mixture eluted as three 
peaks in 137 mM NaCl (green solid line). That at 45 ml corresponded to small amounts 
of the C3u-FH complex, which was followed by a second peak at 70 ml (FH) and a third 
peak at 75 ml (C3u) slightly overlap. Because the FH and C3u peaks eluted earlier than 
those for either proteins on their own (red and blue), this indicated that some complex 
formation had occurred. The excess of uncomplexed C3u and FH compared to the 
complex indicated that the complex is weakly formed in physiological 137 mM NaCl 
with a µM KD value. 
(ii) In 50 mM NaCl (Figure 6.2(b)), C3 (red dashed line) and C3u (red solid line) 
each eluted earlier as a single homogeneous peak at about 75 ml, and this was 
previously explained in terms of greater self-association of both proteins in low salt (Li 
et al., 2010). FH likewise self-associates more in 50 mM NaCl (Okemefuna et al., 
2009a). This self-association was reflected by a new broad FH peak at 50-60 ml, and a 
FH monomer peak that eluted earlier at 68 ml (Figure 6.2(b)). The equimolar C3-FH 
mixture again eluted as two peaks in 50 mM NaCl at the positions of unbound C3 and 
FH (green dashed line), thus no complex formation was observed. The equimolar C3u-
FH mixture eluted as three major peaks (green solid line). The first peak at 45 ml 
corresponds to increased complex formed by C3u and FH, while the second and third 
peaks at 68 ml and 75 ml correspond to unbound FH and C3u. The observation of three 
peaks again indicated a µM KD value, and the increased amount of the C3u-FH complex 
in 50 mM NaCl than in 137 mM NaCl indicates a strong ionic strength dependence of 
complex formation, similar to that reported for the C3b-FH interaction (Soames & Sim, 
1997).   
 
(6.2.2) Sedimentation velocity data for C3-FH and C3u-FH mixtures  
AUC using sedimentation velocity experiments reports on macromolecular 
structures in solution by analysis of the sedimentation time course (Cole et al., 2008). 
The size distribution analyses c(s) calculated using SEDFIT reports on the species that 
are present from the number of peaks observed in the c(s) plot. Macromolecular 
elongation is monitored through the sedimentation coefficient s20,w values. Freshly-
prepared C3 was used to avoid its hydrolysis to C3u during storage. Prior to 
ultracentrifugation, the C3-FH and C3u-FH mixtures were subjected to gel filtration on 
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Superose 6 column to remove pre-existing aggregates (Figure 6.2). The experiments 
were done in 137 mM NaCl and 50 mM NaCl to follow the conditions used for gel 
filtration. Analyses of up to 300 scans in SEDFIT revealed excellent boundary fits 
(Figure 6.3(a,c,e,g)).  
(i) In 137 mM NaCl for the C3-FH mixture, the interference and absorbance data 
sets gave an s20,w value of 5.91 S for FH, and an s20,w value of 8.21 S for C3 (Table 6.1; 
peaks 1 and 2 in Figure 6.3(b)). Additional peaks 3 and 4 were observed in Figure 
6.3(b) that was not expected. This is attributed to experimental error, when the C3-FH 
mixture was stored at 4°C fridge eight days before the AUC run, and C3 became 
hydrolysed to form C3u and other degradation products that were revealed in SDS-
PAGE (not shown). Thus peak 2 was in fact a mixture of peaks for both C3 and C3u, 
although this was not clearly resolved. Peak 3 of the C3-FH mixture was attributed to 
1:1 C3u-FH complex formation, and the small peak 4 was attributed to higher 2:1 
complex (see below). This experiment needs to be repeated using freshly-purified C3. 
(ii) In 137 mM NaCl for the C3u-FH mixture, peaks 1 and 2 for FH and C3u 
were observed with s20,w values of 5.77 S, and 7.63 S respectively (Figure 6.3(d); Table 
6.1). Peak 3 with a s20,w value of 9.62 S corresponded to 1:1 complex formation, while 
very low amounts of peak 4 corresponding to 2:1 complex formation was also observed. 
At a total concentration of 1.02 mg/ml, integration showed that peak 1 corresponded to 
44%, peak 2 to 6% and peak 3 to 50% of the mixture. By converting the c(s) peak 
integrations to molarities, the three peaks in Figure 6.3(d) gave a KD value of 0.59 ± 
0.11 µΜ. This determination is similar to the previous KD value of 0.59 ± 0.04 µΜ 
reported by surface plasmon resonance (Schmidt et al., 2008). FH forms oligomers in 
which the s20,w values of the well-resolved dimer and trimer peaks are approximately at 
7.6 S and 9.4 S (Nan et al., 2008, 2010; Okemefuna et al., 2009a). Because the FH 
dimer and trimer peaks overlap with the s20,w value for C3u at 7.66-7.44 S (Li et al., 
2010) and the s20,w value for the 1:1 complex at 9.62-9.65 S (Table 6.1), it was not 
possible to deduce whether FH dimers and trimers were removed by the C3u-FH 
interaction, although this is likely.   
(iii) In 50 mM NaCl, the C3-FH mixture showed two peaks at 5.80 S and 7.97 S 
for FH and C3 respectively, in which FH accounted for 47 % and C3 account for 53 % 
of the mixture at 1.36 mg/ml (Figure 6.3(f); Table 6.1). The absence of other peaks 
indicated that no complexes were formed, in agreement with gel filtration (Figure 
6.2(b); green dashed line). The baseline between 9-15 S in the c(s) plot was not flat, and  
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Figure 6.3 Size distribution analyses c(s) for mixtures of C3 and C3u with FH 
(Legend overleaf). 
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 Figure 6.3 Size distribution analyses c(s) for mixtures of C3 and C3u with FH 
(continued). 
(a,c,e,g) Sedimentation velocity boundary fits for C3-FH and C3u-FH mixtures at 
approximately 1.5 mg/ml using interference optics in 137 mM (white) and 50 
mM (red) NaCl buffer. Only every third or fifth scans of the fitted boundaries 
are shown for reason of clarity. 
(b,f) The c(s) distributions for C3-FH mixtures in 137 mM and 50 mM NaCl buffer. The 
three colours represent different concentrations. The total C3-FH concentrations 
range from 0.36 mg/ml to 1.07 mg/ml in 137 mM NaCl, and 0.45 mg/ml to 1.36 
mg/ml in 50 mM NaCl buffer. Here and below, the vertical dotted lines show the 
approximate positions of the peaks for FH (denoted by 1), C3 or C3u (2), the 1:1 
complex (3) and the 2:1 complex (4).  
(d,h) The c(s) distributions for C3u-FH mixtures in 137 mM and 50 mM NaCl buffer. 
Individual peaks are labelled. In 137 mM NaCl, the total C3u-FH concentrations 
range from 0.51 mg/ml to 1.53 mg/ml, while in 50 mM NaCl, the total C3u-FH 
concentrations range from 0.54 mg/ml to 1.62 mg/ml.  
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may reflect the presence of unbound FH trimer and higher FH oligomers as well as 
unbound C3 dimer, although these peaks could not be resolved.  
(iv) In 50 mM NaCl, the C3u-FH mixture showed four peaks 1-4 (Figure 6.3(h); 
Table 6.1). Peaks 1 and 2 show similar s20,w values to those of FH (5.88 S) and C3u 
(7.90 S). For the complexes, the mean s20,w value of peak 3 is 9.65 S, and peak 4 is 
12.47 S, both of which have larger peak areas than those in 137 mM NaCl, which 
indicated greater complex formation (Figure 6.3(d)). A concentration dependence was 
seen, where the relative sizes of peaks 1 and 3 at 0.54 mg/ml was reversed at 1.62 
mg/ml. Integration showed that peak 1 corresponded to 35%, peak 2 to 10%, peak 3 to 
48% and peak 4 to 7% of the mixture at 0.54 mg/ml (total concentration). At 1.62 
mg/ml, peak 1 corresponded to 26%, peak 2 to 8%, peak 3 to 51% and peak 4 to 15%. 
The change in percentages showed that more complex formation occurred at higher 
concentration. By converting the c(s) peak integrations to molarities, peaks 1, 2 and 3 in 
Figure 6.3(h) resulted in an approximate KD value of 0.11 ± 0.06 µΜ. This decreased KD 
value showed that C3u binding to FH was stronger when [NaCl] is increased. 
 
The C3u-FH interaction in 137 mM NaCl and 50 mM NaCl were analysed using 
linear regression fits of the s20,w values for FH, C3u and the 1:1 C3u-FH complex (peaks 
1, 2 and 3 in Figure 6.3).  
(i) For 137 mM NaCl, the s20,w values of FH were unchanged from 0.18 mg 
FH/ml to 0.68 mg FH/ml, and give a s020,w value of 5.78 ± 0.09 S (Figure 6.4(a); Table 
6.1). The molecular weight and f/fo values for FH were 152 ± 13 kDa and 1.66 ± 0.11 
respectively. For 50 mM NaCl, the s20,w values of FH showed an almost negligible 
change with concentration from 0.24 mg/ml to 0.72 mg/ml of 5.90 ± 0.25 S to 5.93 ± 
0.06 S. The molecular weight and f/fo values for FH by itself were 153 ± 16 kDa and 
1.68 ± 0.25 respectively. The slightly increased s20,w values compared to 137 mM NaCl 
correspond to a NaCl-dependent conformational change. This s20,w change for unbound 
FH in the presence of C3u is similar to that seen for FH on its own when the NaCl 
concentration is increased (Okemefuna et al., 2009a).  
(ii) For 137 mM NaCl, the s20,w values of C3u were unchanged from 0.28 mg 
C3u/ml to 0.85 mg C3u/ml, and give a s020,w value of 7.63 ± 0.20 S (Figure 6.4(b); 
Table 6.1). For 50 mM NaCl, the s20,w values of C3u increase from 0.30 mg/ml to 0.90 
mg/ml from 8.04 ± 0.09 S to 8.28 ± 0.10 S. It is concluded that the properties of 
unbound C3u in the presence of FH again behaves in the same way as that reported for 
C3u on its own (Li et al., 2010; Chapter 5). 
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Figure 6.4 Concentration dependence of the s20,w values for C3u, FH and their 1:1 
complex (Legend overleaf).  
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Figure 6.4. Concentration dependence of the s20,w values for C3u, FH and their 1:1 
complex (continue).  
(a) The s20,w values for FH (peak 1 in Figure 6.3(d,h)) were fitted by linear regression to 
result in so20,w values at zero concentration of 5.78 ± 0.09 S in 137 mM NaCl 
(black) and 5.88 ± 0.07 S in 50 mM NaCl (red). Here and in other places, 
statistical error bars are shown where visible. 
(b) The s20,w values for C3u (peak 2 in Figure 6.3(d,h)) were fitted to result in so20,w 
values of 7.63 ± 0.20 S in 137 mM NaCl and 7.90 ± 0.40 S in 50 mM NaCl.  
(c) The s20,w values for the 1:1 complex (peak 3 in Figure 6.3(d,h)) were fitted to result 
in so20,w values of 9.21 ± 0.50 S in 137 mM NaCl and 8.91 ± 0.98 S in 50 mM 
NaCl. 
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(iii) For the C3u-FH complex in 137 mM NaCl buffer (peak 3 in Figure 6.4(c)), 
even though the s20,w values appear to increase from 0.32 mg/ml to 1.53 mg/ml (total 
concentration), this increase was not greater than statistical error, although it is visible 
in Figure 6.3(d). For the C3u-FH complex in 50 mM NaCl, the concentration 
dependence of the s20,w values from 9.10 ± 0.20 S to 10.90 ± 0.01 S was greater. The 
molecular mass and f/fo values of peak 3 in 137 mM NaCl were 333 ± 16 kDa and 1.79 
± 0.11 respectively, and those in 50 mM NaCl were 356 ± 46 kDa and 1.68 ± 0.37 
respectively. If C3u and FH form a 1:1 complex, its predicted mass would be 343 kDa. 
The good agreement between the observed and predicted masses showed that a 1:1 
complex was formed in both buffers, and that a reaction boundary between C3u and FH 
was not present. [Footnote: In c(s) plots, reaction boundaries are concentration-
dependent peaks that correspond to the co-sedimentation of two different species if they 
exchange between themselves during sedimentation. They exhibit well-defined s20,w 
values and masses between the s20,w values and masses of the two different species, and 
are distinct from undisturbed boundaries which correspond to the actual sedimentation 
species themselves.] The concentration dependence of peak 3 in 50 mM NaCl is most 
easily explained by the formation of a 1:1 C3u-FH complex from C3u and FH, to which 
there is a small contribution from the concurrent formation of an additional 2:1 C3u2-
FH complex (peak 4 below). A contribution from the concentration-dependent C3u 
dimer formation previously observed in 50 mM NaCl may also be present (Li et al., 
2010).  
 
Trace amounts of peak 4 were visible for the C3u-FH mixtures in 137 mM NaCl 
that were significantly increased in 50 mM NaCl (Figures 6.3(d,h)). Larger but ill-
defined changes in the s20,w values were detectable in 50 mM NaCl. The mass of peak 4 
in 137 mM NaCl was 476 ± 28 kDa, which is in good agreement with the predicted 
mass of 532 kDa for a C3u2-FH complex. The observed mass for peak 4 in 50 mM NaCl 
was lower at 391 ± 47 kDa. While peak 4 can be identified as a 2:1 complex, larger 
amounts of the 2:1 complex is formed in 50 mM NaCl buffer, and there is a possibility 
that peak 4 may correspond to a reaction boundary between the 1:1 C3u-FH complex 
and the formation of one or more 2:1 C3u-FH complexes.   
 
(6.2.3) X-ray scattering data for C3-FH and C3u-FH mixtures  
           Solution scattering is a diffraction technique that studies the overall structure of 
biological macromolecules in solution (Perkins et al., 2008). Freshly prepared C3-FH 
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and C3u-FH mixtures were studied by X-ray scattering in four beam sessions (Figure 
6.5). The interaction between C3 or C3u with FH was assessed by Guinier analyses of 
the X-ray I(Q) data at low Q values to give the radius of gyration RG and forward 
scattered intensities I(0), where Q = 4π sin θ /λ (2θ = scattering angle; λ = wavelength). 
In concentration series, the Guinier fits were linear as required, in an appropriate Q.RG 
range up to 1.5 (Figure 6.5).   
 
The X-ray Guinier results for the equimolar 1:1 C3-FH and C3u-FH mixtures in 
137 mM NaCl (black) and 50 mM NaCl (red) buffers are summarised in Figure 6.6.  
(i) In 137 mM NaCl, the RG values for the C3-FH mixture were unchanged with 
protein concentration at 7.83 ± 0.58 nm (16 values) (Figure 6.6(a)). The I(0)/c value was 
unchanged at 0.0306 ± 0.0006 (Figure 6.6(b)); this is proportional to the mean 
molecular mass. If no complex formation occurs, the weighted mean of the RG values of 
4.52 nm for free C3 (Li et al., 2010; Chapter 5) and 8.90 nm for free FH (Okemefuna et 
al., 2009a) is calculated to be 6.62 nm for an equimolar C3-FH mixture (Perkins et al., 
1985). Since this mean is less than the observed value, and because C3 and FH do not 
interact with each other (Figure 6.3(f)), this RG difference is inferred to reflect the 
propensity of each of C3 and FH to form trace oligomers with increased RG values, 
rather than the formation of complexes.  
(ii) In 137 mM NaCl, the RG values for the C3u-FH mixtures were also 
unchanged with concentration at 8.83 ± 0.34 nm (16 values) (Figure 6.6(c)), but are now 
larger than that of 7.83 nm for C3-FH. The I(0)/c values were also larger at 0.0460 ± 
0.0023 for C3u-FH (Figure 6.6(d)). Because the RG value of 8.83 nm is noticeably 
larger than that of 6.77 nm (Perkins et al., 1985) for the weighted mean of the RG values 
of 4.88 nm for free C3u and 8.90 nm for free FH, this increase reflected the formation of 
C3u-FH complexes.  
(iii) In 50 mM NaCl, the RG values of the C3-FH mixture in 50 mM NaCl 
increased linearly (Figure 6.6(a)). At zero concentration, the RG values were 
extrapolated to 8.07 ± 1.22 nm, which is the same as that in 137 mM NaCl. The I(0)/c 
values of the C3-FH mixture also increased linearly. At zero concentration, the I(0)/c 
values extrapolated to 0.0400 ± 0.0090, which was slightly larger than that in 137 mM 
NaCl. Overall, the changes were attributed to increased oligomer formation for C3 seen 
previously in 50 mM NaCl (Li et al., 2010; Chapter 5). No complex formation between 
C3 and FH was deduced, in agreement with Figure 6.3(f).  
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Figure 6.5 X-ray Guinier RG analyses of C3-FH and C3u-FH mixtures. The Q range 
used for the RG fits was 0.10 to 0.14 nm-1. The data points are denoted by open circles; 
the filled circles were used to determine the RG values based on the best fit lines as 
shown. 
(a,c) Plots for 1:1 mixtures of C3-FH are shown at total concentrations between 0.30 
mg/ml to 0.78 mg/ml in 137 mM NaCl (black) and 0.33 mg/ml to 1.32 mg/ml in 
50 mM NaCl (red) from bottom to top. 
(b,d) Plots for 1:1 mixture of C3u-FH are shown at total concentrations between 0.35 
mg/ml to 1.04 mg/ml in 137 mM NaCl and 0.47 mg/ml to 1.04 mg/ml in 50 mM 
NaCl. 
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Figure 6.6 Concentration dependence of the Guinier RG and I(0)/c values for C3-
FH and C3u-FH mixtures. Each value was measured in quadruplicate and averaged 
for linear regression fits. The fitted lines shown for 137 mM NaCl buffer are the mean 
value. Statistical error bars are shown where visible.  
(a,c) The RG values are shown for 137 mM NaCl (black) and 50 mM NaCl buffer (red). 
For C3-FH in 50 mM NaCl, measurements of 8.47 ± 0.31 nm at 0.33 mg/ml (4 
values), 9.15 ± 0.18 nm at 0.66 mg/ml (4 values), 8.75 ± 0.29 nm at 0.99 mg/ml 
(4 values), and 9.95 ± 0.08 nm at 1.31 mg/ml (4 values) are shown. For C3u-FH 
in 50 mM NaCl, measurements of 10.05 ± 0.06 nm at 0.47 mg/ml (4 values), 
10.38 ± 0.02 nm at 0.52 mg/ml (4 values), 10.67 ± 0.09 nm at 0.78 mg/ml (4 
values), 10.80 ± 0.22 nm at 0.96 mg/ml (4 values) and 10.78 ± 0.04 nm at 1.04 
mg/ml (4 values) are shown. 
(b,d) The corresponding I(0)/c values are shown for 137 mM and 50 mM NaCl buffer.  
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(iv) In 50 mM NaCl, the RG values for the C3u-FH mixture increased linearly 
with concentration. The RG value was 9.66 ± 1.16 nm when extrapolated to zero 
concentration. Because this RG value is larger than that of 8.83 nm for the C3u-FH 
mixture in 137 mM NaCl, this shows that an increased proportion of the C3u-FH 
complex is formed in reduced salt conditions. The I(0)/c values of the C3u-FH mixture 
also increased linearly, which agrees with increased RG values. The I(0)/c value of the 
C3u-FH mixture in 50 mM NaCl was 0.0702 ± 0.0235 when extrapolated to zero 
concentration. This value was larger than the value of 0.0460 above, and showed that 
additional complexes were formed in low salt buffer. 
 
Additional X-ray data were collected for C3-FH and C3u-FH mixtures in 137 
mM and 50 mM NaCl at three different molar ratios of 1:0.3, 1:0.5 and 1:1. The C3 and 
C3u concentration was maintained at 0.50 mg/ml. While linear Guinier plots were 
obtained (Figure 6.7), no further RG or I(0)/c data analysis was performed for reason of 
its complexity. These extra data sets will be useful as controls for the constrained 
analyses of the C3-FH and C3u-FH mixtures in order to refine the KD determination 
from scattering curve fits (see below). 
 
 The distance distribution function P(r) in real space leads to the determination of 
overall lengths L, following an assumption of the value of the maximum dimension 
Dmax. The P(r) function also gives an independent calculation of the RG and I(0) values 
that is based on the full Q range for comparison with the Guinier analyses based on low 
Q values. The four pairs of RG values from the P(r) and Guinier analyses were in good 
agreement, indicating the self-consistency of the pairs of data sets (Table 6.1).  
(i) In 137 mM NaCl, the L value for the C3-FH mixture was 28 nm (Figure 
6.8(a)). The most common distance M for the C3-FH mixture was 5.5 nm at 0.30 
mg/ml, increasing to 6.2 nm at 0.78 mg/ml (Figure 6.8(a)). Previously, the L values of 
unbound C3 and FH were reported to be 16 nm and 28-32 nm respectively in 137 mM 
NaCl, and the most common distance M for unbound C3 and FH were 5.0 nm and 5.4 
nm (Li et al., 2010; Chapter 5; Nan et al., 2008; Okemefuna et al., 2009a). The lack of 
change in L for the C3-FH mixture agrees with the absence of complex formation, while 
the change in M is not considered significant. The P(r) curves thus agreed with the lack 
of interaction in a freshly-prepared mixture of C3-FH in 137 mM NaCl. 
 (ii) In 137 mM NaCl, the C3u-FH mixture showed L values of 30 nm and M 
values of 5.5 to 6.4 nm that increased with decrease in concentration (Figure 6.8(b)).  
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Figure 6.7 X-ray Guinier RG analyses of C3-FH and C3u-FH mixtures in different 
molar ratios. The Q range used for the RG fits was 0.10 to 0.14 nm-1. The data points 
are denoted by open circles; the filled circles were used to determine the RG values based 
on the best fit lines as shown. 
(a,c) C3-FH mixtures in molar ratios of 1:0.3, 1:0.5 and 1:1 with C3 fixed at 0.5 mg/ml 
in 137 mM NaCl (black) and in 50 mM NaCl (red) from bottom to top. 
(b,d) C3u-FH mixtures in molar ratios of 1:0.3, 1:0.5 and 1:1 with C3u fixed at 
0.5mg/ml in 137 mM NaCl (black) and in 50 mM NaCl (red) from bottom to 
top. 
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(d) For C3u-FH in 50 mM NaCl, the first peak M1 is observed at 6.3 nm (0.52 mg/ml), 
6.3 nm (0.78 mg/ml) and 6.3 nm (1.04 mg/ml), the second peak M2 is observed 
at 11.7 nm (0.52 mg/ml), 12.2 nm (0.78 mg/ml) and 12.9 nm (1.04 mg/ml), and 
L is 30 nm (0.52 mg/ml), 32 nm (0.78 mg/ml) and 33 nm (1.04 mg/ml). 
(c) For C3-FH in 50 mM NaCl, M is observed at 6.3 nm, and L is 30 nm at 0.66 mg/ml, 
32 nm at 0.99 mg/ml, and 33 nm at 1.32 mg/ml. 
 
 
 
 
 
 
(b) For C3u-FH between 0.35 mg/ml to 0.93 mg/ml in 137 mM NaCl, M is observed at 
5.5 to 6.4 nm and L is 30 nm. 
(a) For C3-FH between 0.3 mg/ml to 0.78 mg/ml in 137 mM NaCl, the peak maximum 
M is observed between 5.5 and 6.2 nm, and the maximum length L is 28 nm. 
Figure 6.8 X-ray distance distribution functions P(r) for 1:1 mixtures of C3-FH 
and C3u-FH.   
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b Peak 1 correspond to free FH, Peak 2 corresponds to free C3u, Peak 3 corresponds to the 1:1 C3u-FH complex, and Peak 4 corresponds to a 2:1 
complex, being the C3u-FH-C3u complex and/or the C3u2-FH complex. 
a The first value of each pair is from the Guinier RG analyses at zero concentration (Figures 6.5 and 6.6) and the second is from the GNOM P(r) 
analyses (Figure 6.8). 
  
FH Peak 1 
(S) %
C3u Peak 2 
(S)  % 
1:1 complex 
Peak 3 (S) % 
2:1 complex 
Peak 4 (S) % RG (nm) a
Dmax      
(nm) 
             
C3-FH (137 mM NaCl) 5.91 ± 0.06 52 ± 4 % 8.21 ± 0.17 48 ± 4 % n.o.      n.o.  7.83 ± 0.58 28 
   
  
  
       
      8.12 ± 0.58  
C3u-FH (137 mM NaCl) 5.78 ± 0.09 44 ± 4 % 7.63 ± 0.20   6 ± 4 %  9.62 ± 0.32 50 ± 8 %     n.o.  8.83 ± 0.34 30 
       8.80 ± 0.29  
C3-FH (50 mM NaCl) 5.80 ± 0.08 47 ± 4 % 7.97 ± 0.10 53 ± 4 % n.o.      n.o.  8.07 ± 1.22 30-33 
       8.71 ± 0.62  
C3u-FH (50 mM NaCl) 5.88 ± 0.07 31 ± 5 % 7.90 ± 0.40   8 ± 2 %  9.65 ± 0.45 51 ± 8 %  12.47 ± 0.70 10 ± 5 % 9.66 ± 1.16 30-33 
  9.90 ± 0.99   
Table 6.1 Experimental sedimentation coefficient and X-ray scattering parameters for C3u-FH mixtures. 
 
n.o., not observed    
 
 
C3u has an M value of 5.0 nm (Li et al., 2010; Chapter 5). Even though no change in L 
and M values were seen between the free proteins and their mixture, the appearance of 
the overall P(r) curve is different from that for the C3-FH mixture in Figure 6.8(a). In 
combination with the AUC data of Figure 6.3(d), the P(r) curves indicated that C3u and 
FH interact with each other in 137 mM NaCl, and there is no change in the overall 
length of the complex.  
(iii) In 50 mM NaCl, the L values of the C3-FH mixture increased from 30 nm at 
the lowest concentrations of 0.66 mg/ml up to 33 nm at 1.32 mg/ml. The C3-FH mixture 
showed an M value of 6.3 nm (Figure 6.8(c)). In 50 mM NaCl, unbound C3 and FH 
have M values of 5.0 to 5.4 nm, and 5.4 nm respectively. The changes seen with these 
P(r) curves are best explained by the self-association of C3 and FH in low salt 
conditions (Li et al., 2010; Chapter 5; Okemefuna et al., 2009a). 
(iv) In 50 mM NaCl, the L values of the C3u-FH mixture increased from 30 nm 
at the lowest concentrations of 0.52 mg/ml up to 33 nm at 1.04 mg/ml (Figure 6.8(d)). 
Here, the overall appearance of the P(r) curve is different compared to the others in 
Figure 6.8. The C3u-FH mixture showed two M values, with an M1 value at 6.3 nm and 
a second M2 value at about 11.7 nm. In 50 mM NaCl, C3u and FH have different M 
values of 5.0 to 5.2 nm and 5.4 nm respectively. The presence of these large changes 
showed that further C3u-FH complexes have formed as the result of reduced salt 
concentration, in agreement with the AUC data of Figure 6.3(h). Interestingly, there are 
again no indications of changes in the length of FH in this complex.  
 
 Previous literature showed that SCR-1/4 and SCR-19/20 in FH possess binding 
sites for C3b (Sharma & Pangburn, 1996; Jokiranta et al., 2000; Hellwage et al., 2002; 
Schmidt et al., 2008). The cartoon to scale of C3u and FH (Figure 6.1) shows that these 
two C3b binding sites are well separated in FH. For both to interact with one molecule 
of C3u simultaneously, it would be necessary for FH to form a more compact structure. 
The unchanged or increased L values in the P(r) curves of Figure 6.8(b,d) do not 
indicate that such conformational changes take place. The P(r) curves are more in 
accord with the independent binding of two C3u molecules to separate sites on one FH 
molecule.   
  
(6.2.4) Constrained modelling of C3-FH and C3u-FH mixtures 
The modelling of the s20,w values and X-ray scattering curves for the C3-FH and 
C3u-FH mixtures is complicated by the weak interactions and multiple components 
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present in these mixtures. By this study, the availability of AUC and SAXS data sets for 
both C3 and C3u in 50 mM NaCl and 137 mM NaCl at several molar ratios with FH 
provides experimental information that enabled the interaction of C3u with FH to be 
unravelled. This modelling was based on earlier solution structures for free C3u (Figure 
6.9(b)) and FH (PDB codes 3MMQ, 3GAV) (Li et al., 2010, Okemefuna et al., 2009a). 
A newer FH model was recently generated using data for homozygous FH in 137 mM 
NaCl and structures for five major FH fragments (Figure 6.9(a)) (Nan et al., 2010; 
Okemefuna et al., 2010a). The crystal structure of the C3b complex with FH SCR-1/4 
(PDB code 2WII) (Wu et al., 2009) enabled the superimposition of a full-length FH 
structure onto C3b to create a 1:1 C3u-FH complex at SCR-1/4 for curve fitting (Figure 
6.9(d)). The AUC data showed that a 2:1 complex of C3u formed with FH. One possible 
structure corresponding to a C3u2-FH complex was created by superimposition of the 
C3b dimer crystal structure onto the 1:1 C3u-FH model at SCR-1/4 (Figure 6.9(c)). 
Another possible structure was formed by two C3u molecules that interact 
independently with FH binding sites at SCR-1/4 and SCR-19/20. A model for two C3u 
molecules bound to FH was arbitrarily created at SCR-19/20 by recourse to biochemical 
data showing the residues involved in the interaction between the TED domain (C3d) 
and SCR-19/20 (Figure 6.9(e); Table 6.2) (Lambris et al., 1988; Sánchez-Corral et al., 
2002; Hellwage et al., 2002; Manuelian et al., 2003; Jozsi et al., 2006; Lehtinen et al., 
2009; Jokiranta et al., 2006). 
 
 The AUC and SAXS modelling of the C3u-FH mixtures followed the modelling 
procedure for pentameric-decameric mixtures of C-reactive protein based on known 
structures for the pentamer and decamer (Okemefuna et al., 2010b). That previous study 
was validated by the similarity of the resulting three KD values from three analyses of 
the pentamer-decamer association. Here, the six models for FH, C3, C3u, the 1:1 C3u-
FH complex and two possible C3u2-FH and C3u-FH-C3u complexes were first 
evaluated using their predicted s020,w values (Tables 6.1 and 6.3(a)). The difference in 
s020,w values for FH was within 0.3-0.8 S; that for C3 was within 0.1 S; that for C3u was 
within 0.4 S; that for the 1:1 C3u-FH complex was within 0.3 S; and that for two 
possible C3u-FH-C3u or C3u2-FH complexes was within 0.4 S or within 0.8 S 
respectively. An alternative model for the 1:1 C3u-FH complex was formed from C3u 
bound to FH at SCR-19/20. This gave predicted s020,w values of 8.9-9.2 S, which was 
within 0.7-0.4 S of the experimental value of 9.6 S (Table 6.3(a)). For antibody and 
complement proteins, the agreement between predicted and experimental values is on  
 
186
  
 
Figure 6.9 Molecular views of the FH, C3u and C3u-FH structures used for X-ray 
scattering curve fits. 
(a) The 20 SCR domains of the solution structure for FH (PDB code 3N8O) are 
coloured in blue, with eight carbohydrate chains shown in green. The 20 
domains are numbered as shown. The cartoon of Figure 6.1(b) corresponds to 
this view. 
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(b) The C3u solution structure (PDB code 3MMQ) is shown in tangerine, with the TED, 
CUB, C345C and MG1-MG8 domains labelled as shown. 
(c) The C3u2-FH complex is represented by the superimposition of the solution structure 
for FH with the crystal structure of the FH SCR-1/4 complex with C3b and the 
crystal structure of the C3b dimer (PDB codes 3N8O, 2WII and 2WIN).  
(d) The C3u-FH complex is represented by the superimposition of the solution structure 
for FH with the crystal structure of the FH SCR-1/4 complex with C3b (PDB 
codes 3N8O and 2WII).   
(e) The C3u-FH-C3u complex is represented by the superimposition of the solution 
structure for FH with the crystal structure of the FH SCR-1/4 complex with C3b 
and the C3u solution structure in an arbitrary orientation at SCR-19/20 (PDB 
codes 3N8O, 2WII and 3MMQ).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 6.2 Binding sites of FH SCR-19/20 with C3b and C3 
 
 SCR-19/20 residues      C3b (C3d) residues Method References 
Q1139, W1157, R1182, W1183, 
K1188, R1206, R1210, T1184 
   
 
C3b mutagenesis, radioligand 
assay (Lehtinen et al., 2009)  
R1182, W1183, T1184, K1188, 
E1198, R1215 
  
   
   
C3b mutagenesis, SPR and 
docking (Jokiranta et al., 2006)  
 W1183, V1197, R1210 
 C3b ELISA (Sanchez-Corral et al., 2002)  
E1172, R1210, R1215 
 C3d SPR (Manuelian et al., 2003)  
W1157, W1183, V1197, R1210, 
R1215, P1226  C3b and C3d  ELISA,SPR 
 
(Józsi et al., 2006)  
 K1187- A1249  
C3b mutagenesis, ELISA and 
radioligand assay (Lambris et al., 1988)  
 
R1171, E1172, M1174, E1175, 
N1178, L1181, R1182, K1202, 
E1224, Y1225, P1226, R1231 
 
D1216(D223), N1218(N225), 
R1219(R226), E1221(E228), 
Q1226(Q233), D1247(D254), 
P1251(P258), R1254(R261), 
W1255(W262), E1258(E265), 
Q1259(Q266), R1260(R267) a
 
 
 
C3d docking 
 
(Hellwage et al., 2002)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a The first residue number corresponds to C3b (PDB code 2I07), and the parenthesized residue numbering corresponds to C3d. 
 
b The thioester covalent surface-attachment site on C3d is about 3 nm away from the FH binding site in the SCR-1/4 complex with C3b. 
 
 
 
 
189
190
    
Table 6.3 X-ray scattering and sedimentation coefficient modelling fits for the solution structures of C3u and FH 
 
(a) Single 
models Models 
Hydrated 
spheres RG  (nm) Dmax (nm) 
R-factor 
(%) 
Calculated     
s020,w (S) 
Experimental 
s020,w (S) 
FH 1 2126 8.29 29 8a, 9.4b 5.1, 5.5  5.77-5.91     
C3 1 1863 4.35 16 16a 8.11 7.97-8.21     
    
    
    
    
    
C3u 1 1877 4.78 19 13.6b 7.48 7.63-7.90 
C3u-FH 1 1433 9.11 31 8.5b
9.38; 
8.85-9.20 
9.62-9.65 
 
C3u-FH-C3u 1 2104 10.70  33 22.6b 12.87 12.47 
(C3u)2-FH 1 2033 9.12 30 17.9b 13.30 12.47 
(b) C3/C3u-FH 
modelling   FH (%)     C3(%) C3u(%) 
C3u-FH      
(%) 
(C3u)2FH 
(%) 
C3u-FH-
C3u (%) 
C3-FH (137 
mM NaCl) 101 
 
4.89 - 8.17 n.a 3.9 - 15.9 
      
 best fit  7.25 26 3.9 72  28 - - - - 
C3u-FH (137 
mM NaCl) 
 
1326 
 
5.41 - 9.11 n.a 3.6 - 13.6       
     
      
      
best fit  8.59 28 3.6 46 - 2 52 - - 
C3-FH (50 
mM NaCl) 101 
 
4.89 - 8.17 n.a 10.7 – 17.0 
 best fit  6.63 26 10.7 53  47 - - - - 
 C3u-FH (50 
mM NaCl) 
316,260  5.41 - 
10.71 n.a 8.5 - 27.5 
 best fit  9.23 30 8.5 20 - 0 0 60 20 
 
n.a., Not available 
 
a Compared with the C3-FH data in 137 mM NaCl  
b Compared with the C3u-FH data in 137 mM NaCl  
c The first value corresponds to C3u-FH complexed at SCR-1/4; the second to that complexed at SCR-19/20.  
 
 
average within ± 0.21 S, and not normally greater than 0.3 S (Perkins et al., 2009). It 
was concluded that the six predicted and experimental s020,w values were in satisfactory 
agreement with each other (Table 6.3(a)). For the complexes of this study, the s020,w 
differences can be larger because of reduced precisions in determining the experimental 
values in multicomponent mixtures, especially for the broad peak 4. These agreements 
show that these structural models could be used for fits to the SAXS curves. Several 
conclusions were drawn from these modelling results: (i) The explanation of the s020,w 
value for the 1:1 C3u-FH complex required no conformational change in FH; (ii) It was 
not possible to show which of the 1:1 complexes at SCR-1/4 or SCR-19/20 was 
preferred; (iii) The calculations showed a preference for a C3u-FH-C3u complex over a 
C3u2-FH complex in order to explain peak 4 of Figure 6.3; (iv) All the s020,w values 
were explained by the existence of well-defined complexes with no reaction boundaries 
present.  
 
The SAXS curve fits for the non-interacting C3-FH mixtures were based on 
comparisons of the curves calculated from the C3 and FH models with the experimental 
X-ray curves in 137 mM NaCl and 50 mM NaCl. The experimental RG values of 7.83-
8.07 nm for C3-FH in both buffers (Table 6.1) were similar to the modelled RG value of 
8.29 nm for FH alone, but less so to that of 4.35 nm for C3 alone (Table 6.3). Visually, 
the modelled scattering curves for FH alone (blue line) and C3 alone (red dash) do not 
match the C3-FH experimental curve in 137 mM NaCl (cyan circles) with poor high R-
factors (goodness-of-fit) of 8% and 16% respectively (Figure 6.10(a); Table 6.3). 
Likewise the modelled FH and C3 curves do not match the C3-FH experimental curve 
in 50 mM NaCl with even poorer higher R-factors of 15% and 18.6% (Figure 6.10(b)). 
A total of 101 combinations of the C3 and FH modelled curves in increments of 1% was 
created. The 101 R-factors ranged between 3.9-15.9% and 10.7–17.0 % for 137 mM 
NaCl and 50 mM NaCl respectively, for RG values that ranged between 4.89-8.17 nm 
(Figure 6.11(a,c)). For 137 mM NaCl, the lowest R-factor of 3.9% corresponded to a 
mixture of 28% C3 and 72% FH. This combination showed a good visual agreement 
with the experimental curve for C3-FH in 137 mM NaCl (Figure 6.10(e)). The 
proportions of C3 and FH were comparable with the SEDFIT integration of the c(s) 
plots that showed 48% C3 and 52% FH in 137 mM NaCl (Figure 6.3(b); Table 6.1). For 
50 mM NaCl, the lowest R-factor of 10.7% corresponded to a mixture of 47% C3 and 
53% FH (Table 6.3). This combination showed a fair visual agreement with the 
experimental curve for C3-FH in 50 mM NaCl, bearing in mind that the experimental 
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Figure 6.10 Comparison of the experimental and modelled X-ray scattering curves 
(Legend overleaf).  
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Figure 6.10 Comparison of the experimental and modelled X-ray scattering curves. 
The experimental data are shown in cyan. The modelled curves are shown as lines (C3, 
red dashed; C3u, red solid; FH, blue).  
(a,b) For the C3-FH mixture in 50 mM and 137 mM NaCl buffer, the experimental 
curve is compared with the modelled curves for C3 and FH.  
(c,d) For the C3u-FH mixture in 50 mM and 137 mM NaCl buffer, the experimental 
curve is compared with five modelled curves for C3u, FH, and the C3u-FH, 
C3u2-FH and C3u-FH-C3u complexes (Figure 6.9). (C3u-FH, pink; C3u2-FH, 
pink dashed; C3u-FH-C3u, pink dotted).  
(e,f) The best-fit combination of two curves for the analyses in C3-FH in 137 mM and 
50 mM NaCl. Here and in (g,h), the black line represents the best-fit calculated 
curve that was summed from the combination of separate curves. 
(g) The best-fit combination of the three curves for C3u, FH and the 1:1 C3u-FH 
complex in 137 mM NaCl.  
(h) The best-fit combination of the five curves for C3u, FH, and the 1:1 and 2:1 C3u-FH 
complexes in 50 mM NaCl.  
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curve showed evidence of protein aggregation (Figure 6.10(f)). The proportions also 
agreed well with the SEDFIT integration of the c(s) plots that showed 53 ± 4% C3 and 
47 ± 4% FH (Table 6.1). The agreement between the SAXS- and AUC-determined 
proportions of C3 and FH justified the applicability of the X-ray curve fit method to 
analyse the interactions between C3u and FH.  
 
 Next, the SAXS fits for the C3u-FH interactions were evaluated. Greater 
complexity resulted because a weak interaction takes place and the unbound 
components as well as their complexes need consideration in the modelling. For this, 
the five models for FH, C3u, the 1:1 C3u-FH complex and two possible C3u2-FH and 
C3u-FH-C3u complexes were used.  
  (i) For the C3u-FH mixture in 137 mM NaCl, the experimental RG value was 
8.83 ± 0.34 nm (Table 6.1). The modelled curves for C3u, FH, and the three complexes 
all visibly deviated from the experimental I(Q) curve with high R-factors of 13.6% 
(C3u), 9.4% (FH), 8.5% (the 1:1 C3u-FH complex), 22.6% (the C3u-FH-C3u complex) 
and 17.9% (the C3u2-FH complex) (Figure 6.10(c)). A total of 1326 different 
combinations of the summed C3u, FH and the 1:1 C3u-FH curves in 2% increments 
showed that the resulting R-factors ranged satisfactorily between 3.6-13.6%, and the RG 
values ranged satisfactorily between 5.41-9.11 nm (Figure 6.11(b); Table 6.3(b)). The 
experimental RG value of 8.83 nm is close to the predicted RG value of 8.59 nm at the 
minimum R-factor of 3.6%. This combination corresponded to a composition of 2% 
C3u, 46% FH, and 52% of the 1:1 C3u-FH complex (Table 6.3(b)). The X-ray-fitted 
proportions agreed well with the SEDFIT integration of the c(s) plots that showed 6% 
C3u, 44% FH, and 50% C3u-FH (Figure 6.3(d); Table 6.1). By converting the 
percentage of C3u, FH and 1:1 complex to molarities, this composition resulted in a KD 
value of 0.22 ± 0.06 µΜ. This is comparable with the KD determination of 0.59 ± 0.11 
µM from the c(s) analysis of Figure 6.3(d). The use of all five components in 2% 
increments for fitting did not result in an improved curve fit (not shown), although here 
the best-fit combination was comparable at 5% C3u, 50% FH, 25% C3u-FH, 0% C3u-
FH-C3u and 20% C3u2-FH. Overall, we conclude that an analysis of C3u, FH and the 
1:1 C3u-FH complex presented the simplest explanation for the observed X-ray curve in 
137 mM NaCl. This combination resulted in an excellent visual agreement with the 
experimental curve for this C3u-FH mixture (Figure 6.10(g)).  
(ii) For the C3u-FH mixture in 50 mM NaCl, the experimental RG value was 
9.66 ± 1.16 nm (Table 6.1). The modelled curves for C3u, FH, and the three complexes 
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all visibly deviated from the experimental I(Q) curve again. The experimental curve 
now resembled the curves for C3u-FH-C3u and C3u2-FH the most closely, in reflection 
of the larger proportion of complexes formed in low salt (Figure 6.10(d)). The testing of 
316,260 different combinations of the five curves gives the best fit with proportions of 
0% C3u, 20% FH, 0% C3u-FH, 20% C3u-FH-C3u, and 60% C3u2-FH. The RG value of 
9.23 nm at the lowest R-factor of 8.5% from the best-fit model is smaller than the 
experimental RG value of 9.66 nm (Figure 6.11(d); Table 6.3(b)). It is comparable with 
the AUC integration that gave 8% of C3u, 31% of FH, 51% of the 1:1 complex and 
10% of a 2:1 complex (Table 6.1). While the percentages of 1:1 and 2:1 complexes are 
different between the X-ray and AUC integrations, their totals were 80% and 61% 
respectively, showing that large amounts of FH complexes with one or two C3u 
molecules were present in 50 mM NaCl buffer. The most likely reason for the 
difference between the SAXS and AUC integrations is the need for a good structure for 
the 2:1 complex in order to fit this to the SAXS curves. The best-fit C3u-FH 
combination resulted in a very good visual agreement with the experimental curve for 
the C3u-FH mixture in 50 mM NaCl (Figure 6.10(h)). 
 
The availability of SAXS curves with other molar ratios of C3u and FH (Figure 
6.7) will make possible a more extensive analysis of the molar ratios of unbound and 
complexed proteins. This will provide KD values for complex formation for comparison 
with those from AUC.  
 
 
 
 
 
195
 
 
Figure 6.11 Modelling analyses for four C3-FH and C3u-FH mixtures. The vertical 
dashed lines correspond to the measured experimental RG values. All the trial 
combinations of curves are shown in yellow, while the best-fit curve is shown in cyan 
(Table 6.3).  
(a,c) The R-factor values from 100 combinations of the C3 and FH modelled curves in 
1% increments are compared with their RG values.  
(b) The R-factor values for 1326 combinations of the three C3u, FH and C3u-FH 
modelled curves in 2% increments are compared with their RG values.  
(d) The R-factor values for 316,260 trial combinations of the five C3u, FH, C3u-FH, 
C3u2-FH and C3u-FH-C3u modelled curves in 2% increments are compared 
with their RG values.   
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(6.3) Conclusions 
The novel conclusion of this study is that two C3u molecules are able to bind 
independently at separate sites in FH to a relatively inflexible FH structure in solution. 
The “tick-over” conversion of C3 to C3u leads to alternative pathway activation, 
because C3u exhibits C3b-like function and is able to form an initial convertase with the 
Bb fragment of Factor B to enable the rapid generation of active C3b (Law & Reid, 
1995). The interaction of the major complement regulator FH with C3u offers 
regulatory control of the initial activation process, and provides insight into the similar 
processes involving FH regulatory control of fully activated C3b. There are two well-
established C3b binding sites at FH SCR-1/4 and FH SCR-19/20 (Sharma & Pangburn, 
1996; Jokiranta et al., 2000; Hellwage et al., 2002; Schmidt et al., 2008) (Table 6.2). 
Because of the knowledge of two C3b sites in FH, it has often been presumed that the 
20 SCR domains in FH are joined by flexible linkers that are able to bend in order that 
the two sites are brought together to enable FH to bind to a single C3b molecule, or 
alternatively FH binds to two distinct C3b molecules bound to the surface of the 
pathogen (Herbert et al., 2006; Jokiranta et al., 2006; Schmidt et al., 2008). Here, we 
have performed experiments with (i) both C3u and C3 (with C3 acting as a non-binding 
control), and (ii) both physiological 137 mM NaCl and reduced salt 50 mM NaCl (with 
low salt acting as a promoter for the FH-C3u interaction, this being a further control of 
the FH-C3u interaction). There is no evidence from the s20,w values for any major 
conformational changes in FH in the presence of C3u. This indicates that its overall 
structure is not flexible. It was also noticeable that the proportion of C3u (peak 2) in 
equimolar FH-C3u mixtures was diminished, in distinction to the more equal 
proportions of C3 and FH in C3-FH mixtures. Furthermore, the formation of a 
previously-unreported 2:1 complex (peak 4) in addition to the 1:1 complex (peak 3) 
indicated that two C3u molecules were bound to one FH molecule. Hence this study has 
clarified the structures and binding stoichiometry involved in the FH-C3u interaction at 
physiological NaCl concentrations.   
 
The extent to which the presents results are applicable to the C3b-FH interaction 
depend on how similar C3u and C3b are. C3u is prepared by the hydrolysis of the 
thioester in the TED domain using hydrazine, making this easier to prepare in large 
amounts than C3b but retains the C3a (ANA) fragment (Figure 6.1). C3b is purified by 
tryptic cleavage of C3 and has lost the ANA domain, but retains an intact thioester. The 
comparison of the C3u solution structure with the crystal structures of C3b and C3 
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shows that C3u resembles C3b more closely than C3 (Li et al., 2010; Chapter 5). The 
similarity of the C3u-FH and C3b-FH interactions is further indicated by the similar KD 
of 0.59 µM for both complexes (Table 6.4). C3u forms dimers, and C3b dimers have 
been seen in one crystal structure (Li et al., 2010; Rooijakkers et al., 2009). It is likely 
that C3u binds to FH SCR-1/4 in a similar way to that of C3b with SCR-1/4 in the 
crystal structure of this complex (Wu et al. 2009). Nonetheless, further similar studies 
of C3b-FH mixtures will be required to complete this project.  
 
FH enables proteolytic degradation of C3u and C3b by providing a binding 
platform for the serine protease Factor I while stabilizing the overall domain 
arrangement of C3b. The latter is achieved by the cross-linking of the TED and MG1 
domains by the SCR-4 domain (Wu et al. 2009). In unbound C3u, the CUB and TED 
domains are in an extended and flexible arrangement away from its MG domains, this 
being mediated by the linker peptides of length about 9 to 10 residues (Li et al., 2010). 
Flexibility has also been demonstrated by electron microscopy that showed that the 
CUB and TED move freely in C3u (Nishida et al., 2006). In distinction, the lack of 
structural change in FH indicates that the inter-SCR linkers are less flexible than 
commonly thought. In the past, the presumption of flexibility in the inter-SCR linkers in 
FH that enable different SCR arrangements to be formed came from several sources. 
First, crystal structures for the SCR proteins do not show uniformity in their inter-SCR 
orientations, and it has not proved possible to predict their orientations (Perkins et al., 
2002). Second, the FH linkers are of lengths 3-8 residues, where six of the seven longest 
linkers are found between SCR-7 and SCR-15 where they might cause the centre of FH 
to become mobile. This is suggested by analogy with the 8-residue linker between SCR-
1 and SCR-2 in complement receptor type 2, which resulted in a compact folded-back 
domain arrangement in its crystal structure, but was opened up into an extended 
structure in solution (Szakonyi et al., 2001; Gilbert et al., 2005; Prota et al., 2002). The 
lack of structural flexibility in FH when interacting with C3u may be related to the eight 
oligosaccharides chains at SCR-9 and between SCR-12 to SCR-18 (Fenaille et al., 
2007) that may act to separate the N-terminal and C-terminal domains into two 
functionally distinct regions.  
 
The existence of two separate binding sites for C3u on FH can be related to two 
different functionalities in FH. The binding site at SCR-1/4 relates more to the 
regulatory interaction between FH and C3u/C3b that leads to its proteolytic cleavage 
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   FH Ligand Buffer
 
  
Techniques 
Experimental 
KD (µM)   Temperature References 
SCR-1/4       C3b 10 mM sodium phosphate, 150 mM 
NaCl, 0.005% Tween-20, pH 7.4 
SPR 11 ± 2 25°C  (Wu et al., 2009) 
SCR-1/4        C3b 
10 mM HEPES-buffered, 150 mM saline, 
3 mM EDTA, 0.05% (v/v) surfactant 
p20, pH 7.4. 
 
       SPR 9.8±0.3
a to 
13.5± 0.2b 25°C  (Schmidt et al., 2008) 
 
 
SCR-19/20 
  
 
      C3b 
10 mM HEPES-buffered, 150 mM saline, 
3 mM EDTA, 0.05% (v/v) surfactant 
p20, pH 7.4. 
 
 
SPR 
3.5 ±  0.1b to 
4.5 ± 0.5a
 
            25°C 
 
 (Schmidt et al., 2008) 
SCR-19/20       C3b 10 mM acetate buffer (pH 5.0 –5.7) SPR 5.4 ± 0.7 a 22°C  (Jokiranta et al., 2006) 
SCR-1/20   C3b
 
10 mM HEPES-buffered, 150 mM saline, 
3 mM EDTA, 0.05% (v/v) surfactant 
p20, pH 7.4. 
SPR 0.59 ±  0.04
a to 
1.6 ±  0.1b 25°C  (Schmidt et al., 2008) 
SCR-1/20  C3u
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 
mM KCl, 50 mM NaCl, pH 7.4 AUC 0.11 ±  0.06 20°C   This present study 
SCR-1/20  C3u
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 
mM KCl, 137 mM NaCl, pH 7.4 AUC 0.59 ±  0.11 20°C   This present study 
 
 
SCR 16-20 
C3d  
(TED of C3b) 10 mM HEPES, 50 mM NaCl, pH 7.4 AUC 1.6 20°C  (Okemefuna et al., 2009b) 
 
 
SCR 16-20 
C3d  
(TED of C3b) 10 mM phosphate, 137 mM NaCl, pH 7.4 AUC 29 20°C  (Okemefuna et al., 2009b) 
  Table 6.4 Dissociation constants K  for the FH-C3b interaction. D
  
 
 
     a Results from C1 sensor chips 
 
     b Results from CM5 sensor chips 
 
and C3u/C3b degradation. The binding site at SCR-19/20 binds to C3d as well as to 
C3b/C3u, and the C3d interaction leads to multimerisation events that will promote the 
binding of more FH to surfaces that have high amounts of C3d bound to them 
(Okemefuna et al., 2009b). Such surfaces correspond to host cells that were decorated 
with bound C3b which were subsequently degraded to C3d. This same FH SCR-19/20 
region also binds to heparin and C-reactive protein, both of which will decorate host 
cells under appropriate conditions (Okemefuna et al., 2010c). Similar binding 
functionality also exists at SCR-7 which also binds to heparin and C-reactive protein.  
In other words, the binding of SCR-19/20 to C3u, C3b or C3d is more relevant in a 
context of the host cell surface, rather than providing a synergistic means of enhancing 
C3b breakdown mechanisms.  
 
Studies of the interactions between the complement proteins are dominated by 
their weak interactions, in which the µM KD values mean that 100% complex formation 
will never be achieved in a physiological scenario. This was confirmed directly for the 
C3u-FH mixtures in which the AUC- and SAXS-measured sample compositions were 
typically 2-6% for C3u, 44-46% for FH and 50-52% for the 1:1 complex in 137 mM 
NaCl using physiological µM concentration values (Tables 6.1 and 6.3). The use of 
reduced non-physiological NaCl concentrations increased the proportions of the 
complexes, showing that the interaction is electrostatic. The compilation of KD values 
(Table 6.4) shows that the interaction between SCR-1/4 and C3b and that between SCR-
19/20 have KD values that are about 10 times greater than that for intact FH interacting 
with C3b. This discrepancy is most easily explained by the assumption of a 1:1 
interaction model for the C3b-FH study in previous studies (Schmidt et al., 2008). If 
this is replaced by a 2:1 interaction model for the C3b-FH complex, the joint summation 
of the two separate binding sites at SCR-1/4 and at SCR-19/20 wil lead to a much 
reduced KD value for full-length FH. It should be noted that the AUC and SAXS data 
provide an independent method for determining associations compared to those in 
earlier studies (Table 6.4), because both methods correspond to a fluid phase 
measurement, not one based on binding to a sensor chip surface as with surface plasmon 
resonance.  
 
A side-benefit of this study has been the successful demonstration of a new 
method for determining KD values of weakly interacting macromolecules in solution 
based on SAXS curve fits. Previously, one approach for KD determinations is through 
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the use of surface plasmon resonance methods, in which a ligand is bound to a sensor 
surface and an analyte is flowed over this (Tanios et al., 2008). By AUC methods, it is 
possible to determine KD values, either by exponential curve fit analyses of 
sedimentation equilibrium data, or by integration of the peaks in the c(s) size 
distribution plots from analyses of sedimentation velocity data (Cole et al., 2008). By 
X-ray scattering, provided that scattering curves are known for the individual non-
interacting macromolecules A and B and their complex C, and provided that no large 
shape changes occur during complex formation, it is possible to determine the ratio of 
the unbound and bound species by the optimisation of the best-fit combination of the 
scattering curves for A, B and C. This was recently illustrated for C-reactive protein, 
where combinations of the scattering curves for its pentamer and decamer forms 
resulted in a KD value of 16 µM, in good agreement with two other KD determinations in 
that study (Okemefuna et al., 2010b). Here, the application of this SAXS fit approach 
showed that it was possible to generate approximately similar proportions of C3 and FH 
for mixtures of C3-FH in 137 mM and 50 mM NaCl that agreed well with the c(s) 
integrations from AUC data (Tables 6.1 and 6.3). By the same token, the similar 
proportions of 2% C3u, 46% FH, and 52% from SAXS fits and 6% C3u, 44% FH, and 
50% C3u-FH by AUC integrations indicate that this SAXS approach has promise for 
determining KD values.  
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(6.4) Material and Methods 
(6.4.1) Preparation of C3-FH and C3u-FH mixtures 
The purification of C3 from fresh human plasma and C3u by incubation with 
hydrazine and its separation from unhydrolysed C3 by anion-exchange chromatography 
followed that described previously (Dodds, 1993; Li et al., 2010). Reduced SDS-PAGE 
confirmed the presence of α chain (115 kDa) and β chain (75 kDa). C3u but not C3 was 
active in functional assays using factor I and factor H (Nan et al., 2008). After confirmation 
of purity, the proteins were dialysed into phosphate buffer saline (PBS: 8.1 mM Na2HPO4, 
1.5 mM KH2PO4, 2.7 mM KCl, 50 mM or 137 mM NaCl, pH 7.4) overnight at 4ºC, and 
concentrated using Amicon® Ultra-15 centrifugal filter devices with a molecular weight 
cut-off of 50 kDa at a speed of 2,500 g. Throughout the text, the buffer is denoted as 137 
mM NaCl or 50 mM NaCl, even though phosphate is also present. Concentrations were 
determined using an absorption coefficient of 9.4 (1%, 280 nm, 1 cm path length) (Li et al., 
2010; Chapter 5). Prior to mixture with FH, C3 and C3u were gel filtrated to remove non-
specific aggregates using a Superose 6 16/60 column (Amersham Pharmacia Biotech). FH 
was purified from a pool of anonymised human plasma using monoclonal affinity 
chromatography with MRC-OX23 Sepharose column (Sim et al., 1993; Nan et al., 2008). 
Concentrations were determined using an absorption coefficient of 16.2 (Okemefuna et al., 
2009a). Non-specific aggregates and traces of human serum albumin were removed by gel 
filtration using a Superose 6 16/60 column (Amersham Pharmacia Biotech).   
 
To prepare the mixtures of C3-FH and C3u-FH, the C3, C3u and FH proteins 
after gel filtration were dialysed individually into 137 mM NaCl or 50 mM NaCl 
phosphate buffers. The proteins were centrifuged to remove any visible aggregates, then 
mixed in a 1:1 ratio according to their absorbances at 280 nm. The mixtures were 
incubated at 20°C for 6 h with the addition of 1 mM Pefabloc protease inhibitor before 
loading onto a Superose 6 gel filtration column. For C3-FH and C3u-FH in 137 mM 
NaCl and 50 mM NaCl, the fractions at the peak centres were collected and 
concentrated for data collection. Prior to and after AUC and X-ray experiments, sample 
purities were checks by non-reduced and reduced SDS-PAGE (Figure 6.2(c)).  
 
(6.4.2) Analytical ultracentrifugation of C3-FH and C3u-FH mixtures  
  Sedimentation velocity experiments were performed at 20°C using two 
Beckman XL-I analytical ultracentrifuges (Beckman-Coulter Inc, Palo Alto, CA) 
equipped with both absorbance and interference optics. An eight-hole AnTi50 rotor was 
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used with standard double-sector cells with column heights of 12 mm at 20ºC, and 
sedimentation was monitored using absorbance optics at 280 nm and interference 
optics. Below a total concentration of 1 mg/ml, both absorbance and interference optics 
data were analysed. Above 1 mg/ml, only interference optics data were used for reason 
of the saturation of the absorbance optics at 280 nm. Data for the C3-FH and C3u-FH 
mixtures were acquired in 137 mM and 50 mM NaCl phosphate buffer at rotor speeds 
of 30,000, 40,000 and 50,000 r.p.m. The C3-FH mixture in 137 mM NaCl used a total 
concentration of 1.43 mg/ml, prepared by mixing 320 µl of 1.26 mg/ml C3 and 260 µl 
of 1.72 mg/ml FH in a 1:1 molar ratio. The C3-FH mixture in 50 mM NaCl used a total 
concentration of 1.36 mg/ml, prepared by mixing 220 µl of 1.37 mg/ml C3 and 135 µl 
of 1.81 mg/ml FH in a 1:1 molar ratio. The C3u-FH mixture in 137 mM NaCl used a 
total concentration of 1.53 mg/ml, prepared by mixing 455 µl of 1.21 mg/ml C3u and 
193 µl of 2.30 mg/ml FH in a 1:1 molar ratio. The C3u-FH mixture in 50 mM NaCl 
used a total concentration of 1.62 mg/ml, prepared by mixing 300 µl of 1.21 mg/ml C3u 
and 104 µl of 2.81 mg/ml FH in a 1:1 molar ratio. Each mixture was studied in a 
dilution series from 100% to 10%. The buffer density of 137 mM and 50 mM NaCl 
phosphate buffers were measured at 20oC using an Anton-Paar DMA5000 density meter 
to be 1.00542 ml/g and 1.00167 ml/g, in good agreement with the predicted values of 
1.00543 ml/g and 1.00175 ml/g from SEDNTERP (Laue et al., 1992). A mean partial 
specific volume of 0.728 ml/g was used for the C3-FH and C3u-FH mixtures based on 
the values of 0.739 ml/g for C3 (mass 189 kDa) and 0.715 ml/g for FH (mass 154 kDa) 
calculated from its amino acid and carbohydrate content, respectively (Li et al., 2010; 
Okemefuna et al., 2009a). The continuous c(s) size distribution analysis method was 
used to determine sedimentation coefficients s20,w of the C3-FH and C3u-FH mixtures 
using SEDFIT (version 11.7) (Dam & Schuck, 2004; Schuck, 2000). The final c(s) fits 
were determined using a resolution of 200 and by floating the meniscus, frictional ratio 
f/f0, and baseline and holding the cell bottom, partial specific volume and solvent 
density fixed until the overall root-mean-square deviations and visual appearance of the 
fits were satisfactory (Figure 6.3). Because f/f0 is floated in the fits, the final f/f0 values 
may be affected by oligomerisation. The SEDFIT analyses assumed that all species 
have the same frictional ratio f/fo. Molecular masses were determined by converting the 
c(s) plots to c(M) mass distributions within SEDFIT. 
 
(6.4.3) X-ray scattering of C3-FH and C3u-FH mixtures 
X-ray solution scattering data of the C3-FH and C3u-FH mixtures were collected 
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in four sessions on the camera at the ID02 high brilliance beamline at the European 
Synchrotron Radiation Facility (ESRF) at Grenoble, France with a ring energy of 6.0 
GeV (Narayanan et al., 2001). In all four sessions except one, data were collected in 16-
bunch mode using beam currents of 68-93 mA, 66-90 mA and 68-74 mA. In one 
session, data were collected in 4-bunch mode using beam currents of 32-34 mA. Data 
were acquired using an improved fibre optically-coupled high sensitivity and dynamic 
range CCD (charge-coupled device) detector (FReLoN) with a smaller beamstop. The 
sample-to-detector distance was 2.0 m. A flow cell was used to eliminate radiation 
damage in conjunction with on-line checks for the absence of radiation damage through 
the optimisation of exposure times in sets of ten time frames. Each sample was 
measured in four set of ten time frames of length 0.08, 0.1, 0.15, 0.2 and 0.3 sec for the 
C3-FH and C3u-FH mixtures. The time frames for each run were averaged to maximise 
signal-noise ratios. Sample temperatures corresponded to ambient conditions at 20°C. 
The C3-FH mixtures in 1:0.3 and 1:0.5 molar ratios in 137 mM NaCl were studied at 
four total concentrations of 0.32 mg/ml – 1.29 mg/ml and 0.32 mg/ml – 1.27 mg/ml 
respectively. The 1:1 C3-FH mixtures in 137 mM NaCl were studied at seven total 
concentrations of 0.30 mg/ml – 1.46 mg/ml. The C3-FH mixtures in 1:0.3 and 1:0.5 
molar ratios in 50 mM NaCl were studied at single total concentrations of 0.56 mg/ml 
and 0.63 mg/ml respectively. The 1:1 C3-FH mixtures in 50 mM NaCl were studied at 
four total concentrations of 0.33 mg/ml – 1.32 mg/ml. C3u-FH 1:0.3 and 1:0.5 in PBS 
137 mM NaCl were collected at 0.37 mg/ml, 0.75 mg/ml and 0.39 mg/ml, 0.80 mg/ml 
respectively. C3u-FH 1:1 in PBS, 137 mM NaCl were studied at 0.26 mg/ml – 1.04 
mg/ml (nine concentrations). C3u-FH 1:0.3 and 1:0.5 in PBS 50 mM NaCl were 
collected at three concentrations from 0.40 mg/ml – 1.13 mg/ml and 0.42 mg/ml – 1.15 
mg/ml respectively. C3u-FH 1:1 in PBS, 50 mM NaCl were studied at 0.22 mg/ml – 
1.04 mg/ml (eleven concentrations).  
 
Guinier analyses were used to characterise the mean degree of structural 
elongation of macromolecules in solution. Guinier plots at low Q values gives the RG 
and forward scattering at zero angle I(0) (Glatter & Kratky, 1982):  
ln I(Q) = ln I(0) - RG2 Q2/3 
For a single macromolecule, this expression is valid in a Q.RG range up to 1.5. In a 
given solute-solvent contrast, the radius of gyration RG is a measure of structural 
elongation if the internal inhomogeneity within C3, C3u or FH has no effect. For 
elongated structures, the mean radius of gyration of the cross-sectional structure RXS and 
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the mean cross-sectional intensity at zero angle [I(Q).Q]Q→0 parameters are obtained 
from:  
ln [I(Q).Q] = ln [I(Q).Q]Q→ 0  - RXS2 Q2/2 
The RXS value monitors the elongation of its cross-section shape along its longest axis. 
The RG and RXS analyses were performed using an interactive PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics 
OCTANE Workstations. Indirect Fourier transformation of the full scattering curve I(Q) 
in reciprocal space gives the distance distribution function P(r) in real space. This yields 
the maximum dimension of the macromolecule L and its most commonly occurring 
distance vector M in real space:  
dQ (Qr) Qr I(Q)  
2
1 = P(r)
o
2
sin∫∞π  
The transformation was implemented using GNOM software (Semenyuk & Svergun, 
1991). For the C3-FH and C3u-FH mixtures in 137 mM and 50 mM NaCl, the X-ray 
I(Q) curves with 242-394 data points used the Q range between 0.10 nm-1 and extending 
up to 1.61-1.85 nm-1.  
 
(6.4.4) Constrained scattering and sedimentation coefficient modelling  
The constrained modelling of the experimental scattering curves for the C3-FH 
and C3u-FH mixtures required molecular models for each component present in the 
mixture in order to initiate this procedure. The modelling of the non-interacting C3-FH 
mixtures in 137 mM NaCl and 50 mM NaCl was based on two components. These were 
the crystal structure for human C3 (PDB code 2A73, Jenssen et al., 2005) and the 
solution structure for FH (PDB code 3N8O, Okemefuna et al., 2010a). The modelling of 
the interaction between C3u and FH in 137 mM NaCl was based on three components. 
These were the solution structures of human C3u (PDB code 3MMQ, Li et al., 2010; 
Chapter 5) and FH (PDB code 3N8O, Okemefuna et al., 2010a), together with the 
crystal structure of C3b in complex with FH SCR-1/4 (PDB code 2WII, Wu et al., 
2009). That FH solution structure was the most-recently determined one based on the 
constrained modelling searches of the SCR-1/5, SCR-6/8, SCR-8/11, SCR-11/15 and 
SCR-16/20 fragments whose structures were previously determined (PDB codes 2QFG, 
2QFH, 2UWN, 3N8P, 3N8Q, Okemefuna et al., 2010a). The solution structure of the 
1:1 C3u-FH complex was approximated by the C3b-FH complex. This structure was 
formed by the superimposition of SCR-4 in the C3b-FH-SCR-1/4 crystal structure upon 
the SCR-4 domain of the solution structure of FH, after which the SCR-1/4 domains in 
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the FH solution structure model were deleted. The modelling of the interaction between 
C3u and FH in 50 mM NaCl was based on five components. Three were taken from the 
solution structural models of C3u and FH and their 1:1 C3u-FH complex (above). The 
fourth was represented by the solution structure of the C3u2-FH complex, which was 
generated starting from the crystal structure of the C3b dimer (PDB code 2WIN, 
(Rooijakkers et al., 2009). The MG-1/8 domains of one monomer in this C3b dimer 
were superimposed upon the MG-1/8 domains in the 1:1 C3u-FH model, after which the 
C3b monomer within that dimer was removed to result in a 2:1 C3u-2FH structural 
model. The fifth was represented by a model for the C3u-FH-C3u complex, in which 
C3u interacted at two independent FH sites at SCR-1/4 and SCR-19/20. For this, a C3u 
structure was positioned close to the SCR-19/20 domains in the 1:1 C3u-FH model 
(above) was adapted. This positioning was guided according to binding sites identified 
from previous mutation studies and sequence analyses (Table 6.2). Thus the residues 
K1187- A1249 in the TED domain of C3b were placed close to the residues R1182, 
W1183, R1210 and R1215 of SCR-20 and W1157 of SCR 19.  
 
Each of the five molecular models was used to calculate its X-ray scattering 
curve following their transformation into Debye sphere models (Perkins & Weiss, 
1983). For C3, C3u and FH, cube side lengths of 0.540 nm, 0.540 nm and 0.498 nm in 
conjuction with a cut off of 4 atoms were used. For C3u-FH, C3u2-FH and C3u-FH-
C3u, a cube side length of 0.762 nm in conjunction with a cutoff of 9 atoms was used. 
Since these structures are unhydrated, and correspond to the amino acid and 
carbohydrate residues expected to be present, hydration in each sphere model was 
achieved by cover the surface of the sphere model with additional spheres to correspond 
to 0.3 g H2O/ g glycoprotein using HYPRO (Ashton et al., 1997). The optimum totals of 
dry and hydrated spheres were 1557 and 2047 (C3u), 1564 and 2074 (FH), 991 and 
1308 (C3u-FH) and 1547 and 2038 (C3u2-FH and C3u-FH-C3u) respectively. The X-
ray scattering curve I(Q) was calculated using the Debye equation adapted to spheres 
(Boehm et al., 1999; Perkins, 2001b; Li et al., 2010). The X-ray curves were calculated 
without instrumental corrections because these are considered to be negligible for the 
pinhole optics used in synchrotron X-ray scattering instruments. In order to model the 
experimental X-ray scattering curve for C3-FH mixtures in 137 mM and 50 mM NaCl, 
for which C3 and FH do not interact, the C3 and FH scattering curves were merged in 
increments of 1% from 0% to 100% of C3 and FH in order to generate 101 predicted 
curves for comparison with the experimental X-ray curves for each of the two buffers, 
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following the method used to analyse pentamer-decamer mixtures of C-reactive protein 
(Okemefuna et al., 2010b). In order to model the experimental X-ray scattering curve 
for C3u-FH mixtures in 137 mM NaCl, where a 1:1 complex was formed, the three 
individual curves for C3u, FH and the 1:1 complex were merged in 2% incremental 
steps to generate 1326 predicted curves for comparison with three different 
experimental X-ray curves in 137 mM NaCl. In order to model the experimental X-ray 
scattering curve for C3u-FH mixtures in 50 mM NaCl, where a 1:1 complex and two 
2:1 complexes were formed, the five individual curves for C3u, FH, the 1:1 complex 
and the two 2:1 complexes were merged in 2% incremental steps from 0% to 100% to 
generate 316,260 predicted five-component curves for comparison with five different 
experimental X-ray curves in 50 mM NaCl. The three sets of predicted curves for the 
four experiments were evaluated to identify the proportions that resulted in the best fit 
to the experimental curves. Firstly, the RG values from the predicted curves were 
required to be within 5% of the experimental values, using Guinier fits in the same Q 
ranges used for the experimental Guinier analyses. Secondly, the overall goodness-of-fit 
R-factor between the predicted and experimental curves were calculated in order to 
identify the best-fit model from the lowest R-factor.  
 
Sedimentation coefficients s0 20,w were calculated directly from the hydrated 
Debye sphere models using the program HYDRO (Garcia de la Torre et al., 1994). 
They were also calculated from the atomic coordinates for each model using the 
HYDROPRO shell modelling program using the default value of 0.31 nm for the atomic 
element radius for all atoms to represent the hydration shell (Garcia de la Torre et al., 
2000). Previous applications of these calculations to proteins 
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7.1 Prologue 
The projects presented in this thesis have defined the solution structures and 
associations of CR2 SCR 1-15, C3d, C3 and C3u, and have mainly focused on the weak 
interactions between CR2-C3d and C3u-FH. These weak interactions were researched 
both in low salt buffers, where a stronger interaction is promoted, and in a more 
physiological salt buffer. The major projects in this thesis investigated the structure of 
CR2 SCR 1-15 and the effect of C3d on this, and also the structure of C3u and the 
interaction between C3u and FH and placed the latter in the context of the relationship 
to C3b and the C3b-FH complex.  
 
Protein-protein interactions can be strong with 100% of complex formed (with 
nanomolar dissociation constants) or weak ones where the complex is partially 
dissociated (with micromolar dissociation constants) (Perkins et al., 2010a). The 
majority of the complement proteins function through their relative abundance and their 
weak interactions. The advantage of AUC is that in principle this identifies all the 
species in solution through c(s) size-distribution analyses; however, interpretations need 
to be cautious in case reaction boundaries are present (Cole et al., 2008). AUC is a 
powerful method for the protein interaction studies in this thesis because AUC extracts 
KD values from sedimentation equilibrium and sedimentation velocity fits, and displays 
all the components present from c(s) distribution analyses. X-ray scattering is a 
technique which is most powerful when it is used to extract medium-resolution 
structural information through constrained modelling on the basis of atomic resolution 
structures. Although the scattering technique works best if the sample is monodisperse 
(Perkins et al., 2008, 2009), the combination of AUC and scattering methods takes 
advantage of the strengths of both approaches. Interestingly, it proved possible in this 
thesis to use scattering modelling (Chapter 6) with the combination of the scattering 
curves from the individual components to give independent information on the 
stoichiometry and the KD of a complex protein interaction.  
 
The solution structures of CR2 and C3u suggested that flexibility is important 
for these two large complement proteins (Chapter 4, Chapter 5). For FH, there are 
reasons to believe that flexibility may be a less significant property. To evaluate this, 
the combination of atomic resolution structures and solution data complement each 
other, and this combination was most useful for understanding the relative contributions 
of structure and flexibility to function in these proteins. 
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7.2 Interaction of CR2 SCR 1-15 with C3d 
The knowledge of how CR2 bound with C3d from this thesis provided clearer 
insight into the function of CR2. Here, the effect of C3d binding to full-length CR2 was 
determined by a joint AUC and X-ray scattering study (Chapter 4). First, it was 
necessary to understand the behaviour of the free proteins. The sedimentation 
coefficient of unbound CR2 (4.03 S) in 50 mM NaCl agrees well with that in 137 mM 
NaCl (3.93 S), so the overall CR2 structure is unaffected by change in ionic strength 
(Section 4.2.1). Previously it was presumed that unbound C3d underwent dimerisation 
in 50 mM NaCl buffer (Gilbert et al., 2005). In this thesis,my study of sedimentation 
velocity and sedimentation equilibrium data illustrated that this self-association is best 
described by two monomer-dimer and monomer-trimer equilibria in 50 mM NaCl, but 
as a monomer only in 137 mM NaCl instead (Figure 4.3 and 4.4).  
 
For the CR2-C3d complex, the c(s) size-distribution analyses by AUC using 50 
mM NaCl showed that the complex is formed (Figure 4.2); while in 137 mM NaCl the 
c(s) analyses revealed dissociated components (Section 4.2.4). The previous solution 
structural models for the CR2 SCR-1/2 complex with C3d (Gilbert et al., 2005) was 
superimposed on the solution structure for full-length CR2 SCR-1/15. This model gave 
an average sedimentation coefficient of 4.57 S for the complex, in good agreement with 
the observed value of 4.52 S (Figure 4.6; Table 4.1). It is concluded that CR2 did not 
detectably change conformation when C3d was bound to it, and also that the interaction 
of CR2 with C3d demonstrates a substantial dependence on charge. This outcome 
agreed with surface plasmon resonance studies in 50 mM NaCl that included SCR 1-2, 
SCR 1-4 and SCR 1-15 which demonstrated a high affinity for C3d, but in more 
physiological 125 mM NaCl salt, the binding interaction between CR2 and C3d was 
much weakened (Asokan et al., 2006; Moore et al., 1989; Guthridge et al., 2001; 
Hannan et al., 2005). To our knowledge, this is the first solution structural study of a 
large multidomain SCR protein CR2 bound to its physiological ligand C3d. Consistent 
with previous analyses, the CR2-C3d complex is not formed in physiological salt 
conditions. The lack of an observed interaction by AUC that is known to exist in vivo is 
best explained by the physiological context of this interaction. CR2 is a membrane 
bound protein, and will interact with an abundance of C3d fragments that are also cell 
surface bound. Such an interaction between two surfaces would be promoted by local 
surface concentration effects. 
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7.3 Solution structures of C3 and C3u 
The same strategy was applied to study the C3u-FH interaction. First, the self-
association properties and solution structures of each of C3 and C3u were determined 
using AUC and X-ray scattering (Chapter 5). Sedimentation coefficients identified two 
different types of dimerisation events in both proteins. A fast dimerisation was observed 
in 50 mM NaCl that was removed in 137 mM NaCl (Figure 5.3(e,f)). A low amount of a 
slow dimerisation was observed for C3u and C3 in both buffers (Figure 5.5). The X-ray 
radius of gyration RG values were unchanged for both C3 and C3u in 137 mM NaCl, but 
depend on concentrations in 50 mM NaCl (Figure 5.7). Solution structures were also 
determined. The C3 crystal structure gave good X-ray scattering fits for C3 in 137 mM 
NaCl. For C3u, constrained modelling in 137 mM NaCl showed that the TED/CUB 
domains in C3u were extended and differ from the more compact arrangement seen in 
the crystal structures of C3b that were crystallised in low salt (Figure 5.15 (a,b)). This 
TED/CUB conformation is intermediate between those seen in the C3 and C3b crystal 
structures. The greater exposure of the TED domain in C3u (which possesses the 
hydrolysed reactive thioester) accounts for the greater self-association of C3u in low salt. 
In addition, the conformational variability of the functionally-important TED/CUB 
domains would facilitate their interactions with a broad range of antigenic surfaces. One 
of the two dimerisation events seen for C3 and C3u may correspond to a dimer observed 
in one of the crystal structures of C3b. 
 
7.4 Interactions of C3/C3u with Factor H in solution 
To study the C3u-FH interaction itself, the C3u-FH interaction (Chapter 6) was 
studied by sedimentation velocity experiments that showed that both 1:1 and 2:1 
complexes of C3u-FH were observed in both buffers. In 137 mM NaCl buffer, the 1:1 
complex is predominant, while the relative proportion of 2:1 complexes was increased 
in 50 mM NaCl buffer (Figure 6.3(d,h)). Dissociation constants KD of 0.59 µM and 0.11 
µM were determined in these buffers from integrations of the c(s) plots. Starting from 
previously-determined structures for FH, C3u, the FH (SCR-1/4)-C3b complex and the 
C3b dimer, a novel scattering curve fit procedure was developed for weakly-interacting 
macromolecules. For 137 mM NaCl, a three-component system gave the best curve fit, 
with 48% of unbound C3u and FH, and 52% 1:1 complex (Table 6.3), leading to a 
similar KD value of 0.22 µM (Table 6.4). In 50 mM NaCl, good fits were obtained using 
a five-component analysis with a 1:1 complex and two different types of 2:1 complexes 
(Figure 6.11). In summary, the ability to model the sedimentation coefficient of the 1:1 
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complex showed that no conformational changes in FH were detected in the C3u-FH 
complexes (Figure 6.9). In addition, two independent binding sites for C3u were shown 
to exist in FH, even though it is often assumed in the literature that one FH molecule is 
bent around one molecule of C3u when the FH-C3u complex is formed. Our results 
provide new insight on how FH achieves regulatory control of C3u activation.   
 
7.5 Biological significance  
Complement activation causes inflammation in the host, so control mechanisms 
are crucial for protection of the host cells. This includes ways to stop the formation of 
excess amounts of the C3 convertase by promoting the decay of activated C3b. My 
thesis illustrates newer insights on how FH and CR2 play a role in the regulation of C3 
and its fragments. The combination of AUC, X-ray scattering analyses and constrained 
modelling has established the solution structures of CR2-C3d, C3u and C3u-FH. These 
findings are related to many broader aspects of complement function. Thus, in the 
alternative pathway, FH regulates the active central complement protein C3b. C3b 
shares functional similarity with C3u (also known as C3H20), thus the studies of the 
C3u-FH interactions are expected to be useful in terms of the C3b-FH complex. The 
results on the flexibility of the TED-CUB domains in C3b are expected to apply to the 
TED-CUB domains in the related proteins C4b and C5b.  
 
An understanding of the complement protein interactions will clarify the role of 
complement in disease. For example, it was suggested that the complement-mediated 
antibody-dependent enhancement of HIV infection is mediated by the association of 
CR2 expressed on FDC or B cells with the C3d fragment attached to the surface of HIV 
virons (Xu et al., 2009). Depletion of FH from serum dramatically increases the 
sensitivity of HIV to complement-mediated lysis, thus enables the HIV virions to spread 
more rapidly; however in the presence of FH, C3b is regulated and lysis will be 
inhibited (Stoiber et al., 1996, 2001; Willey & Assa-Chapman, 2008). The studies of the 
CR2-C3d and C3u-FH interactions in this thesis build a clearer foundation by which the 
HIV infection and blockage mechanism operates. Additionally, the solution structure of 
the C3u-FH complexes provides new insight on the involvement of FH in atypical 
haemolytic uraemic syndrome (aHUS), where mutations in FH are associated with 
aHUS. In summary, the solution structures of this thesis lead to a greater understanding 
of complement activation regulation and possibilities for new drug discoveries.  
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